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Abstract
The combination of heterogeneous biological datasets is a key requirement for mod-
ern molecular systems biology. Of particular importance for our understanding of
complex biological systems like the human cell are data about the interactions of
proteins with other molecules. In this thesis, we develop and apply methods to im-
prove the availability and the quality of such interaction data. We also demonstrate
how these data can be used in interdisciplinary studies to discover new biological
results.
First, we develop technical systems for the instant integration of interaction data
that are stored and maintained in separate online repositories. Second, we imple-
ment a computational framework for the application of multiple scoring algorithms
to qualitatively assess different aspects of interaction data. Our methods are based
on distributed client-server systems, ensuring that the services can be updated con-
tinuously. This promotes equal access to interaction data and allows researchers to
expand the client-server systems with their own service.
Third, we focus our application studies on integrative network-based analyses of
human host factors for viral infections. Our applications provide new biological in-
sights into the life cycle of the hepatitis C virus and identify new potential candidates




Die Kombination verschiedener biologischer Datensa¨tze ist fu¨r die moderne moleku-
lare Systembiologie unumga¨nglich. Eine besondere Bedeutung fu¨r unser Versta¨ndnis
von komplexen biologischen Systemen wie der Zelle haben dabei Daten u¨ber die
Wechselwirkungen von Proteinen mit anderen Moleku¨len. In dieser Arbeit entwickeln
und verwenden wir Methoden zur Verbesserung der Verfu¨gbarkeit und Bewertbarkeit
von solchen Interaktionsdaten. Wir zeigen auch, wie diese Daten in interdisziplina¨ren
Studien genutzt werden ko¨nnen, um neue biologische Erkenntnisse zu gewinnen.
Zuerst entwickeln wir technische Systeme, um Interaktionsdaten von verschiede-
nen Quellen des Internets zusammenzufu¨hren. Danach entwickeln wir ein computer-
gestu¨tztes System, welches die Anwendung verschiedener Algorithmen ermo¨glicht,
um unterschiedliche Aspekte von Wechselwirkungen qualitativ zu bewerten. Unsere
Methoden basieren auf verteilten Client-Server-Systemen, die sicherstellen, dass ein-
zelne Dienste dauerhaft aktuell gehalten werden ko¨nnen. Zudem fo¨rdert dies einen
gleichberechtigten Zugang zu Interaktionsdaten, und Wissenschaftler ko¨nnen die Sy-
steme mit eigenen Diensten erweitern.
Unser Anwendungsschwerpunkt liegt auf der netzwerkbasierten Analyse humaner
Wirtsfaktoren fu¨r virale Infektionen. Unsere Auswertungen tragen zu einem besseren
Versta¨ndnis des Lebenszyklus des Hepatitis-C-Virus bei und zeigen Ansatzpunkte
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Fu¨r Mutsch – und die beiden, die nicht mehr hier sein ko¨nnen.

1 Introduction
This chapter introduces the topic of the thesis. First, some problems are detailed
that motivated our research in biomedical data integration and its application to
particular scientific problems in human systems biology. Then, the work that has
been carried out during the course of the thesis will be presented, followed by an
outline of the thesis structure.
1.1 Motivation
Over the last years, molecular biology has been undergoing a fundamental change,
largely driven by the development or improvement of experimental techniques that
allow studying diseases and associated molecular processes in ways that have not
been possible before. For example, RNA interference screening, a technology that
has only been established about a decade ago, now is capable of selectively inves-
tigating the effect of every single gene in our genome on certain disease-associated
pathways or infections1. This opens up exciting new avenues for basic research and
clinical diagnostics, which were wholly unthinkable a few years ago.
The technological breakthroughs also impacted the general way research is carried
out. The traditional reductionist and hypothesis-driven approach splits problems
into sub-problems until they can be experimentally tested. Now, experiments may
be performed in a less biased fashion, via ome-wide high-throughput techniques
that are not limited to preselected study objects. Instead of investigating whether
two particular proteins physically bind to another, researchers can test thousands
of proteins or even complete proteomes, that is, all proteins of an organism, against
each other in a single large-scale experiment.
This new way of approaching research questions in molecular biology is also re-
flected in the paradigm of systems biology, an interdisciplinary research area that
tries to analyze and model cells and other complex biological units as highly inter-
connected components that need to be investigated as a whole. Different omics disci-
plines evolved to this end, for example, proteomics, which investigates the proteome,
lipidomics, which researches connections between all cellular lipids, or metabolomics,
which analyzes chemical processes and the molecules involved.
Vast amounts of heterogeneous data are produced by the multitude of high-
throughput techniques in the different omics disciplines of systems biology. Analyz-
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ing these data may easily be beyond the capabilities of the individual experimenters,
requiring expertise in areas like statistics and information processing. Bioinformat-
ics is becoming increasingly relevant because it provides the link between biological
knowledge and means to analyze large quantities of data systematically using com-
puters and sophisticated algorithms.
Of central importance to this thesis is the area of interactomics, which investigates
the interactions of proteins and other molecules. Proteins, the key players involved
in virtually every cellular process, perform their functions through interactions with
other molecules. A comprehensive understanding of complex cellular systems is thus
not conceivable without knowing the interactome, the set of all molecular interac-
tions in a cell78. In addition, protein interactions emerge as potential targets for
novel therapeutic approaches to combat disease328,429.
Several issues are currently associated with protein interaction data, limiting their
usefulness for systematic studies392. Two particular problems are general data avail-
ability, as interaction data are not stored centrally, but spread over multiple online
repositories, and data quality, as different determination techniques produce results
that are difficult to assess and compare. In this thesis, I will present methodological
improvements and new systems, which may help to ensure that interactome data are
available to interested researchers in a convenient, high-quality, and timely manner.
Interactomics is not only concerned with measuring and modeling interaction
data. Molecular interactions and the networks and pathways they form, are also an
important resource for the applied, integrative bioinformatics analysis of different
experimental datasets. For example, knowledge about the interaction partners of a
protein may be used to infer information about its biological function. Incorporating
additional, complementary datasets like expression profiles or functional annotations
into such network-based analysis approaches, may allow detecting patterns in the
experimental data that could not be uncovered by individual investigations.
1.2 Overview
The work performed while preparing this thesis can be divided into two parts. First,
the development of methods and software to improve the availability and data qual-
ity of protein interactions. Second, the combination of molecular interactions and
other types of biomedical data in application studies to answer particular research
questions. Importantly, by closely working together with external research groups,
expertise in biological domains is brought together with our bioinformatics knowl-
edge.
The methodological developments in the first part consist of distributed systems
that we implemented in collaboration with biomedical data providers. After show-
casing the potential of data decentralization with our Distributed Annotation System
for Molecular Interactions40,40,181, we (co-)developed two follow-up projects in the
context of the Proteomics Standards Initiative of the Human Proteome Organiza-
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tion, building on experiences gained with the initial prototype14.
The application studies, which form the second part of the thesis, apply different
techniques for the integration, analysis, and prioritization of heterogeneous biomed-
ical data types in order to answer questions of direct biological or medical relevance.
A long-lasting and fruitful collaboration was established with the Department of
Molecular Virology at the Heidelberg University, which we supported with the anal-
ysis of several large-scale RNA interference screens to determine human host factors
required for viral infections105,321.
The work presented in this thesis resulted in six co-authored publications in peer-
reviewed journals or conference proceedings and three book chapters. For the sake
of brevity and clarity, the applied bioinformatics work that led to two additional
co-authored publications127,423 is not described here in more detail.
1.3 Outline
The remainder of this thesis is split into five chapters followed by a bibliography
and an appendix.
Chapter 2 introduces the basic types of interactions between proteins and other
molecules, an area that is important for all other chapters. First, experimental and
computational techniques for determining those interactions are presented. This is
followed by descriptions of resources for storing and retrieving interaction data and
the main data formats and standards.
Chapter 3 presents computational methods to improve the general availability of
molecular interaction data. After introducing the Distributed Annotation System
(DAS), our extension named DAS for Molecular Interactions (DASMI) is presented
in detail. Today, DASMI is largely superseded by a successor system named Pro-
teomics Standards Initiative Common Query Interface, which is briefly described in
the remainder of the chapter.
Chapter 4 focuses on the evaluation of interaction data quality. After detailing the
existing quality problems, an overview of various approaches to assess interaction
data quality is provided. We then show how DASMI can be used for the integration
and visualization of different scoring approaches. Based on DASMI, we develop
the Proteomics Standards Initiative Common Confidence Scoring System that is
described thereafter.
Chapter 5 contains applications of different data integration techniques to the
analysis and prioritization of functional genomic screens determining human host
factors for viral infections. After providing an introduction to the hepatitis C virus
(HCV) and systems for studying host factors, I will describe the computational
platform that we have developed for the analysis of such screens. Then, a network-
based functional analysis of HCV host factors is presented and the application of
our analysis platform to two RNA interference studies for determining HCV host
factors is presented.
4 1 Introduction
Chapter 6 summarizes the thesis and provides an outlook on future advancements.
The Appendix 6.2 or Appendix 6.2 contains the technical documentations of the
distributed systems we developed and a list of own publications.
2 Basics of molecular interactions
This chapter provides an introduction into the basic concepts and types of molecular
and protein interactions, as this biological data type is relevant for all chapters of
the thesis. The different molecular interaction types and the required terminology
is introduced in Section 2.1. In Section 2.2, I will present several techniques for
experimental interaction detection or for their computational prediction. The main
resources for storing and retrieving interaction data are presented in Section 2.3.
Only a brief overview of interaction data quality is provided in Section 2.4, as Chap-
ter 4 is dedicated to this topic. A description of the relevant standards, data formats,
and guidelines in the field of molecular interactions is presented in Section 2.5.
2.1 Molecular interaction types
Proteins are essential building blocks of all organisms that have manifold roles as
molecular machines of our cells. Different groups of proteins are fundamental to
virtually every aspect of cellular functioning, including membrane and signaling pro-
teins that form cellular signaling pathways, structural proteins that stabilize cells
or cellular compartments, enzymes that catalyze chemical reactions, transport pro-
teins that deliver molecules, or immunoproteins that mediated the human immune
response292. Most of this functionality is not accomplished by individual proteins
but via an interplay with other proteins or molecules likes lipids, nucleic acids,
or metabolites101,123. An illustrative example is the adenosine triphosphate (ATP)
driven interaction between the proteins actin and myosin, that ultimately leads to
the contraction of muscle fibers and thus to our ability to move168.
Proteins The interaction between proteins or other molecules is referred to as pro-
tein or molecular interaction. There is no strict definition for these terms and they
are sometimes used synonymously. Throughout this thesis, I will use the term pro-
tein interaction for relationships that only involve proteins, while the term molecular
interaction will be used as a more general, higher-level term that denotes interac-
tions involving other molecules like nucleic acids, hormones, or drugs. Using this
definition, protein interactions are a subset of molecular interactions.
Depending on the type and the number of interacting molecules, which in the fol-
lowing are also named interactors , protein interactions may be grouped into different
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Figure 2.1: Schematic drawing of different types and levels of molecular interactions40.
In general, physical and non-physical interactions can be distinguished. (a) Non-physical
interactions are also known as associations and describe a functional relationship between
two entities, for example, the co-mentioning of two genes in a sentence of a scientific
publication or their co-expression in a certain cellular condition. (b) Physical interactions
imply an actual physical contact between the interacting entities (interactors). (c) By
raising the level of detail, the interacting atoms or residues of the binding sites can be
identified.
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categories (see Figure 2.1). If up to two proteins are interacting, this is termed a
protein-protein interaction (PPI) or dimer. The term binary may be added to em-
phasize the fact that exactly two proteins are involved. An assembly of more than
two proteins is named protein complex , oligomer, or n-ary interaction. Depending
on the identity of the interacting proteins, dimers and oligomers can be further di-
vided into homodimers and homooligomers if identical proteins are interacting, and
heterodimers and heterooligomers if different proteins are involved, respectively266.
Throughout this thesis, I will use the term protein interaction to refer to both,
binary PPIs (homo- and heterodimers) as well as protein complexes (homo- and
heterooligomers). The similarly looking term protein-protein interaction, in con-
trast, will only be used when referring to binary interactions involving exactly two
interactors, thus excluding protein complexes.
Domains and motifs Most proteins are modular and are composed of subunits
like protein domains or short linear motifs258,292. A protein domain is commonly
defined as a unit comprising at least 30 amino acids that can fold stable and in-
dependent of the rest of the protein. Oher definitions also include the functional
and evolutionary role of protein domains44,253,292. Short linear motifs (SLMs) are
smaller units, usually consisting of only three to ten amino acids, that do not form
independent structures and are usually found in disordered, unstructured regions of
a protein258,263. By increasing the level of analysis detail, protein interactions can
often be traced to underlying interactions between protein domains (domain-domain
interaction (DDI)116,287,307,358) or to short linear motifs that bind to the domain or
other parts of a protein (domain-motif interaction2,258,260). With respect to the in-
teraction lifetime, one can distinguish transient interactions and stable or permanent
interactions. For example, interactions mediated by DDIs are more stable compared
to transient domain-motif interactions21.
Ligands Non-protein interactors will in the following be named ligands, the inter-
action between a protein and such a molecule consequently protein-ligand interaction
(see Figure 2.1). Ligands may refer to molecules of different types, ranging from large
macromolecules such as nucleic acids (protein-DNA interaction 89 and protein-RNA
interaction 201) to small compounds like drugs or hormones431. Examples for such
protein-ligand interactions are the muscular transport protein myoglobin, which re-
versibly binds an oxygen molecule189, or the interactions of transcription factors,
proteins that bind to specific DNA sequences and thereby regulate genomic infor-
mation flow112. The region within the protein that is binding to the ligand is named
ligand-binding site240. In enzymes, these regions are termed active sites and the
ligands that bind to these sites are called substrates292.
Associations All the molecular interaction types described thus far are examples of
physical or direct interactions that imply an actual contact between the interacting
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entities, for example, the binding of protein interfaces. The molecular basis for these
interactions are the formation and dissociation of non-covalent atomic interactions
like hydrogen bonds, van der Waals, or electrostatic interactions292. In contrast,
non-physical interactions or associations describe functional relationships between
molecules but do not imply a physical contact. Two proteins may be associated if
they are mentioned in the same sentence of a scientific publication or if they are co-
expressed in the same cellular condition or compartment243. Genetic interactions,
such as synthetic lethality, where mutations in two genes produce a combined effect
that is unexpected considering the individual mutational effects, are another example
for such non-physical associations232. It is obvious that physical interactions and
functional associations are fundamentally different and should not be unintentionally
mixed in analyses.
Interactome and interactomics In our current age of ”-ome”and ”-omics”terms212,
it is not surprising that there is a catchy name for the complete set of all molec-
ular interactions that may occur within a cell: the interactome 335. Consequently,
the research area that deals with molecular interactions is named interactomics 196.
The determination of the complete human interactome has always been an impor-
tant research aim in systems biology78,391. Estimates about the size of the human
interactome are diverse, ranging from 130 000 to 650 000 PPIs125,148,285,355,363,388,396.
As of December 2013, the integrative interaction database mentha58 provides about
140 000 binary human PPIs (see Figure 2.2). However, a significant number of those
interactions are likely to be false positives, that is, interactions that are wrong-
fully reported by a single experiment or publication and cannot be reproduced. In
fact,Venkatesan et al. estimated in 2009 that only about 9 percent of the complete
human interactome was known at the time388.
The singular term interactome and ”hairball” representations like in Figure 2.2,
may lead to the wrong impression that there is only one static set of interactions.
However, the interactome is highly dynamic, both in terms of time and space305.
Certain interactions may or may not occur under particular circumstances, for in-
stance, when the cell is under stress. As proteins elicit their functions through
interactions with other proteins101, it is obvious that interactions do not constantly
or randomly occur, but only when a particular cellular function is mediated. In
addition, not all interactions that could in theory take place, for instance, because
two proteins have complementary, energetically favorable binding sites, can also take
place in the living cell. In order to interact with each another, proteins need to be
expressed at the same time and in the same cellular components, cells, tissues, or
organs226. While the dynamic nature of the interactome is well accepted, the fact is
still not adequately represented by predominant experimental detection techniques,
databases, or analysis software305,345.
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Figure 2.2: Network representation of the currently known human interactome. Nodes
indicate proteins, edges depict binary PPIs. Protein complex data are not included. The
network, retrieved from mentha58 on 11 December 2013, consists of 14 650 proteins and
143 947 interactions. Visualization was done in Cytoscape 3.0.2 using a force-directed
layout and a color gradient which places nodes with a higher degree (many interactions,
colored in red) towards the center of the ”hairball”, whereas nodes with fewer interac-
tions (green) are located towards the borders. The vast majority of nodes are in a large
connected component.
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2.2 Determination techniques
This section provides a brief description of the most important methods for deter-
mining potential molecular interactions. In general, the approaches for interactome
mapping can be classified into experimental (in vivo and in vitro) and computational
(in silico) techniques.
2.2.1 Experimental detection
Interactions between proteins have been analyzed experimentally even before the
concepts of proteins, let alone their interactions, were clearly established48. The
traditional way, in line with the reductionist approach of classical biology318, was to
study one molecule at a time. Today, a great number of experimental approaches ex-
ist for determining protein and molecular interactions on different scales45,348. The
separation into small-scale or low-throughput and large-scale or high-throughput
techniques is not always feasible, as some technologies may be used for a detailed
characterization of individual protein interactions, but also for high-throughput
studies414. In addition, technological progress can scale up the throughput of a
method significantly, moving it from low- to high-throughput114. Modern high-
throughput techniques allow for screening complete proteomes of organisms in par-
allel392. In the following, I will describe the two most widely used technologies for
experimental interaction detection in a high-throughput fashion.
Yeast-two hybrid (Y2H) Yeast-two hybrid is a genetic system that has been devel-
oped more than 20 years ago for the detection of binary PPIs. Y2H takes advantage
of some properties of the GAL4 system in yeast115. GAL4 is a transcription factor
that is composed of two domains, a binding domain (BD) that binds to an enhancer
named upstream activation sequence (UAS), and an activation domain (AD) con-
taining acidic regions that are necessary to activate transcription of a downstream
reporter gene115. By splitting these domains and fusing them to two different pro-
teins (the protein fused to the binding domain is called prey , the protein fused to the
activation domain bait), a physical protein-protein interaction can be detected, as
transcription of the reporter gene will only take place if the two domains are brought
into proximity. The individual domains will not activate transcription. Y2H started
as a system for studying single PPIs114, but through continuous developments has
evolved to a versatile platform that has successfully been used in a number of high-
throughput studies in various organisms120,136,171,219,308,327,360,382.
Affinity purification (AP) Affinity purification is a technique that uses specific tags
to detect and ”pull out” assemblies of proteins or other molecules. In the tandem
affinity purification (TAP) protocol, TAP tags are fused to a target or bait protein.
The tagged bait is introduced into a host cell where the protein may interact with
2.2 Determination techniques 11
other prey proteins under physiological conditions324 (see Figure 2.3). Through a
two-step purification process, the tagged protein and all molecules attached to it are
then extracted, for example, from a lysed cell. The individual proteins that have
been pulled out are then identified via mass spectrometry (MS). TAP-MS has been
developed as a high-throughput technology, which has since been used in a number
of large-scale studies56,129,130,204. While the composition of protein complexes can
be determined by TAP-MS experiments, their exact structures remains unclear and
computational methods are needed to infer pairwise physical protein interactions
within these complexes339. In order to represent n-ary protein complexes as binary
PPIs, a number of complex expansion models have been proposed (see Section 2.5.4).
While the majority of large-scale interaction maps is determined using Y2H or
TAP-MS, a number of additional technologies with lower throughput are commonly
used for validation purposes388, including luminescence-based mammalian interac-
tome mapping (LUMIER25), mammalian protein-protein interaction trap (MAP-
PIT111) or fluorescence or Fo¨rster resonance energy transfer (FRET414). It is im-
portant to know that each of the experimental techniques by design has certain
strengths and weaknesses. For example, Y2H is capable of detecting interactions
with very low affinities, while AP-MS requires a stronger binding between the pro-
teins, as weaker links might be removed in the purifications process200. Generally,
false positive and false negative interactions will occur with every technology49,230.
Wherever feasible, interactions are ideally experimentally determined using a variety
of different approaches388.
2.2.2 Computational prediction
The experimental detection of molecular interactions is time-, work-, and cost-
intensive, despite the establishment of high-throughput techniques like Y2H and
TAP-MS388. As large parts of the human interactome still remain to be deter-
mined148,363, a variety of computational methods have been proposed in order to
predict potential interactions in the uncharted regions200. These in silico approaches
will not replace experimental detection, which remains the only way of detecting
true positive interactions. However, they might be used to narrow down the search
space, complement experimental results, or even spot potential errors in experimen-
tal data403.
A popular in silico approach is to predict interactions based on different types
of homology. In interolog mapping, an interaction is inferred between species via
sequence homology, based on the assumption that if an interaction between two
proteins A and B has been found in one species, most commonly a well-studied
model organism like yeast or fly, and homologous proteins A* and B* exist in
another species, for example, human, an interaction between A* and B* may be
inferred51,128,237,419. Homology is also used on a structural level for predicting in-
teractions between proteins that have binding interfaces similar to those found in
known interactions7,194,211,403,427. Additional methodologies employ genomic or se-
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quence features62,107,179,234, orthology166,172, phylogenetic profiles289 or combinations
thereof31,109,386,426. Computational text mining is also considered as a prediction
technique197,200. A comprehensive description of the different prediction algorithms
is provided in numerous reviews45,225,294,349,384.
2.3 Interaction databases
Interaction databases are resources that try to collect all the interaction data that
are or have been produced in research laboratories around the world and make them
available to the research community. The first dedicated public databases for human
interaction data, among them the Database of Interacting Proteins (DIP)234,411 and
the Biomolecular Interaction Network Database (BIND)17,19, appeared at the end
of the 1990s, in a time where the first large-scale protein interaction screens have
been published410. With the ever-growing attention in the research community, the
number of available resources has since kept increasing. As of 2013, the pathway
and interaction repository Pathguide18 lists well over 100 resourcesa that, at least
partly, provide interaction data. In practical terms, this number will be slightly
smaller, as not all of these resources are still actively maintained and some are
highly specialized, including those that list ”proteins that interact with GroEL and
factors that affect their release” (GroEL PPI, no longer available) or the ”database
of human GPCRs, G-proteins, Effectors and their interactions” (Human-gpDB336).
2.3.1 Primary interaction databases
BIND5 and DIP333 are examples of primary interaction databases, other popu-
lar examples are BioGRID64, the Human Protein Reference Database (HPRD138),
IntAct190, or the Molecular Interaction Database (MINT220). The term ”primary”
indicates that these are the first line between the raw interaction data and the user,
in contrast to aggregate resources that pool together data from other databases
(see Section 2.3.2). Many of the primary interaction databases have originally not
been established with the aim of becoming general repositories, but have resulted
from small, focused studies270. As a consequence, several of the primary resources
listed in Pathguide, like the aforementioned GroEL PPI, BIND, or the microbial
protein interaction database (MPIDB140), are no longer actively maintained170,270.
A number of primary databases, however, have existed for more than a decade and
have established themselves as important pillars for interactomics, among them DIP,
IntAct and MINT, which have recently joined forces in the MIntAct project270.
Direct data submission Primary interaction databases generally have two ways to
acquire new data. First, they receive interaction data as direct submissions from
awww.pathguide.org/
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experimentalists274,279. Inspired by the microarray, sequencing, and protein struc-
ture fields, where it was agreed by major journals that only such manuscripts are
published, where the referenced entities have been stored in a publicly accessible
database before publication, a similar system has recently been established in the
field of interactomics98. Currently, however, not many journals are participating
in this initiative. In addition, guidelines named minimum information required for
reporting a molecular interaction experiment (MIMIx) have been developed to help
experimentalists in providing the primary databases with all the information neces-
sary for describing a molecular interaction in detail279,281. Direct data submission
is more common for dedicated interactome studies, for instance, large-scale Y2H or
TAP-MS screens that yield hundreds of interactions and is promoted by journals
that commonly receive such datasets61.
Text mining and data curation Very often, however, interaction studies between
proteins are only performed as means of testing a certain biological hypothesis.
For example, in order to characterize the molecular role of the human protein kinase
phosphatidylinositol-4 kinase III alpha (PI4KIIIα) in hepatitis C virus (HCV) infec-
tions (see Section 5.3.1), Reiss et al. 321 have used a small-scale co-immunoprecipitation
experiment to test for interactions between PI4KIIIα and all HCV proteins. The
two interactions they found between PI4KIIIα and the viral proteins NSA5A and
NSA5B were consequently described in the publication and illustrated in the cor-
responding figures321. However, they were not directly submitted to any of the
primary interaction databases.
Therefore, another way of incorporating interaction data is by mining the scientific
literature, an invaluable resource where interactions have been described as parts
of experiments for decades, if not centuries48. However, the incredibly large body
of text makes this an enormous challenge. The MEDLINE/PubMed databaseb, for
example, currently contains more than 20 million entries spanning more than two
centuries.
Computational text mining In general, current text-mining approaches can be di-
vided into manual and computational techniques. Computational text-mining tries
to automatically detect biological entities and relationships between them, for in-
stance, using natural language processing316. This is a very powerful technique that
enables the analysis of huge bodies of text, like the complete PubMed database.
Without going into the details, the challenges of text mining can be nicely illus-
trated by the aforementioned interaction between PI4KIIIα and the HCV proteins,
which was described in the sentence: ”We found that NS5A and NS5B, but not the
NS3/4A protease/helicase or NS4B, interacted with the kinase.”321. For a human,
this sentence is not overly complicated, but computational algorithms are faced with
bhttp://www.ncbi.nlm.nih.gov/pubmed
14 2 Basics of molecular interactions
several potential pitfalls. First, NS3 and the other viral proteins need to be iden-
tified as HCV proteins, not as proteins of the same name from Dengue or other
viruses. Second, PI4KIIIα is not clearly described by a name, database identifier,
or accession number, but only described as ”the kinase”. Third, the two interactions
that have explicitly been identified as not taking place might be mistaken for true
interactions if the ”not” keyword is not appropriately considered.
While the number of false positive and false negative interactions may be signif-
icant, several approaches utilize computational text mining for detecting molecular
interactions in the scientific literature155,177,197,310.
Manual text mining Fully automated computational text-mining is currently not
considered a technique for identifying experimentally determined interactions but
is seen as a form of computational prediction200. Primary interaction databases,
in contrast, use a manual text-mining approach13. Curators are employed to read
scientific articles and extract detailed interaction records. During peak times, for
example, the Biomolecular Interaction Network Database (BIND) employed 40 cu-
rators170. Compared to automatic text mining, manual curation has a significantly
lower throughput but a much higher accuracy332. In addition, the interaction records
can be far more detailed, as the curator comprehends the complete article and can
thus detect parts that describe experimental conditions, cell lines, study systems,
or protein modification. In the PI4KIIIα example, another sentence described the
experimental conditions: ”Individual HCV proteins were therefore coexpressed with
HA-tagged PI4KIIIα in Huh7-Lunet/T7 cells, and coimmunoprecipitation experi-
ments were performed with monospecific antisera”321.
IMEx consortium Particularly noteworthy in this regard is the IMEx consortiumc,
which has formed to coordinate and improve the cooperation between primary in-
teraction databases278. Before forming the IMEx consortium, the databases did
not coordinate their text-mining endeavors, with the result that identical publica-
tions were potentially curated multiple times in different databases. As each of
the databases used other curation standards, the same interactions could even be
reported in different ways270.
In contrast, the participating IMEx databases have now agreed on common stan-
dards and procedures for curating interaction data. As a result, an interaction record
in DIP should now contain the same level of information as an interaction record in
MINT, as both follow IMEx curation guidelines. In addition, IMEx databases have
assigned responsibilities for certain journals to each contributing database, prevent-
ing re-curation of the same article by different databases. In order to harmonize the
data that are contained in the databases, the consortium has furthermore agreed on
exchanging data on a regular basis278. Recently, several IMEx databases including
IntAct and MINT have even gone further and decided on a common computational
chttp://www.imexconsortium.org/
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platform that is directly filled by curators from the different projects, reducing po-
tential redundancies to a minimum270. As of December 2013, eleven databases are
participating in the IMEx consortium.
Despite the joint efforts, coverage will still remain an issue for the majority of
organisms. While BioGRID claims to have reached complete coverage of the inter-
action literature for yeast64, the protein interactions of PI4KIIIα described by Reiss
et al. 321, which I have used in several examples, are not yet available in any inter-
action database.
2.3.2 Aggregate databases
Primary interaction databases are essential components of interactomics, as they
provide the most recent interaction data with the highest level of detail92,199. How-
ever, manual curation of the scientific literature is time-intensive and the majority of
these resources restrict their focus to experimentally determined interactions277. De-
spite harmonization approaches like the aforementioned IMEx consortium, the cover-
age of a single interaction database is still remarkably low and each of the databases
contains unique information that is not found in the other resources236,313,381.
Aggregate databases try to improve this situation by merging interaction data
from various primary resources into a single repository. A significant number of
the resources listed in Pathguide are aggregate database. Examples for protein
interactions are the Agile Protein Interaction DataAnalyzer (APID298), HINT82,
HitPredict284, iRefIndex315, mentha58, Michigan Molecular Interactions (MiMI180),
the Protein Interaction Network Analysis (PINA) platform77, the Search Tool for
the Retrieval of Interacting Genes (STRING369), or the Unified Human Interac-
tome (UniHI67). Aggregate databases that focus on domain-domain interactions
include the Domain Interaction Map (DIMA227) or DOMINE307. Several resources
like iRefIndex, STRING, or DOMINE combine computational predictions with ex-
perimentally determined interactions, while resources like UniHI or MiMI focus on
experimental data. Compared to the source interaction entries, the records stored
in aggregate databases usually do not maintain the same level of detail.
An important characteristic of almost all aggregate databases is that they perform
a static unification of the interaction data into central repository346. That is, these
databases represent a snapshot of the interactome at a certain point of time. Further
efforts and short update cycles are required to assure that the data are kept in sync
with the primary databases, as these are usually constantly evolving58.
2.4 Interaction data quality
Data quality has been recognized as an important issue in the field of interactomics,
ever since the first large-scale studies have been published. In particular, the low
overlap between studies that had been performed independently in the same organ-
16 2 Basics of molecular interactions
ism and with the same experimental technique raised questions about interaction
data reliability86,171,382,396. In the years since, a lively debate has formed in the
scientific community about the reliability of certain experimental procedures230,388
or literature curation80,332, which has even led to general prejudices and premature
conclusions133. Due to the great importance of data quality, this subject is described
in more detail in Chapter 4.
2.5 Interaction data formats and standards
The scientific literature is the traditional way of reporting the results of interaction
experiments48. As I have shown in the Reiss et al. 321 example (see Section 2.3.1),
information is either textually described or placed in tables or figures. With the
emergence of high-throughput screening, which can result in hundreds or thousands
of reported interactions, this information was increasingly moved to dedicated text
files or tables. In addition, the information is collected and made available by
interaction databases. Until a few year ago, each of the files, tables, or databases
used different specifics to represent the data153. As a consequence, researchers had
to constantly adapt to new presentation standards and develop dedicated parsers
when using interaction data from various sources in their work.
2.5.1 HUPO-PSI-MI
In 2001, the Human Proteome Organization (HUPO) was established as an interna-
tional collaboration to facilitate proteomics research145. Within this organization,
the Proteomics Standards Initiative (PSI) was formed with the aim of developing
and promoting community standards for the representation and exchange of pro-
teomics data152,275. One of the standards that was developed under its guidance is
the Molecular Interactions (MI) standard, which was published by a consortium of
the major interaction data providers and primary databases in 2004153. Version 1.0
of the PSI-MI standard consists of an Extensible Markup Language (XML) format
definition (see Section 2.5.2) and a controlled vocabulary. The initial adaption was
diverse, while databases that were involved in designing the standard, such as In-
tAct, DIP, or MINT, offered data in this format, smaller databases did not support
the format for some time362. In addition, the standard was often interpreted dif-
ferently by the various databases, with the result that PSI-MI files from different
databases were not fully compatible37,315. One factor that contributed to this situa-
tion, and thereby had a large influence on the design of our Distributed Annotation
System for Molecular Interactions (see Section 3.2), was the unavailability of official
software tools for creating or parsing standard-compliant documents within the first
years after publication. Given the complexity of the XML document definition, for
example, the XML schema definition comprises more than 1000 linesd, and the con-
dhttp://psidev.sourceforge.net/molecular_interactions//rel25/src/MIF25.xsd
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stantly evolving nature of the MI controlled vocabulary, this initially hampered the
usability of PSI-MI.
The PSI-MI standard was developed and released in an incremental approach.
While the initial version was only designed for protein interactions, the successor
version, HUPO-PSI-MI 2.5e, extended the scope to molecular interactions in gen-
eral, also covering protein-ligand interactions or nested protein complexes191,271. The
transition phase from PSI-MI 1.0 to version 2.5 spanned over several years, as ini-
tially few tools supported the new format37. Fortunately, as of 2013, PSI-MI 2.5 is
the widely accepted standard for the representation of molecular interactions.
Arguably a contributing factor for today’s wide acceptance was the adaptation
of a less complex way for representing interaction data. While PSI-MI XML files
allow for a very detailed characterization of experimentally determined molecular
interactions, they can hardly be created or parsed without adequate tools. PSI-MI
2.5 now also defines a more lightweight data standard named MITAB2.5, a tab-
delimited plain text file format. In the following sections, I will briefly describe the
two key components of PSI-MI 2.5, namely, the XML format description and the
MITAB format.
2.5.2 PSI-MI 2.5 XML format
Markup languages like XML or the Hyper Text Markup Language (HTML) define
document formats that are readable for both humans and computers. While HTML
is primarily used to describe the structure of internet websites, XML may represent
almost arbitrary data. The structure of an XML documents which is composed
of nestable elements with optional attributes and content, is defined by an XML
schema (see Section 3.1.2.2). Compared to plain text formats, a great benefit of
XML documents is that using such XML schemas, it is possible to validate the
content of a document and its elements.
Main elements The PSI-MI 2.5 XML document format is built around three main
entities191: interactor, experimentDescription, and interaction. An inter-
actor defines the interacting entities, for example, genes, proteins, protein domains,
or small molecules. The purpose of this element is not a detailed description of
the entity, rather a unique identification via its protein sequence or references to
external databases like UniProt375, RefSeq, or Entrez Gene406.
An interactor element is linked to interactions via its role as a participant.
This way, a once-defined interactor can take part in multiple interactions via differ-
ent biological or experimental roles, for instance, as bait or as prey in a TAP-MS
experiment. The interaction element may also contain further information on the
interaction itself, including its type or confidence scores.
eVersion 2.5 directly followed version 1.0, no version 2.0 was officially available.
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The interaction element not only links to interactors, but also to experi-
mentDescriptions that specify how an interaction has been determined by providing
details on the experimental procedures, detection methods, or protein modifications.
As all these elements may occur multiple times, for example, several interactors par-
ticipate in an interaction that is confirmed by various experiments, they are listed
within container elements named interactorList, experimentList, and inter-
actionList, respectively.
While the aforementioned elements are the most important entities of the PSI-
MI XML format, there is a multitude of additional elements, which can be used
within different contexts to describe aspects like the host organism, details on the
level of data curation, or the availability of interaction data. A full description of
the XML definition can be found on the PSI-MI websitef, a valid PSI-MI 2.5 XML
document describing the binary interaction between two proteins can be found in
the Appendix.
Compact and expanded form PSI-MI XML documents may exist in two inter-
changeable formats. In the compact form, interactors and experimentDescrip-
tions are defined once in the respective interactorLists and experimentLists in
the beginning of a document. Later occurrences of these elements in an interaction
are cross-referenced using their id attributes.
In the expanded form, interactorList and experimentList are not defined in
the beginning of the PSI-MI document. Instead, each interactor and experiment-
Description is completely defined within the respective interaction element. This
expanded form has the advantage that each interaction element is self-contained,
that is, includes all the relevant information without cross-referencing to other parts
of the document. This improves document handling, in particular for humans, as
jumps within potentially large files are prevented. The downside of this verbosity
is an increased file size, as additional markup is required and potentially identical
information is repeated multiple times. Both representations are interchangeable
and there are tools that allow transforming one representation into the other. The
exemplary PSI-MI XML document listed in the Appendix has been downloaded
from IntAct in the standard compact form.
2.5.3 MITAB format
MITAB has been defined as a simplified alternative to PSI-MI XML in PSI-MI
version 2.5191. The MITAB format was a response to the growing demand within the
scientific community for a more lightweight data standard that focuses on reduced
file size and, due to less complexity, ease of use. MITAB files are tab-delimited plain
text files, each line describes an interaction. The format is based on the BioGRID
TAB formats356 and defines the following fifteen mandatory columns:
fhttp://www.psidev.info/mif
2.5 Interaction data formats and standards 19
1. Identifier interactor A
2. Identifier interactor B
3. Alternative identifier interactor A
4. Alternative identifier interactor B
5. Alias interactor A
6. Alias interactor B
7. Interaction detection method
8. First author of the publication that first showed the interaction
9. Identifier of the publication
10. NCBI Taxonomy identifier interactor A
11. NCBI Taxonomy identifier interactor B
12. Interaction type
13. Source database
14. Interaction identifier in source database
15. Confidence score
Each column may contain multiple values, which are separated by a vertical dash
(”|”). If a column has no entry, this is indicated by a horizontal dash (”-”). Soon after
the MITAB format had been released, different databases like IntAct or iRefIndex
started to extend it with additional columns to describe data that were not covered
in the initial specification. On the basis of the initial MITAB version and these
custom extensions, two official format updates have been defined as MITAB2.6273
and MITAB2.7271. MITAB2.6g extends the 15 columns of MITAB2.5 with 19 ad-
ditional columns. Among the new columns are descriptions of the experimental
and biological roles of the interactors, further external references, taxonomical in-
formation of the experimental systems, dates when an interaction record has been
created or updated, and checksums that can be used to verify the correctness of
the interactors. On the basis of this extension, MITAB2.7h has been released re-
cently, now defining 42 columns in total. The six new columns in this release can be
used to describe general interaction features like binding sites or post-translational
modifications, stoichiometry, and participant identification methods for both inter-
actors. MITAB2.7 allows the representation of binary interaction records according
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2.5.4 Binary representation of protein complexes
From the MITAB definitions above, it can be seen that the standard was designed
for binary interactions that involve one pair of interactors. Protein complexes can-
not be represented without different ways of representing the data, as a complex
assembly of multiple proteins cannot be split into an interactor A and interactor B.
Consequently, different models have been proposed to represent or expand protein
complexes in a binary fashion. The three approaches most commonly used are ma-
trix, spoke, and bipartite expansion (see Figure 2.3). In MITAB2.6 and MITAB2.7,
the sixteenth column can be used to indicate that a binary entry resulted from a
complex expansion.
Figure 2.3: Binary representations of protein complexes. a) Real complex, exemplarily
illustrated with a tagged bait and three preys. Node contacts indicate four binary protein-
protein interactions (Bait - Prey A, Bait - Prey B, Prey A - Prey B, Prey B - Prey C).
b) Bipartite representation, resulting in four virtual binary interactions (blue). c)
Spoke expansion, resulting in two true positive interactions (green), one false positive
(red), and two false negatives (Prey A - Prey B, Prey B - Prey C). d) Matrix expansion,
resulting in four true positive binary interactions (green) and two false positives (red).
2.5.4.1 Matrix expansion
In a matrix expansion, each protein within a complex is assumed to be interacting
with all other proteins apart from itself. The exemplary complex in Figure 2.3,
assembled by four proteins, would be represented by six binary interactions. This
expansion does not make any assumptions about the actual structure of the complex
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and disregards information about baits or preys. Consequently, the number of false
negative interactions is zero. However, a number of false positive interactions will
be predicted, as not all proposed interactions could take place at the same time in
the actual complex106.
2.5.4.2 Spoke expansion
The spoke expansion of a protein complex is centered on a bait protein, which is used
to (virtually) pull out multiple preys. The exemplary protein complex in Figure 2.3,
composed of four proteins, would be represented by three binary interactions. Com-
pared to matrix expansion, spoke expansion has a higher number of false negatives,
as only interactions between baits and preys are considered and interactions be-
tween baits are ignored. The number of false positive and false negative interactions
depends on the selected bait. In the illustrated example, choosing ”Bait” as the cen-
tral spoke protein would yield two false negative and one false positive interaction,
while selecting ”Prey B” as the bait for the spoke expansion would result in one false
negative and no false positive interactions.
2.5.4.3 Bipartite representation
Bipartite representation is not an actual complex expansion model, as no real binary
protein interactions are deduced. In a bipartite representation, one of the binary
interactors is used to represent the complex itself, while the other interactor is used
to represent each protein of the complex. The exemplary protein complex in Fig-
ure 2.3 would be represented by four binary membership representations. Bipartite
representation is used by the aggregate database iRefIndex to prevent the accidental
confusion of real binary interactions with expanded complexes in MITAB files315.

3 Data decentralization in inter-
actomics
This chapter presents methods that we have developed to simplify the process of
working with molecular interaction data, in particular with respect to data accessi-
bility and exchange. Section 3.1, will introduce the Distributed Annotation System
(DAS), a decentralized client-server system for genomic and proteomic sequence an-
notation. This system is the basis for our extension, named DAS for Molecular
Interactions (DASMI), which I will described in detail in Section 3.2. While DASMI
has been the first distributed system for molecular interactions, today it is largely
superseded by a successor named Proteomics Standards Initiative Common Query
Interface that I will briefly describe in Section 3.3. I will end the chapter in Sec-
tion 3.4 with summarizing remarks and an outlook on potential future developments.
3.1 Introducing the Distributed Annotation Sys-
tem
Chapter 2 highlighted the great importance of molecular interactions for under-
standing biological and cellular processes and described the resulting growth in the
amount of available interaction data. However, it also described, how these data
are scattered over a multitude of online repositories, with each providing different
means for data access359.
A similar situation existed in the field of genomic sequence annotation around
the year 2000, when breakthroughs in sequencing technologies and the competitions
for the first sequenced genomes, most notably the one between the International
Human Genome Sequencing Consortium and Celera Genomics209,389, led to a sub-
stantial increase in available sequence data. In fact, more raw genomic data were
produced than the central repositories like GenBank or EMBL could annotate94. As
a consequence, third parties needed to step in and take over parts of the annotation,
for instance, by predicting the position of genes or by computing general sequence
features104. This, however, lead to a fragmentation of annotations, which were no
longer present in the centralized resources, but spread over a multitude of online
repositories and databases.
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Dowell et al. developed the Distributed Annotation System (DAS) as one poten-
tial solution to overcome this fragmentation94. The basic idea of DAS is to replace
centralized repositories with distributed storage systems. DAS refers to two things,
the general architecture of servers and clients, illustrating the idea of data federa-
tion (see Section 3.1.1), and the actual data exchange protocol, which defines the
communication between the individual DAS components (see Section 3.1.2). While
the DAS architecture is more or less static and has not changed much since its first
publication, the DAS protocol is constantly evolving in response to the different
demands from the scientific community (see Table 3.1).
As we selected DAS as the basis for our proposal to the challenge of data distribu-
tion in interactomics (see Section 3.2), I will describe the individual DAS components
in the following sections.
Table 3.1: Versions of the Distributed Annotation System (DAS). The table lists the
name, specification URL and if present the year and publication. Versions ending with an
E are unofficial protocol versions that bundle extensions.








DAS is designed as a client-server system, where servers provide different types of
biological information that clients integrate and visualize for the end user. DAS
distinguishes two types of servers. Reference servers (SR) provide the biological
reference, commonly a nucleotide or protein sequence. Annotation servers (SA)
make additional information available, which can be related to the reference entity,
for example, the position of exons, introns, or protein domains.
In the most basic form, DAS can be classified as a CSRS
+
A system, indicating that
one client (C) visualizes the reference entity provided by a single reference server
along with annotations from at least one annotation server. In modern practice,
DAS clients may embed other clients that incorporate a different reference entity,
for instance, the DAS-based Ensembl genome browser that incorporates a protein
structure view301.
The distinction between reference and annotation server does not have to be
physical. Depending on the query type, a single DAS server instance can act as
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both, reference and annotation server. In the DAS terminology, there is a further
distinction between DAS servers and sources. The term server is used for the actual
server instance, which is set up as a specific piece of software on a (physical or
virtual) server machine. Each dataset that is provided by such a server is referred
to as a source.
Figure 3.1: Schematic drawing of the client-server architecture of the Distributed Anno-
tation System (DAS)37,94. Reference servers provide the reference sequence, annotation
servers one to three make additional information available, which can be related to this
reference entity. A DAS client communicates with all servers it retrieves from the DAS
registry, unifies the individual results, and presents them to the user.
3.1.1.1 Reference server
Reference servers provide the biological entity that annotations are relating to. In the
initial DAS implementation, the reference was a nucleotide sequence, for instance,
a chromosome or a gene94. As DAS evolved, proteomics became a second large
domain, with the reference entity being the amino acid sequence of a protein267.
For those two areas, the reference sequence is usually curated and provided by
large consortia like Ensembl167 or UniProt12,375. In the context of the eFamily
project, Prlic´ et al. have extended the use of DAS beyond the sequence world, with
a DAS extension that uses protein structures as reference entities299–301. Within the
BioSapiens framework, DAS was further used for the exchange of proteomics data
in general, not limited to protein sequences and their annotations377. The biological
entity type, which a server is using, is specified with specific a coordinate system
(see Section 3.1.1.5).
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3.1.1.2 Annotation server
The majority of DAS servers are annotation servers, which provide different types
of information that can be related to the reference entity (see Figure 3.1). The
information is either positional, such as the coordinates of genes, protein domains,
introns, exons, signal peptides, or splice sites, or non-positional, such as links to
scientific publications or database identifiers. Like reference servers, annotation
servers are assigned to certain coordinate systems that specify the biological en-
tity their annotations are relating to, for instance, genes, proteins, or chromosomes
(see Section 3.1.1.5).
In the early days of DAS, there was little regulation of the annotation features that
a server provided, that is, features were described in free text, with a few proposals
listed in the official specification94. While this promoted a rapid adaptation of
DAS, as setting up servers and providing sequence features was straightforward, it
also limited the analyses capabilities, as automated exploration of the features was
hampered by the free text annotations, which were more targeted towards humans
than computers. In order to improve computational analysis of DAS annotations,
for instance, allowing a grouping of similar features, an ontology of feature types
has been developed within the BioSapiens framework181,317.
3.1.1.3 Client
One of the fundamental principles of DAS, is the separation of data, which are offered
by the two types of DAS servers, from their visualization that is performed by DAS
clients. As DAS has its origins in sequence annotation, most of the existing DAS
clients are genome or proteome browsers, tools that display sections of nucleotide
or amino acid sequences alongside user-selected feature tracks. These browsers do
not necessarily retrieve all their data from DAS servers, but combine DAS results
with other data sources, for instance, from centralized data warehouses167. Gener-
ally, available DAS clients can either be accessed through a website, such as En-
sembl167, Genome Maps242, Dalliance95, the CBS viewer267, MyKaryoView393, and
Dasty185,393, or run on local computers as stand-alone tools, such as the Integrated
Genome Browser (IGB)150, Spice300, and Jalview73. A feature almost all modern
DAS clients support, is the communication with the DAS registry in order to deter-
mine the available DAS sources and allow the user to select the desired ones.
3.1.1.4 Registry
In the original implementation, DAS did not include a component for keeping track
of the, initially few, available servers and sources. As a result, in order to incorpo-
rate a DAS source, clients or their human end users needed to know its URL. The
steady growth in both, the number of available DAS sources and their diversity in
terms of provided features, necessitated the development of a central repository that
maintains all these data in a format accessible for humans and DAS clients. The
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resulting service, named DAS registry, was developed at the Wellcome Trust Sanger
Institute by Prlic´ et al. 301. Service providers may register their DAS sources to make
them available to all DAS clients that communicate with the registry. In addition,
the registry constantly checks the availability of every server and tests their con-
formity with the DAS specification. As of November 2013, the DAS registrya lists
more than 1 500 DAS sources from 18 different countries.
3.1.1.5 Coordinate system
Coordinate systems define the biological entities that DAS sources are providing
or annotating, for example, human chromosomes, protein structures, or UniProt
proteins. Coordinate systems have been introduced into DAS with the appearance
of the DAS registry, as means for automatically classifying the available data301.
Each coordinate system is composed of an authority (the responsible institution, for
example, NCBI, Ensembl, or UniProt), an optional version, an optional organism
taxonomy identifier, and a type (for example, protein sequence, chromosome, or
protein structure). Further, it is identified via a unique Uniform Resource Identifier
(URI), currently based on the Uniform Resource Locator (URL) of the DAS registry.
Two coordinate systems, one based on NCBI Human genome assembly 36 and one
based on UniProt sequences, are shown in the XML document in Listing 3.1. All
coordinated systems known to the DAS registry, 791 as of November 2013, can be
requested via a specific URLb. 
1 <DASCOORDINATESYSTEM>
2 <COORDINATES uri="http://www.dasregistry.org/dasregistry/coordsys/CS_DS40"









Listing 3.1: XML representation of two DAS coordinate systems
3.1.2 DAS protocol
The DAS protocol defines the communication between DAS servers and clients. In
contrast to the general architecture (see Section 3.1.1), which, apart from the in-
troduction of a registry, remained more or less unchanged of the years, the DAS
protocol repeatedly evolved by introducing new application areas (see Table 3.1).
ahttp://www.dasregistry.org/
bhttp://www.dasregistry.org/das/coordinatesystem
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The initial protocol version 1.01 was tailored towards the annotation of nucleotide
sequences94. Version 1.53, released shortly after in 2002, brought improvements like
error handling. Importantly, it extended DAS for protein sequence annotation by
introducing sequence as a general alternative to the nucleotide-specific dna com-
mand (see Section 3.1.2.1). This version of DAS became increasingly popular and
was the standard for several years. As it was also the basis for our molecular inter-
action extension to the DAS system (see Section 3.2), all references to DAS in the
remainder of this chapter will refer to DAS1.53, unless otherwise stated.
The DAS protocol is deliberately simple. Requests have the form of Hypertext
Transfer Protocol (HTTP) Uniform Resource Locators (URLs), responses are XML
documents of limited complexity. The intention behind this was to maximize the
support in the biological community, by making the whole protocol human readable
and easily parseable94. The downside of this simplicity is limited expressiveness
and, due to the verbose XML response formatting, a potentially large overhead in
document size.
DAS/2 The fixation of DAS on verbose XML was one of the main reasons, why in
2004 work on DAS/2 started. In contrast to all 1.x versions, DAS/2 was not intended
to be backwards compatible. It was designed as a completely new protocol, with
the aim of making the whole system more powerful and flexible. However, after an
ambitious and promising start, backed by an National Institutes of Health (NIH)
grant from 2004 to 2006, work on DAS/2 has stagnated over the last years and there
is very little ongoing development. As of 2013, only the software suite GenoViz149
and the IGB client built upon it150 support DAS/2. Consequently, there is no
support in the DAS registry, and only a few server instances are currently available.
Extensions Especially in Europe, since the mid 2010th the driving force of DAS
development95,117,132,181,185,259,267,300,301,329,330,387, where most of the currently avail-
able DAS servers are hosted, there was a strong opposition towards a backward-
incompatible DAS version. The approach favored by the European DAS community
is to extract the parts from DAS/2 that could improve the overall usability and
incorporate them into the DAS standard in the form of extensions. This was pio-
neered with DAS1.53E181, an unofficial DAS version that combines DAS1.53 with
three DAS extensions, one of them being our molecular interaction extension that
is described in Section 3.2.
If extensions are well accepted by the community and are widely used, they may
be incorporated into a later version of the official DAS standard. This was shown
by DAS1.6, the latest official protocol specification, which was released in 2010.
In addition to general clarifications and cleanups, this version officially included
support for coordinate systems and the DAS registry. Since the release of DAS1.6,
there have been a number of additional extensions and proposals, such as write-back,
that is, the possibility to upload comments or changes from the client to the server,
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search, or authentication capabilities. These are bundled into an unofficial version
DAS1.6E. Table 3.2 lists all DAS requests and associated response formats of the
different official DAS version.
Table 3.2: DAS commands and associated XML response formats from the different
official DAS specifications (see also Table 3.1). Unofficial commands from the extended
specifications 1.53E and 1.6E are not listed. The commands dsn, dna, and link have been
deprecated in version 1.6. SA indicates that a command can be issued to an annotation







dna SR 1.01-1.53 DASDNA Nucleotide sequence of the
corresponding segment.
dsn SA, SR 1.01-1.53 DASDSN Available data sources
entry_points SR 1.01-1.6 DASEP Either entry points into a se-
quence (e.g. chromosomes)
or reference objects (e.g.
proteins)
features SA, SR 1.01-1.6 DASGFF Annotations for a reference
object
link SA, SR 1.01-1.53 - Additional human-readable
information on annotations,
e.g., a web page
sequence SR 1.53-1.6 DASSEQUENCE Nucleotide or protein se-
quence of the corresponding
segment
stylesheet SA, SR 1.01-1.6 DASSTYLE Server recommendations for
displaying annotations
structure SR 1.6 DASSTRUCTURE Three-dimensional struc-
tural coordinates
types SA, SR 1.01-1.6 DASTYPES Available annotation types
3.1.2.1 DAS requests
Requests to a DAS server are issued in the form of a Hypertext Transfer Protocol
(HTTP) Uniform Resource Locator (URL). These URLs have a specific format that
is composed of:
• a site-specific prefix (http://www.ebi.ac.uk/das-srv/uniprot/),
• the keyword das,
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• a data source name (uniprot),
• a DAS command (sequence),
• optional parameters, depending on the DAS command (segment=P09497:0,50).
Joined by the appropriate HTTP connectors, the above examplec would retrieve the
first 50 amino acids of the Clathrin light chain B protein (UniProt accession number
P09497) from the UniProt DAS server that is hosted at the European Bioinformatics
Institute (EBI). Table 3.2 lists all commands that are part of official DAS specifica-
tions, commands that are part of unofficial extensions like alignment301, volmap229,
or interaction (see Section 3.2.1.1) are not listed. Most DAS commands accept
additional parameters to further specify a query, for example, by selecting a certain
range or feature types. These parameters and some exemplary queries can be found
in the respective DAS specifications, which are listed in Table 3.1.
3.1.2.2 DAS response
A DAS server responds to a request with an XML document that is wrapped in
an HTTP envelope. Since DAS1.53, this envelope does not only contain standard
HTTP header information, but additional DAS status codes, which can be utilized
by DAS clients. Each of the DAS commands is associated with a server response
that is formatted according to a particular XML schema (see Table 3.2). Listing 3.2
shows the response to the aforementioned exemplary sequence request. As can
be seen, the response document is very simple, only consisting of a DASSEQUENCE
root element that contains one SEQUENCE element. This SEQUENCE element has the
attributes id, start, stop, version, and label and contains the actual amino acid
sequence in its main element content. 
1 <DASSEQUENCE>
2 <SEQUENCE id="P09497" start="1" stop="50" version="9484




Listing 3.2: Exemplary DASSEQUENCE XML document.
XML schema definition A great strength of XML and other markup languages is
that their structure can be defined via a schema. Thus allows testing documents for
their standard conformity and validity. There are various languages for defining an
XML schema; this section will only briefly introduce the three that are relevant for
DAS.
chttp://www.ebi.ac.uk/das-srv/uniprot/das/uniprot/sequence?segment=P09497:0,50
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Document Type Definitions (DTDs) are one of the oldest ways to specify markup
languages. While they allow for a very compact and simple definition, the limited
expressiveness, mostly due to the missing support for namespaces and other elements
than strings, were major reasons why two alternative schema languages have been
implemented around the year 2001.
XML Schema Definitions (XSDs) are the official recommendation of the World
Wide Web Consortium (W3C) for defining the content of XML documents, as such
they have the largest support in the community. The REgular LAnguage for XML
Next Generation (RELAX NG) is an alternative schema language that appeared
around the same time and has many similarities to XML Schema. Both languages
are themselves based on XML and can thus make use of namespace and complex
element types (see Listing 3.4 and Listing 3.5).
Unfortunately, there is a mixture of schema definitions in the different DAS ver-
sions. In the first versions, 1.01 and 1.53, all documents were defined via DTDs94.
The extensions to DAS1.53 were defined using XML Schema Definitions, leading to a
mixture of DTDs and XSDs in DAS1.53E181. DAS/2, the re-design of DAS1, based
their schemas on RELAX NG. DAS1.6, the latest official version, subsequently also
replaced their DTD schemas with RELAX NG specifications.
In order to compare the three schema definition languages, listings 3.3, 3.4, and
3.5 show the corresponding definitions of the DASSEQUENCE XML format, a valid
XML document is shown in Listing 3.2. The slight discrepancies between the three
schemas are due to the different DAS versions they are based on. For example, the
attribute molecule that is defined in the DTD was deprecated in DAS1.6 and a
new, optional label attribute was introduced. 
1 <!ELEMENT DASSEQUENCE (SEQUENCE+)>
2 <!ELEMENT SEQUENCE (#PCDATA)>
3 <!ATTLIST SEQUENCE id CDATA #REQUIRED>
4 <!ATTLIST SEQUENCE start CDATA #REQUIRED>
5 <!ATTLIST SEQUENCE stop CDATA #REQUIRED>
6 <!ATTLIST SEQUENCE version CDATA #REQUIRED>
7 <!ATTLIST SEQUENCE molecule CDATA #REQUIRED> 
Listing 3.3: DASSEQUENCE schema as Document Type Definition (DTD) 
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13 <xs:attribute name="id" use="required"/>
14 <xs:attribute name="start" use="required" type="xs:integer"/>
15 <xs:attribute name="stop" use="required" type="xs:integer"/>




Listing 3.4: DASSEQUENCE schema as XML Schema (XSD) 
1 <?xml version="1.0" encoding="UTF-8"?>








8 <attribute name="start"><data type="integer"/></attribute>












Listing 3.5: DASSEQUENCE schema as RELAX NG
3.1.2.3 Limitations of DAS
Since its publication in 2001, DAS has seen a substantial growth in popularity181. It
has been used as an architecture for proteome annotation within European projects
like BioSapiens and eFamily and is supported by major bioinformatics resources
like the Ensembl genome browser or the UniProt knowledge base192,299,317. As of
November 2013, there are more than 1 500 DAS sources from eighteen countries
registered in the DAS registry.
Despite this success, DAS still has a number of limitations, several of those have
already been discussed in my Diploma thesis six years ago37. Still amongst them is
the missing access control, as DAS does not specify any user authentication. Every-
body knowing the URL of a DAS source can access its content, which is problematic
especially with respect to personalized genomic data. Another weakness is the ab-
sence of a search functionally, that is, the ability to determine if a certain feature is
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present in a server, without retrieving all its content. The large footprint of a DAS
document, due to the use of verbose XML, and the lacking support for binary data,
limits the use of DAS for the annotation of next-generation sequencing data.
The DAS community has acknowledged many of the limitations. A particular
forum for discussions were the annual workshops at the EBI, which were held be-
tween 2008 to 2012. While there are proposals in DAS/2 and DAS1.6E for user
authentication and search functionality, no robust implementation is yet available.
3.2 DAS for Molecular Interactions
Chapter 2 described the reasons, why interaction data were being made available in
a multitude of online repositories, hampering easy access for researchers. One way
of trying to improve this situation was shown by aggregate interaction databases like
iRefIndex or STRING, which collect and combine data from a number of primary
resources (see Section 2.3.2). However, the static data integration performed by
those aggregate databases has several drawbacks, as it only provides a fixed snapshot
of a number of databases at a certain point of time. Aggregate resources can only
remain relevant for research if they ensure that their data is still more or less in sync
with the original sources, which are often continuously updated58. In addition, the
authority that hosts the aggregate resource usually performs the integration of data
centrally. As a result, the data cannot easily be changed or extended by the user,
for instance, with confidential results from in-house experiments.
When we started working on a different approach for interaction data aggregation
in 2006, our aim was to overcome the aforementioned shortcomings of the static
integration frameworks by adopting a decentralization strategy like it was shown
by the Distributed Annotation system (DAS, see Section 3.1). DAS comprises a
number of servers, providing the relevant data, and clients that integrate those
data into a unified view for the user. The standardized protocol, which clients and
servers use for communication, and the availability of server software, allows for easy
extensibility of the system. In contrast to aggregate databases, there is theoretically
no additional maintenance effort, as the data are kept with their original producers
and are therefore automatically up to date.
Our system, named DAS for Molecular Interactions (DASMI), consists of three
main components (see Figure 3.2):
1. the specification of a DAS extension for exchanging interaction data and ad-
ditional annotations,
2. DAS servers for providing interaction data using the extended DAS protocol,
3. DAS clients to unify and visualize the interaction data in a suitable way.
A prototype of DASMI has been defined during the course of my Diploma the-
sis37. Building on this prototype, the first official DASMI version was described in
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a dedicated publication40 and, together with other extensions to the DAS protocol,
in the DAS1.53E bundle181. The DASMIweb client (see Section 3.2.3.1) has further
been described separately as a gateway to interactome data41. In the following, I will
summarize the findings from these publications and introduce the different DASMI
components in detail.
Figure 3.2: Schematic drawing of the client-server architecture of the Distributed Anno-
tation System for Molecular Interactions (DASMI)40.
3.2.1 DAS protocol extension
Our DAS protocol extension defines, how molecular interaction data and additional
annotations are exchanged between servers and clients. At the project initiation in
2006, we faced the question, whether an extension to the DAS protocol, that is, the
definition of a new request command and associated response format, was actually
required, or if the data could also be transferred using the protocol that was already
in place.
Protocol overloading An example of protocol overloading was provided by the
DAS server that had been set up at the Max Planck Institute for Informatics (MPII)
as part of our contribution to the ENCODE protein complement annotation379. The
serverd used the normal features command for interaction requests. Consequently,
it overloaded the associated DASGFF response format in order to transfer protein
dThe server is no longer available as of November 2013
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interaction data (see Listing 3.6). Overloading here means that the METHOD element,
which, according to the DAS specification, should describe the method that has been
used for detecting a certain feature, was used to identify the interaction partner
of a query protein. Another proposal for DAS document overloading, provided
by Antony Quinn in a personal communication, was to use the TARGET element
to identify the interaction partner and use METHOD to describe the experimental
interaction detection technique.
Both approaches use XML elements in ways that are not according to the DAS
specification. This can easily lead to problems with DAS clients that strictly follow
the specification. In addition, the expressiveness of the overloaded documents is
rather limited, as all the information has to be fitted into the few elements of the
DASGFF format. Complex cases, like the interaction between two protein complexes
that are each assembled by various proteins, would only fit into such a schema using
a number of tricks. 
1 <SEGMENT id="RP4-696P19.1-002" start="1" stop="1" version="1.0">
2 <FEATURE id="Q5VU07:RP4-696P19.1-002/295189" label="RP4-696P19.1-002">














Listing 3.6: DASGFF feature representation of a binary protein-protein interaction
Protocol extension Faced with a similar question, Prlic´ et al. chose an alternative
approach, when searching for a way to utilize DAS for the exchange of protein
structures and their alignments. They developed two new DAS request commands,
alignment and structure, and the corresponding response formats DASALIGNMENT
and DASSTRUCTURE301. In addition, they developed the client software SPICE, as no
DAS client was capable of displaying protein structures300. Another extension to the
DAS protocol was proposed by Mac´ıas et al., who developed the volmap command
and a DAS client named PeppeR to distribute, annotate, and visualized volume
maps created with electron microscopy229. Compared to protocol overloading, the
design of a protocol extension has the benefit that it can be fully tailored towards
its designated use-case, maximizing the expressiveness of the format. Importantly,
an extension only affects DAS infrastructure that supports the extension, legacy
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infrastructure, which has been developed for classic DAS commands, can operate
unchanged.
The design of our molecular interaction extension was strongly influenced by the
extensions of Prlic´ et al. In close collaboration with its main author, Andreas Prlic´,
Robert Finn, and Andrew Jenkinson, all at the time working at the Wellcome Trust
Sanger Institute or the European Bioinformatics Institute, in Hinxton, UK, we de-
fined a new request command named interaction (see Section 3.2.1.1) and the
corresponding DASINT response format (see Section 3.2.1.2)181.
3.2.1.1 Request: DAS interaction command
Requests to a DASMI server are issued in the same form as to a standard DAS
server, as an HTTP URL (see Section 3.1.2.1). We defined the new command named
interaction, which accepts three additional parameters: interactor, detail, and
operation. The syntax of the interation command is shown in Listing 3.7. The







Listing 3.7: Syntax of the interaction DAS command
The interactor parameter represents an identifier of the query interactor. One or
several interactor parameters can be provided. If only one interactor parameter
is present, all available interaction partners of this interactor will be returned. The
optional operation parameter can be used for defining the response type if more
than one interactor parameter is provided. If operation is not provided or has the
value ”intersection”, the interaction partners that interact with all query interactors
will be returned. If operation has the value ”union”, the interactions for each of
the query interactors will be returned.
The detail parameter can be used to refine a query further. If the optional ref
parameter is used, it indicates that the detail, for example, an experimental role, is
linked to the interactor with the same ID. If ref is omitted, the detail, for example
a literature reference, is linked to the interaction. A detail can be described in a
short and a long form. The short form detail=property:A_PROPERTY will return all
interactions for which there is a certain property of the type A_PROPERTY, regardless
of what the value of this property is. The long form detail=property:A_PROPERTY,
value:A_VALUE will return all interactions for which a certain property of the type
A_PROPERTY is present and has a specific value (A_VALUE). Examples for the short
form are the retrieval of all interactions that contain a confidence score or a literature
reference, whereas the long form would retrieve only those interactions for which the
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confidence score or literature reference has a specific value.
Examples In the following exemplary queries, PREFIX represents the base URL
to a DAS server (e.g. http://dasmi.de/), followed by the keyword das, and DSN,
which indicates a particular data source name (e.g. intact).
• PREFIX/das/DSN/interaction?interactor=3406
Request all interactions for the interactor with the identifier 3406, in this case
representing an Entrez Gene ID.
• PREFIX/das/DSN/interaction?interactor=PF00121
&detail=property:confidenceScore
Request all interactions for the protein domain with the Pfam identifier PF00121,
which have an assigned confidence score, regardless of the value of that score.
• PREFIX/das/DSN/interaction?interactor=P52597
&interactor=P60010
Request all interactions that involve the proteins with the UniProt accession
numbers P52597 and P60010.
• PREFIX/das/DSN/interaction?interactor=P52597
&interactor=P60010&operation=UNION
Request interactions, in which either the interactors with the UniProt accession
numbers P52597 or P60010 are participating.
• PREFIX/das/DSN/interaction?interactor=P38330
&nteractor=P32324&interactor=P10591&interactor=P16140
Request protein complexes, in which the four proteins with the UniProt ac-
cession numbers P38330, P32324, P10591, and P16140 are participating.
• PREFXI/das/DSN/interaction?interactor=P38330
&detail=ref:P38330,property:experimentalRole,value:bait
Request all interactions, in which the interactor with the UniProt accession
number P38330 has the experimental role bait.
3.2.1.2 Response: DASINT XML format
This section defines the response to a DASMI request. Section 3.2.1 described, that
in order to prevent confusion and maximize the expressiveness, we decided against
overloading the existing DASGFF format.
Alternative formats Instead of developing a wholly new XML format, one option
would have been to wrap an existing HUPO-PSI-MI format within a DAS envelope.
When we started this project in 2006, PSI-MI XML was available in version 1.0153.
In Section 2.5.2, I have described PSI-MI XML as a very detailed and complex data
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format with numerous elements in a deeply branched hierarchy, hardly manageable
without adequate software tool support. This can also be seen in the exemplary
PSI-MI file listed in Appendix 1, which describes a single binary interaction using
more than 250 lines of XML code. PSI-MI XML and our data format DASINT can
thus be regarded as complementary approaches. PSI-MI XML is used to exchange
comprehensive and static interaction datasets between databases, whereas DASINT
is used to provide a fast and dynamic overview with entry points to other databases
for further studies. In that sense, DASINT follows the basic principle of DAS, as it
aims to be as simple as possible without compromising expressiveness.
After its publication in 2007, the MITAB2.5 format191 would have been another
possible data exchange format (see Section 2.5.3). However, several reasons spoke
against adapting this format. First, by the time the new standard appeared, we
had already implemented a working prototype based on DASINT. Second, MITAB2.5
cannot be used to represent protein complexes without transforming the data into
a representation like the spoke or matrix model (see Section 2.5.4). Third, unlike
all other DAS formats, MITAB is a tab-delimited flat file format and not an XML
format, which would have resulted in acceptance problems with the DAS community.
In summary, at the time neither PSI-MI XML nor MITAB were suitable to act
as response formats in our DAS extension. Consequently, we developed the DASINT
format that is present in the following.
XML schema Due to several optional elements and attributes, the length of the
DASINT XML format may vary significantly. Figure 3.3 shows an illustration of the
DASINT schema definition, the complete W3C XML Schema Definition can be found
in Appendix 1 or the Supplemental data of Blankenburg et al. 40.
Figure 3.3: DASINT XML Schema Definition.
The main XML elements within the root DASINT element are called INTERAC-
TOR, INTERACTION, PARTICIPANT, and DETAIL. To avoid redundancy and reduce
the document size, we decided to us cross-references within the XML document,
inspired by the compact form of the PSI-MI XML format (see Section 2.5.2). Cross-
referencing means that interacting molecules are defined only once (INTERACTOR) and
later participations of these molecules (PARTICIPANT) in interactions (INTERACTION)
are linked to the initial definition.
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The INTERACTOR element contains general, interaction independent information.
Mandatory attributes are shortLabel, dbSource, dbAccessionId, and dbCoordSys,
which define the source of the interactor. The optional dbSourceCvId and dbVer-
sion can be used to define the source database in more detail. The mandatory
INTERACTOR attribute intId is used to link interactors to their participations in
interactions. The sequence of an interactor may be contained in the SEQUENCE ele-
ment. The type of sequence, nucleotide or amino acid, is implicitly defined by the
coordinate system of the interactor.
The INTERACTION element has the mandatory attributes shortLabel, dbSource,
and dbAccessionId that define the origin of an interaction. As for the INTERACTOR,
the attributes dbSourceCvId and dbVersion can be used to define a source database
in more detail. The sole attribute of the PARTICIPANT element is intId, which is
used to link this element to its initial INTERACTOR definition.
The long-term sustainability of the protocol should be ensured by adopting a
property/value attribute combination for the DETAIL element. This enables trans-
ferring all different kinds of information, even the kind of information not specified
today. For example, including a DETAIL element with the attribute ”direction” and
one of the values ”in” or ”out” within PARTICIPANT elements, allows for assigning
directions to interactions and thus for representing pathways in the DASINT format.
Optional RANGE elements may be used to describe positional details like the bound-
aries of protein domains or binding sites. To specify the provided information in
terms of controlled vocabularies, we introduced several optional attributes ending
with the term CvId.
Listing 3.8 shows an exemplary XML response that contains two proteins and one
interaction between them. The interaction is annotated with additional information
in the form functional similarity based confidence scores342. 
1 <DASINT xsi:schemaLocation="http://dasmi.de/dasint.xsd">
2 <INTERACTOR intId="1" shortLabel="HNRPF_HUMAN" dbSource="uniprotkb"
dbSourceCvId="MI:0486" dbVersion="13.3" dbAccessionId="P52597" dbCoordSys="
UniProt,Protein Sequence"/>
3 <INTERACTOR intId="2" shortLabel="ACT_YEAST" dbSource="uniprotkb" dbSourceCvId
="MI:0486" dbVersion="13.3" dbAccessionId="P60010" dbCoordSys="UniProt,
Protein Sequence"/>
4 <INTERACTION name="P52597-P60010" dbSource="FunSimMat" dbVersion="2.0"
dbAccessionId="">
5 <DETAIL property="BPscore" value="0.976656009021968"/>
6 <DETAIL property="CCscore" value="0.488117560317015"/>





Listing 3.8: Exemplary DASINT XML document describing a binary protein-protein
interaction with additional confidence scores
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3.2.2 DASMI server
A DASMI server is processes interaction requests by providing interaction data and
potential annotations in the DASINT XML format. As in the original DAS archi-
tecture, which consists of reference and annotation servers, there are different types
of servers in DASMI (see Figure 3.2). The majority of DASMI servers provide in-
teraction data and optionally additional information, making them the equivalent
of reference servers. Examples for additional information, which can be related to
particular interactions, are predicted or known interaction regions or the conditions
under which the interaction occurs. Confidence servers, the equivalent of annotation
servers, provide reliability scores for interactions.
Compared to the original DAS, the distinction between the two server types in
DASMI is not made via different DAS commands (see Table 3.2). In DASMI, both
server types respond to the same interaction command with a DASINT XML for-
mat, making them both capable of acting as reference and annotation servers. The
distinction is made via additional server annotation in the form of keywords, which
a DASMI client may use to incorporate those servers in a different way (see Sec-
tion 4.2.1).
Each DASMI server belongs to a coordinate system (see Section 3.1.1.5) that
specifies how interaction data can be retrieved from the server, for example, if it uses
UniProt accession numbers or Entrez Gene identifiers for describing the interactions.
3.2.2.1 DAS server software
The DAS community has developed several software tools to aid in the process of
setting up a DAS server. The most commonly used server tools are ProServer117,
implemented in Perl, and the Java-based Dazzle134 and MyDAS329. During my
Diploma thesis37, I have implemented DASMI support for Dazzle, which will briefly
be described in the following section. The DASMI support for ProServer and MyDAS
has been implemented by Robert Finn and the DAS community, respectively, in an
effort to make all major DAS servers DAS1.53E capable181.
Dazzle DAS server All modern DAS servers are implemented in a modular fashion,
which will be exemplified in the following by describing our extension to Dazzle. The
Dazzle server has originally been implemented by Thomas Down at the Wellcome
Trust Sanger Institute and is now part of the BioJava project302. When our work on
DASMI started, Dazzle was the only available Java-based DAS server. Dazzle works
as a Java Servlet and is composed of classes that can be categorized as core, handler,
and data source classes. The core classes provide essential DAS functionality, such
as initializing server components or generally handling DAS requests and responses.
Handler classes are specific to the different DAS commands and are responsible for
recognizing the particular query parameters and generating the associated XML re-
sponse formats. Data source classes provide access to the actual data that are to
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be made available as a DAS resource, for example, by connecting to a database
or reflecting the specifics of a certain data format. The configuration of a particu-
lar server instance via appropriate handlers and data sources is done via an XML
configuration file.
Implementation details of the Dazzle DASMI extension In order to add DASMI
support to Dazzle, I implemented the new handler class named InteractionHandler
and a number of data source classes for providing access to interaction data residing
in different file formats like HUPO-PSI-MI XML2.5 (see Section 2.5.2), the Sim-
ple Interaction Format (SIF) used by Cytoscape352, or in-house MySQL databases
schema37. To simplify working with different interaction data formats, I developed
a common data model that is used to represent interaction data within Dazzle. This
data model is tightly linked to the DASINT XML Schema and is thus composed of
object classes named Interaction, Interactor, Participant, Detail, Range, and
Sequence, with the object variables representing the XML attributes and values.
The interplay of all Dazzle components is best illustrated by a schematic exam-
ple. When an interaction request is received by a DASMI server instance, the
core classes forward this request to the InteractionHandler. The handler extracts
the interactor and detail query parameters and issues a request to the particular
data source class that has been associated with the requested DAS source in the Daz-
zle configuration file. The data source class retrieves the requested interaction data
and returns them to the handler as a collection of Interaction objects. In the ulti-
mate step, the InteractionHandler transforms this collection into a DASINT XML
document, which is wrapped inside a DAS header and returned to the requester.
Most of the interaction data that have been collected in different projects within
the MPII313,343 are stored in MySQL database tables. The data source classes I im-
plemented to make these data available as DASMI sources, MPIPPIReferenceSource
and MPIDDIReferenceSource, make use of a technique named database connection
pooling to efficiently retrieve binary protein-protein interactions (PPIs) and domain-
domain interactions (DDIs), respectively. In a database connection pool, a number
of connections to the database are constantly maintained in an open and active
state and can be requested from the application. This is in contrast to the classic
approach of opening a database connection prior to a request and closing it right
after. Especially in situations, where a large number of databases requests are made
within a short period of time, the overhead produced by opening and closing those
connections can lead to performance bottlenecks.
For the data source classes that retrieve interaction data directly from files like
PSI-MI XML 2.5 documents, I implemented a caching solution based on (embedded)
database support, ensuring that the performance of a DASMI server is sufficiently
fast even when a large number of requests are made within a short time. Assum-
ing that data are stored on normal hard-drives and not entirely kept in the main
memory, the access on normals files is considerably slower than data retrieval from
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indexed databases. Therefore, I developed two versions of database caching, one en-
abling access to user-uploaded PSI-MI XML documents in the DASMIweb client (see
Section 3.2.3.1), and the PSIMIReferenceSource, which is distributed with Dazzle
and intended for users who want to set up their own DASMI server instance. The
difference between the two versions is that the latter uses an embedded database,
which is initialized and filled at server startup, while the DASMIweb version uses
standard in-house MySQL databases of the MPII. The embedded database ensures
that Dazzle can be used even if there is no complex database management system
installed on a server.
3.2.2.2 Data sources available via DASMI
Tables 3.3 list the sources that are available via DASMI servers as of November
2013. We developed DASMI to support different levels of molecular interactions
and demonstrated this by providing a range of protein-protein and domain-domain
interaction datasets, which have been determined with experimental and computa-
tional approaches on a large- and small-scale. The majority of DASMI servers is
hosted at the MPII. Many of the sources contain final datasets that are not changed
or updated, while some servers provide snapshots of data that are constantly up-
dated, for example, IntAct or MINT. Ideally, these DASMI sources would not be
hosted at the MPII but directly by the responsible institutions like (see Section 3.4).
3.2.3 DASMI client
A DASMI client is a gateway to distributed interaction data, allowing users to seam-
lessly communicate with multiple DASMI sources, without requiring any knowledge
about the underlying data exchange protocol. In general, after a user requests a par-
ticular query, a DASMI client will communicate with the suitable DASMI sources,
retrieve and unify their results, and present them to the user. During my Diploma
thesis, I developed the prototype of a web-based client capable of unifying a range
of molecular interaction types from DASMI servers37. Subsequently, additional fea-
tures have been added to this client, eventually resulting in a dedicated publication41.
In the following sections, I will describe this tool named DASMIwebe in more detail.
3.2.3.1 DASMIweb
DASMIweb was developed to act as a starting point for interactome studies, by con-
solidating molecular interactions from various resources. Our primary design goals,
when developing DASMIweb, were interactivity and general usability. The former
means that the user should have instant feedback and should not experience unnec-
essary delays, for example, allowing to change the DASMI server composition by
ehttp://www.dasmi.de/web/
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Table 3.3: DASMI sources providing domain-domain interactions (DDIs) and protein-
protein interactions (PPIs). DDI sources all have the coordinate system Pfam,Protein
Sequence. PPI sources can either be queried by UniProt accession numbers or Entrez
Gene identifiers.
Data source name(s) Reference Coordinate system
3did 357 Pfam,Protein Sequence




DPEA 325 Pfam,Protein Sequence
InterDom 261 Pfam,Protein Sequence
iPfam 116 Pfam,Protein Sequence
IPPRI, IPPRI-hc 339 Pfam,Protein Sequence
LDSC, LDSC-core 213 Pfam,Protein Sequence
LLZ 224 Pfam,Protein Sequence
LP 143 Pfam,Protein Sequence




RDFF 68 Pfam,Protein Sequence
Wuchty 409 Pfam,Protein Sequence
Bioverse, Bioverse-core 239 Entrez,Gene ID
CCSB-HI1 327 Entrez,Gene ID
DIP 333 UniProt,Protein Sequence
HiMAP, HiMAP-core 322 Entrez,Gene ID
HomoMINT 290 UniProt,Protein Sequence
HPRD 193 UniProt,Protein Sequence
MDC 360 Entrez,Gene ID
MINT 65 UniProt,Protein Sequence
OPHID 50 UniProt,Protein Sequence
POINT 166 Entrez,Gene ID
Sanger, Sanger-core 215 Entrez,Gene ID
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adding new resources and instantly seeing the changes in the web interface (see Fig-
ure 3.2.3.1.2). Usability comprises features like automatic input identifier detection
(see Section 3.2.3.1.1) or the clean and intuitive, yet configurable, user interface.
Figure 3.4: Graphical user interface of the web-based client DASMIweb. The client is
embedded in the MPII website, centered between the header (top), footer (bottom) and
the general navigation (left). The welcome view shown here is split into a Query Panel
on the left and an Information Panel to the right. The blue box on the right can be used
to show the myDASMI Panel (see Figure 3.6).
DASMIweb has been implemented as a three-layer application, consisting of a
data access, business, and presentation layer. The presentation layer describes the
graphical user interface (GUI), the only part of the application directly exposed
to the user (see Figure 3.4). The programming logic, which defines how data are
retrieved, unified, or temporarily stored, is contained in the business layer. The
physical data access is defined in the data access layer. In the following, I will
concentrate on selected features of the presentation and the business layers, as data
access via our DAS protocol extension has already been detailed in Section 3.2.1.
For the communication between presentation and business layer, we build upon
a technology named Asynchronous JavaScript and XML (AJAX). Compared to a
classic web-application, where a request results in a reload of the complete website,
AJAX allows for replacing or updating parts of a website without refreshing the
whole page. Today, such dynamic web-applications are ubiquitous, a prominent
example being the panning view within Google Mapsf, which dynamically loads the
map tiles that are currently visible on a user screen. In DASMIweb, an example for
the use of AJAX is the gradual generation of the interaction table as soon as the
fhttp://maps.google.com/
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DASMI servers respond, which allows the compensate for different server response
times. The AJAX functionality in DASMIweb is provided by a software library
named Direct Web Remoting (DWRg).
3.2.3.1.1 Identifier mapping Proteomics affords a great diversity of identifiers to
describe genes, proteins, or other biological entities76,424. As a result, interaction
databases use a variety of identifier systems (the equivalent of coordinate systems in
the DAS community) for describing their data313. In order to request and unify re-
sults from different servers, DASMIweb converts between different identifiers system
by using internal mapping tables derived from iProClass164 and Pfam118. DASMI-
web supports the following identifier systems for protein interactions:
• Entrez Gene identifier (e.g. 3064)
• UniProt accession number (e.g. P42858)
• UniProt identifier (e.g. HD HUMAN)
• GeneInfo identifier (e.g. 30582895)
• RefSeq identifier (e.g. NP 002102.4)
• Ensembl Gene identifier (e.g. ENSG00000100296)
These identifier systems are compatible in the sense that mappings between them
exist76. For example, if a user requests interactions for the Huntingtin protein by
querying with the UniProt identifier ”HD HUMAN”, DASMIweb will convert this
identifier to the UniProt accession number ”P42858”, the Entrez Gene identifier
”3064” and other compatible identifier systems, in order to query interaction data
from DASMI servers in their supported identifier or coordinate systems. After the
individual DASMI servers have reported their results, a second mapping step is
performed to unify and present the data to the user. In this mapping step, all gene
and protein identifier systems are converted to Entrez Gene IDs. The reason for this
mapping is that there is usually a one-to-one mapping from UniProt or Ensembl
Gene ID to Entrez Gene ID, whereas there are multiple mappings for the opposite
direction.
Fortunately, domain-domain interactions (DDIs) are predominantly reported us-
ing stable Pfam identifiers. Therefore, no identifier mapping is needed for DDI
queries.
Querying One of our usability-related goals was to simplify querying DASMIweb
by only using a single search box. Instead of asking the user to explicitly specify the
identifier system of the input, DASMIweb tries to determine it automatically and
ghttp://getahead.org/dwr/
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Figure 3.5: Querying and identifier mapping in DASMIweb. The user is asked to resolve
the ambiguous query input ”1213”, which can either represent an Entrez Gene or GeneInfo
identifier, but is also part of two additional gene descriptions.
only asks for confirmation in case of ambiguities (see Figure 3.5). DASMIweb can
be configured to use partial or exact query string matching. In the default, partial
matching, an exemplary query for ”1213” would result in four potential interactors,
as this query string is a valid Entrez Gene and GeneInfo identifier, but is also part
of two gene descriptions. The latter two options would not be shown if the search
behavior is changed to exact query string matching.
3.2.3.1.2 Interaction view The main view of DASMIweb presents all interaction
results for a query interactor (see Figure 3.6). Like all views in DASMIweb, the
interaction view comprises the Query and Information Panel. However, the latter
now contains a brief description of the query interactor, listing database identifiers,
names, and synonyms. The interactions are presented in a table in the central
Interaction Panel below.
Visualization Each interaction partner of the query interactor, or multiple part-
ners in the case of protein complexes, is listed in a separate row. The first three
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Figure 3.6: DASMIweb interaction view. The top right Information Panel describes the
query interactor, the central Interaction Panel below contains all interactions in a tabular
representation. Table columns identify DASMI sources that have been queries; colors
indicate if the source provides experimentally determined data (green) or computational
predictions (yellow). Table rows identify interaction partners; particular interactions are
represented by blue squares at the intersections of rows and columns. The small myDASMI
Panel on the right border allows setting visualization details like the number of interactions
that are shown per page.
columns contain the Entrez Gene or Pfam identifier(s), name(s), and description(s).
A separate column represents each DASMI source that has been queried for inter-
actions thereafter. The source label in the table header lists the number of reported
interactions and color-codes the type of interactions the data source provides: a
green background indicates data that have been experimentally determined or cu-
rated from the scientific literature, a yellow background represents datasets that
have been computationally predicted. Individual interactions between the query in-
teractor and the interaction partner(s) in a row are marked by a blue square at the
intersection of the row and the column of the DASMI source reporting the interaction
(see Figure 3.6).
Customization The interaction table is built gradually. As soon as a server reports
its results, new interactions are added to the end of the table. The table may be
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sorted according to individual columns or a consensus over all DASMI sources. The
latter allows for a quick visual inspection of the interaction results, based on the
assumption that interactions that are reported by different databases have a higher
likelihood of being true positive interactions. For the sake of clarity, sources that did
not return any interaction can be excluded from the results table. A tabbed display
allows to select the number of interactions that are shown per page, by default set
to 50. All display and sorting options can be adjusted in the myDASMI Panel,
which can be displayed by clicking on the small label on the right screen border (see
Figures 3.4 and 3.6).
Interaction details Additional information about a particular interaction and the
interaction partners involved may be requested by clicking on any of the interaction
squares (see Figure 3.7). The data presented this way may contain links to the
original publication or the full interaction record in the source database, information
about the binding interfaces, or details on the experimental conditions. All details
are provided by the DASMI sources, thus the amount of information may vary.
Data export All interaction results may be exported from DASMIweb in order to
make them available for further analyses. Currently available data export formats
are MITAB2.5 (see Section 2.5.3) and the Simple Interaction Format (SIF), a flat
file format that is in particular supported by the network analysis and visualization
platform Cytoscape352.
Source configuration DASMIweb retrieves a list of available DASMI sources from
the DAS registry. This list is combined with an internal list in order to incorporate
sources that are not officially registered or that are web-services not following the
DASMI protocol (see Section 3.3). Without any further configuration, DASMIweb
will include all compatible interaction data sources into a user query. The user can
change this selection in the Source Configuration Panel, which can be requested via
a link in the Query Panel (see Figure 3.8).
Sources are grouped based on their coordinate or identifier systems. For each
source, basic information like the name, URL, or a brief categorization of its data is
provided. The latter is also indicated by the background color. As in the aforemen-
tioned source label in the interaction table (see Figure 3.6), green indicates data that
have been experimentally determined, yellow represents computational predictions.
Blue is used for servers that provide interaction confidence scores (see Section 4.2.1).
By default, all compatible sources are active, indicated by a checkmark in the respec-
tive entry. By removing this checkmark, the source will be deactivated, indicated
by the lighter background color, and will not be used for further queries. If a source
is not responding to a query or is responding with errors, it will also be deactivated.
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Figure 3.7: Part of the DASMIweb interaction view showing additional details for the
interaction between the query gene BRCA2 with RAD51A, as reported by IntAct. In-
teraction details from other sources, which also report this interaction, are listed in grey,
followed by details on the interaction partner RAD51A.
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Figure 3.8: DASMIweb Source Configuration Panel. Interaction sources are retrieved
from the DAS registry and an internally maintained list. Sources are sorted according
to their coordinate systems and are described by basic information like name and URL.
Sources with a leading checkmark are active, inactive sources are do not have the check-
mark and are indicated by a lighter background color. Green backgrounds indicate sources
that provide experimentally determined or manually curated data, yellow represents com-
putational predictions, blue is used for sources that provide interaction confidence scores.
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Including new data DASMIweb supports different means for adding new interac-
tion sources. If a DASMI source is registered at the DAS registry, it will auto-
matically be available to all DASMIweb users without any further efforts. Another
option, for instance, if the source and its data should not be released to the general
public, is the local registration of an existing DASMI source via the respective sec-
tion of the DASMIweb Source Configuration Panel. These two approaches require
that the data that are to be included have already been made available as a server.
The difference is that the registration at the DAS registry affects all DASMIweb
users, while a local registration will only be available to the single user. A third
option is to upload a PSI-MI XML2.5 file and make its content available in the
user session of DASMIweb. This last option allows for comparing unpublished data
with the results from public data sources or to annotate these data with interaction
confidence scores.
3.2.3.1.3 Interaction confidence scoring A feature that is only briefly mentioned
here, as it is described in more detail in Chapter 4, is the ability of DASMIweb
to assess interaction data quality via different measures. In addition to confidence
scores already provided by the source interaction datasets, DASMIweb can incorpo-
rate dedicated scoring servers, which are marked blue in Figure 3.8. The retrieval
of interaction confidence scores has to be explicitly requested by the user in order
to minimized unnecessary computational overhead. This can be done by clicking on
the corresponding button at the top of the Interaction Panel. DASMIweb lists all
scores in the detail section of a particular interaction (see Figure 3.7) and addition-
ally uses a graphical representation via different node colorings to afford an intuitive
assessment (see Figure 4.2).
3.2.3.2 iPfam graphical domain interaction browser
The iPfam graphical domain interaction browserh is a DASMI client that has been
developed by the iPfam group of Robert Finn at the Wellcome Trust Sanger Insti-
tute. iPfam is a database of Pfam domain interactions derived from proteins with
an experimentally determined 3D structure116. The graphical domain interaction
browser uses DASMI to complement the results of the iPfam database with those
from other domain-domain interaction resources (see Table 3.3). For a user-selected
Pfam domain, the iPfam browser retrieves results about interacting domains from
a number of user-selected DASMI servers and represents them in a graphical net-
work view (see Figure 3.9). By clicking on a node in this network, the interaction
results for this domain are requested, allowing a quick exploration of the extended
domain interaction network. Unfortunately, since Robert Finn moved to the Howard
Hughes Medical Institute (HHMI) Janelia Farm in 2010, taking the iPfam project
with him, the URL of the graphical domain browser is no longer active and the
hhttp://ipfam.sanger.ac.uk/graph
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resource currently not available.
Figure 3.9: The iPfam graphical domain interaction browser combines various domain-
domain interaction sets in a graphical network view40. Protein domains are depicted by
ovals, interactions as connecting edges. Edge colors distinguish individual data sources.
By clicking on a node, the interactions for this particular domain are requested.
3.3 PSI Common Query Interface
The Proteomics Standards Initiative Common Query Interface (PSICQUIC) is a
decentralization approach for molecular interaction data retrieval that is very similar
to DASMI14. While the idea for this distributed system dates back to the time
when we started working on DASMI (see Section 3.2), its realization was delayed
and it was still merely a concept when DASMI was officially published40,191,268,276.
The PSICQUIC architecture is very similar to DASMI. It too consists of a data
exchange specification, servers providing interaction data, clients for data retrieval
and unification, and a registry that maintains a list of available servers.
The major difference between DASMI and PSICQUIC is the data exchange speci-
fication. While DASMI has its origin in the DAS community, PSICQUIC was started
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as a HUPO-PSI project to standardize access to interaction data. It is thus built
around the PSI-MI formats272.
PSICQUIC web service Web services such as PSICQUIC are traditionally accessed
using the Simple Object Access Protocol (SOAP), an XML-based official W3C stan-
dard that may be used to transmit arbitrary messages over a transport protocol like
HTTP. The interface of a SOAP web service, that is, the methods it provides and
the data and parameters it accepts are defined using another XML dialect named
Web Service Description Language (WSDL). In addition to XML-based requests via
SOAP, PSICQUIC also supports queries via specific URLs. These URLs are based
on Representational State Transfer (REST), a paradigm that defines a certain server
output in response to a particular URL request. PSICQUIC REST queries are com-
parable to DASMI interaction requests (see Section 3.2.1.1).
The initial PSICQUIC specification14i, defined the following methods for data
retrieval:
• getByInteractor and getByInteractorList retrieve interactions via database
identifiers of the query interactor(s). These queries are thus similar to the in-
teraction request in DASMI (see Section 3.2.1.2).
• getByInteraction and getByInteractionList allow for retrieving particular
interactions by their identifier(s).
• getByQuery enables more complex queries via the Molecular Interaction Query
Language (MIQL, see Section 3.3).
• getSupportedDbAcs, getSupportedReturnTypes, and getVersion can be used
to retrieve meta information about the PSICQUIC service.
Molecular Interaction Query Language (MIQL) The Molecular Interaction Query
Language (MIQL14j) is a query language based on Apache Lucenek. Compared
to queries by interactor or interaction identifiers, MIQL is much more powerful,
allowing complex queries using wildcards and logical operators. The exemplary
MIQL query ”park2 AND cask AND ”pull down”” would retrieve all interactions
that involve the gene products of Parkin and Cask, which have been determined via
pull down experiments. As this query uses gene names, it would not be restricted
to human interactors, but would return interactions from other organisms.
MIQL queries can be restricted to certain fields of a MITAB file. For instance, the
search string ”species:human” could be added to the last example to filter unwanted
species. In MIQL 2.6, which is based on MITAB 2.6, and later versions, the query




54 3 Data decentralization in interactomics
from the spoke expansion of a protein complex. In MIQL 2.5, the query would not
be restricted, as the complex expansion method was not available in MITAB2.5
(see Section 2.5.4).
Reference implementation The HUPO-PSI, essentially led by the IntAct team of
the European Bioinformatics Institute (EBI), has developed a reference implementa-
tion for PSICQUIC to facilitate the installation of new PSICQUIC servers14. This
reference implementation is based on a MITAB file that contains all the interac-
tion data. Via an indexing process, the content of this file is made available as a
PSICQUIC server.
Initially, the reference implementation only supported MITAB 2.5. A new refer-
ence implementation, which was recently published88, now also provides support for
versions 2.6 and 2.7. However, still no support is available for PSI-MI XML files.
In order to serve their content, these files still have to be transformed to MITAB
documents, a transformation that is not fully reversible, as not all the information
can be preserved. In particular, protein complexes cannot be described in MITAB
without the prior application of a complex expansion method (see Section 2.5.4).
PSICQUIC has a strong support in the interaction community. The project
started with 4 servers, when it was officially published in 2011, this number al-
ready grew to 16. As of December 2013, 28 servers are registered at the PSICQUIC
registry, including most of the key databases in the field.
PSICQUIC registry The PSICQUIC registry, currently hosted at the EBIl, main-
tains a list of all available PSICQUIC servers. Like in the DAS registry (see 3.1.1.4),
individual servers may be described with certain keywords, such as ”spoke expan-
sion”, ”predicted”, or ”imex curation” to allow for a general categorization of their
data. Furthermore, the version of the reference implementation used and the num-
ber of interactions provided in total is listed. PSICQUIC clients may retrieve a list
of servers that follow specific requirements programmatically.
PSICQUIC clients PSICQUIC clients allow access to interaction data that are pro-
vided via the PSICQUIC specification. If the REST interface of a single PSICQUIC
server is used, MITAB data can directly be retrieved via a standard browser, not
requiring a specific client. For individual computational access, the project web-
sitem contains source code to facilitate the retrieval of interaction data via different
programming languages. In addition, a number of clients exist, which can be used,
without requiring any programming efforts, in particular, PSICQUIC view14, molec-









In this chapter, I presented two systems for the dynamic exchange and integration
of molecular interaction data. The idea for these approaches was born, when the
growing public attention for systems biology and the technological and methodolog-
ical improvements in the area of interaction determination, have led to substantial
amounts of interaction data being generated in numerous laboratories. While most
of these data were made publicly available, they were not readily accessible to the
research community, as they were scattered over a multitude of online resources. In
contrast to the protein structure and sequence fields, where single large resources like
PDB34 or UniProt375 act as central data repositories, the collection of molecular in-
teractions has traditionally been spread over a number of smaller resources18. These
primary interaction databases, which acquire their data directly from experimental-
ists or by curating the scientific literature, are invaluable resources for proteomics.
However, they are commonly focused on specific biological aspects like extracellular
interactions or certain signaling pathways270.
In 2004, the HUPO-PSI introduced an XML format for the representation of inter-
action data, later complemented by a tabular representation153,277. This fostered the
development of integrative interaction databases, which collect and unify interaction
data from a number of primary databases66,180,298,315. These centralized repositories
can be useful resources for researchers, as a great number of interaction data are
available at a single site. However, in order to remain relevant and up to date, the
unification has to be constantly repeated, as the source databases keep on updating
and expanding. In addition, a central authority decides about the interaction data
that are to be incorporated into these systems, for instance, limiting the focus on
experimentally determined interactions and neglecting computational predictions.
The complementary approach to data centralization is federation, where the data
are kept with their providers and are retrieved on request. This approach, suc-
cessfully showcased by the Distributed Annotation System (DAS) for genome and
proteome annotation, empowers the users, as they can decide, which data are to be
incorporated or left out. In addition, data maintenance is greatly improved, as the
original providers keep full control over their data.
In order to transfer the concept of data federation to the field of interaction data,
we developed an extension to DAS named Distributed Annotation System for Molec-
ular Interaction (DASMI37,40). The basic idea of DASMI is to leave the interaction
data with their original providers and collect them upon request. For the user, the
system should act like a centralized repository, that is, the interaction data should
phttp://www.bioconductor.org/packages/release/bioc/html/PSICQUIC.html
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be unified across the different data sources and be available at a single location.
To this end, we developed DASMI as a client-server system, where interaction data
are provided by multiple DASMI servers and are presented to the user in a DASMI
client. The communication between client and server is handled by a data exchange
protocol.
First, we required a data exchange protocol capable of describing different types of
molecular interactions. We started by evaluating existing alternative data formats.
The one with the largest community support, PSI-MI XML153, can be used to
describe molecular interactions with a fine level of detail, necessarily resulting in
very complex, deeply branched documents. Since DAS was built around the idea
of simplicity, and because tool support for processing PSI-MI documents was very
basic at the time, we decided against the use of PSI-MI XML. Interestingly, even
in 2013, PSI-MI XML is still not supported as input to the PSICQUIC reference
implementation, although both are official standards of the HUPO-PSI88. MITAB,
on the other hand, which was originally published as a simple tabular alternative to
the complex PSI-MI XML, became increasingly popular and has grown from 15 to
42 columns in its current version 2.7.
Our data exchange protocol, consisting of a new DAS command named inter-
action and the corresponding DASINT XML response format, was developed in the
context of the European BioSapiens Network of Excellence377 and in close collabora-
tion with the DAS community. Together with other DAS extensions, it was bundled
into the unofficial DAS version 1.53E181. Following the definition of the data ex-
change specification, we developed a DAS server capable of providing interaction
data in the new format. We started by extending the existing Java-based server
library Dazzle94,302, the DAS community later followed with extensions to the other
major DAS servers ProServer117 and myDAS329. These servers can now be used
to serve interaction data residing in different database schemas, flat files, and PSI-
MI XML files. Using this extended Dazzle library we set up a number of DASMI
sources providing experimentally determined or computationally predicted protein
and domain interactions, which had been collected in previous projects at the MPII.
All these servers were also registered at the DAS registry, making them available to
every DAS user.
In order to retrieve, unify, and present the interaction data to the user, we de-
veloped the web-based client DASMIweb41. As the name suggests, this client is
primarily based on the DASMI protocol, but can incorporate other web services like
PSICQUIC. DASMIweb is a dynamic client that strongly depends on Asynchronous
JavaScript and XML (AJAX) for ad-hoc data retrieval and presentation. In addi-
tion to binary protein-protein interactions and protein complexes, DASMIweb may
also be used to incorporate knowledge about the interacting domains, thus helping
to elucidate protein interaction networks.
DASMI was the first published approach for decentralized interaction data re-
trieval40. It showcased the potential of data distribution for interactomics and has
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successfully been used in a number of research projects60,92,199,206,295,387,407. How-
ever, a major factor limiting a wider use of DASMI, in particular, a larger number
of external data providers, was our data exchange format. While the DASINT format
proved to be sufficient for its task and was well accepted by the DAS community181,
it was not supported by the major interaction data providers, like those associated
with the HUPO-PSI and the IMEx consortium278. These database providers in-
stead developed their own distributed system for interaction data exchange, named
PSI Common Query Interface (PSICQUIC276). The similarities of PSICQUIC and
DASMI are immanent: both consist of interaction data servers, clients for presenting
the results, a data exchange specification, and a registry keeping track of available
resources14. As such, PSICQUIC can be seen as the more sophisticated successor
to DASMI. PSICQUIC has a great support in the interaction community, as of
December 2013, 28 servers are available at the PSICQUIC registry. In addition,
PSICQUIC client libraries exist for various programming language, Cytoscape352
and BioConductor134 and the system is used for collaborative annotation efforts like
IMEx14,271.
3.4.2 Outlook
Further development on DASMI has largely stopped since PSICQUIC was published
as its successor system. In particular, no additional work will be invested in DASMI
servers or the data exchange protocol, despite potential improvements with respect
to the supported input data formats. The client DASMIweb, however, may be ex-
tended to a general interactome browser. In particular, it already supports several
features that no other PSICQUIC-enabled client provides, including the easy incor-
poration of unpublished, private interaction data or the visualization of interaction
confidence scores. When DASMIweb was published in 2009, it already supported the
then unpublished PSICQUIC standard41 but as no PSICQUIC registry was avail-
able at the time, selected servers had to be manually curated in an internal list.
The first step to an improved PSICQUIC support would thus include the automatic
access to the PSICQUIC registry. In addition, a closer integration of the Molecular
Interaction (MI) controlled vocabulary would be beneficial for a better unification
and presentation of the data.
PSICQUIC, as the official successor to DASMI, already has a strong support in the
interaction community and is likely to continue its success story with more servers
being made available. One area that still needs improvement is the unification of
results from various servers. PSICQUIC view, for instance, only uses identifiers from
UniProt, iRefIndex, DDBJ/ EMBL/ GenBank, RefSeq, and ChEBI for unification.
Entrez Gene IDs, as they are used for gene-centric unification in DASMIweb, are
not supported. Identifier mapping in general remains an important issue for PSIC-
QUIC, for instance, limiting its query capabilities. The search index of a PSICQUIC
server is currently built using only the information present in the input MITAB file.
Some servers provide UniProt accession numbers, others use RefSeq or Entrez Gene
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identifiers, with the result that their data can only be retrieved if a query of the
corresponding identifier system is made. A query approach like implemented in
DASMIweb, where a query identifier is first mapped to all compatible identifier
systems, could prevent this.
Distributed systems like DASMI and PSICQUIC are generally not the first choice
when genome-wide interaction data are required. Integrative data warehouses like
iRefIndex, which provide unified interactome data, are largely used due to their
faster analyses capabilities. However, with a suitable client, PSICQUIC could pro-
vide the basis for a data warehouse that can easily be maintained, a hybrid mixture
between distributed and centralized systems58. We are currently developing such
an integrative interaction data warehouse, which is built upon individual MITAB
files retrieved from PSICQUIC servers. Compared to ad-hoc PSICQUIC queries,
this pre-built PSICQUIC-based warehouse allows for faster queries, an improved
identifier mapping procedure, and above all better control of versioning and repro-
ducibility.
A key requirement for PSICQUIC in the future is the support of PSI-MI XML
files, such that protein complexes or cooperative interactions do not need to be
expanded. Currently, these data have to be fitted in a tabular data format that was
not designed for such complex interactions.
4 Assessing molecular interaction
data quality
This chapter is dedicated to the assessment of interaction data quality, an area that,
apart from general data availability, poses another challenge for interatomics. Sec-
tion 4.1 will describe the relevant data quality problems that are associated with
different interaction determination and prediction techniques. This is followed by a
brief description of the various confidence scoring approaches that have been pro-
posed. In Section 4.2, two systems will be presented that use the principle of data
decentralization in order to make these different scoring algorithms easily available
to the scientific community. Our first approach uses the Distributed Annotation
System for Molecular Interaction, which was presented in Section 3.2. Building on
this proof-of-concept study, I will then describe a successor system that we designed
in collaboration with the Human Proteome Organization (HUPO) Proteomics Stan-
dards Initiative (PSI). I will end the chapter in Section 4.3 by summarizing the
current status and providing an outlook on potential future development
4.1 Introduction
Chapter 3 described how distributed systems can be used to improve the availability
of interaction data. A second major issue in interactomics, which despite intense
research efforts is not adequately resolved, is data quality. While the error rate
in genomic experiments is below the percentage level169, large-scale protein inter-
action studies have been linked with false positive rates in the order of up to 50
percent86,148,252,396.
4.1.1 Interaction data quality issues
Within the research community, individual techniques for determining molecular
interactions are perceived differently with respect to their data quality and reliability.
While some opinions and reservations are explainable, there is no profound scientific
reason for others133.
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Yest-two hybrid The experimental detection technique that has been particularly
associated with varying data quality is the yeast-two hybrid system (Y2H, see Sec-
tion 2.2.1). Y2H has been used in most of the early large-scale studies, and it
was argued that the low overlap between similar studies performed in yeast171,382
or in human327,360 is an indicator of technical limitations163,165,208. Self-activating
reporter baits or the unphysiological overexpression of baits and preys in the yeast
nucleus, are reasons that may lead to false positive results, spurious interactions that
are wrongfully reported. Misfolded proteins or proteins requiring post-translational
modifications that are not available in yeast, on the other hand, may result in false
negative interactions that are not detected in a screen426. For reported interactions,
it also remains questionable whether they are biological, that is, true positive inter-
actions also present in the cell, or biophysical interactions that could take place, but
may not388.
Affinity purification High-throughput studies using affinity purification followed
by mass spectrometry (AP-MS, see Section 2.2.1), have long been considered to be
superior to Y2H screens, in particular, because AP-MS screens may be performed
under physiological conditions130. Nevertheless, AP-MS also has its limitations, such
as weak connections that might be diluted in the purification process and result in
incomplete complexes396, or sticky proteins that might be purified regardless of
the actual bait protein110,264. In addition, the extracted purifications only indicate
indirect co-complex relationships, which in the past have often been mistaken with
true binary interactions like those detected with Y2H339,418. Comparative studies
have recently shown that the error rates of large-scale studies are much lower than
initially anticipated and that no experimental protocol is superior to another49,388,421.
Literature curation Manual curation of the scientific literature (see Section 2.3.1),
in particular, curation of small-scale experiments that reported few interactions,
has long been considered to be of higher quality than results obtained via large-
scale experiments126,319,396. Consequently, such data were used as gold standard in
various studies123,214,309.
In a much debated series of articles, literature curation has recently been asso-
ciated with significant false positive rates, mostly caused by mistakes in human
curation79,80,332. According to Venkatesan et al., large-scale techniques like Y2H
may even be of technically better quality than literature curation388. This state-
ment is too general, however, as literature curation may be performed according
to different quality standards332. In addition to deep curation according to IMEx
guidelines278, more shallow curation following the MIMIx guidelines281 or curation
following no particular recommendations 79,193 is common. Unsurprisingly, the lat-
ter approach has been shown to have the highest error rates79. Further complicating
this distinction, IMEx databases like MINT also contain data that have not been
curated according to the high IMEx standards220.
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Compared to potentially less biased large-scale approaches396, literature curation
is also faced with a study or selection bias, as there is significantly more literature on
well studied or medically relevant genes, such as the famous cancer related BRCA2
and TP53, than there is for uncharacterized genes. This bias is then also reflected
in the corresponding protein interaction databases80,125,252.
Need for assessment Computational predictions (see Section 2.2.2) are generally
approached with skepticism392, despite their heterogeneous nature and reports that
at certain specificity rates some approaches might yield data of a quality comparable
to large-scale studies179,215.
In summary, it can be seen that every interaction determination or prediction
technique has certain strengths and weaknesses. Different approaches are required
as they are complementing each other and are thus able to detect interactions that
others are missing196,221,418. Regardless of the technology that is used, however,
errors are inevitable48,388. It is thus evident that in order to achieve a high quality
map of the human interactome, means for individual assessment of interaction data
are crucial.
4.1.2 Methods for assessing molecular interactions
A great variety of methods have been developed for scoring individual protein in-
teractions or complete datasets, for example, reviewed by Chua and Wong 72 . In
the following, I will present a brief categorization of the techniques that are com-
monly employed. In general, the underlying methodology can be used for assessing
interactions that have already been determined, but may also be used in order to
predict interactions de novo 367. Therefore, a significant overlap exists between the
methods mentioned below and the computational prediction algorithms presented
in Section 2.2.2.
4.1.2.1 Experimental replication
It is common sense that an experimental finding that can be replicated in other ex-
periments has a higher likelihood of being a true positive finding. In particular, it has
been found that protein interactions that are reported in more than one study have
a greater chance of being true positives215,355,396. This approach has been employed
by various experimental groups for creating core or high confidence subsets contain-
ing only interactions that appeared in multiple repetitions of an assay130,171,219,382.
Compared to such replications with the same assay, an even greater probability of
being a true positive is assigned to interactions that can be replicated using a dif-
ferent experimental setup215. This assumption also provides the basis for overlap
computation, which is widely used for comparing interaction screens20,125,236,313,396.
Experimental replication is incorporated into various scoring approaches. A pop-
ular example is the MINT-score220 that is computed based on all experimental ev-
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idences and scientific publications that support a particular interaction. Weight
factors are assigned to individual detection techniques, scoring direct interactions
higher than co-complex associations, and the number of interactions a publication
reports in total, granting higher weights to small-scale studies that reported at most
50 interactions than to large-scale studies220. An updated MINT-score is used in the
integrative interaction database mentha58 (see Figures 2.2 and 4.1). IntAct190 also
recently implemented a weighted replication based protocol to score experimentally
determined interactions. In particular, this should filter out low-confidence inter-
actions before exporting data to the UniProt consortium375 or the Gene Ontology
Annotation project59.
4.1.2.2 Gold standard
The term gold standard, sometimes also golden standard , is used for datasets that
can be trusted to represent the biological truth, at least up to a reasonable ex-
tent178. Transferred to interactomics, two gold standard or reference sets can be
distinguished48. First, the positive gold standard or positive reference set that de-
scribes true interactions. This set is commonly built as a high confidence subset
of interactions that have been reported in multiple different experiments and that
have been extensively validated49,86,215,367,388. Second, the negative gold standard or
negative reference set that should describe interactions that are not taking place
in vivo 32. The definition of this set is more difficult, as an interaction that is not
reported in a database does not imply that the interaction is not taking place, it
might just not have been detected. Approaches for defining negative reference sets
are based on some forms of randomization86,388,426, protein pairs with contradicting
subcellular localizations52,179, network distances20, or experimental repetitions378.
The group headed by Marc Vidal has recently proposed community efforts for refin-
ing common positive and negative reference sets that would allow different groups
to globally calibrate and score their assays in order to make them more compara-
ble49,388.
4.1.2.3 Evolutionary conservation
The idea behind evolutionary conservation is that an interaction that is conserved
across different species has a greater likelihood of being biologically relevant. Wal-
hout et al. have introduced the concept of interologs for such orthologous proteins
that have maintained their ability to interact in different organisms400. Evolution-
ary conservation has not only been used as a measure of data quality, but also to
predict protein interactions in species without sufficient interaction data coverage,
by transferring interologous interactions from model organism that are usually bet-
ter studied166,215,399. Lim et al. have found that, based on functional annotations,
interologous predictions have a quality similar to data from literature curation or
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Figure 4.1: Network representation of a high confidence subset of the human interactome.
As in Figure 2.2, nodes indicate proteins, edges depict binary PPIs. Only interactions with
a mentha58 confidence score above 0.7 have been considered, reducing the network size
from originally 14 650 proteins and 143 947 interactions to a subset of 5 175 interactions
between 3 017 proteins. The network has been illustrated in Cytoscape 3.0.2 using a force-
directed layout, maintaining the original color gradient from Figure 2.2, where proteins
with few interaction partners are colored yellow and those with more than ten partners
are dark red. Compared to the unfiltered one, this network is split into more disconnected
components.
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alogs, that is, products of genes that resulted from inner-species gene duplication
events86.
4.1.2.4 Functional annotation
An observation that has early been made in interactome analysis is that biologi-
cally relevant interactions often involve proteins that have similar functional anno-
tations20,215,367,382. This fact has been employed by scoring methods that compute
the functional similarity of protein interactors, for instance, using semantic similar-
ity of Gene Ontology (GO) annotations176,187,291,343. Functional similarity has been
shown to be a good filter for high-confidence interactions93,215,249. Biologically rele-
vant protein interactions have been found between proteins with different annotation
profiles388. In addition, GO, which is commonly used as a source for functional an-
notations, has been linked with significant annotation errors and biases due to its
incompleteness57,385,397.
4.1.2.5 mRNA (co-)expression
It has been shown that proteins that are involved in biologically relevant PPIs exhibit
higher correlations in their expression profiles than non-interacting protein pairs142.
This finding has been incorporated into different scoring approaches20,86,338,355,367
or was used to create tissue-specific interaction subnetworks226. Co-expression is a
useful indicator for true biological interactions. Bader et al. have shown that co-
complex proteins can show low co-expression values due to differences in protein
degradation. For co-immunoprecipitation experiments, they even found an inverse
correlation20. In addition, the incompleteness of expression data can lead to biases
as it generally favors proteins that have annotations over those without.
4.1.2.6 Topological network measures
The network representation of interactions, in which nodes correspond to proteins
and connecting edges indicate different kinds of relationships between them (see Fig-
ure 4.1), allows for applying graph-theoretical analysis approaches22,23,183,392. For
example, using different measures of network topology16,304, it has been shown that
disease-associated networks show a higher connectivity than expected306 and that
their modularity is altered373. Graph-theoretical network analysis measures are com-
monly used for comparisons125,226,313 and are the basis for various confidence scoring
schemes, for instance, building on the local network neighborhood of a protein139,
by using clustering algorithms187,203, or network transformations416.
4.1.2.7 Protein domains
The interaction between proteins is often mediated by an underlying interaction
of protein domains or short linear motifs286,287,320. Based on this assumption, the
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domain compositions of the protein interactors, for instance, their assigned Pfam
domains118, can be probed for known domain-domain interactions (DDIs) in order
to identify a subset of higher confidence3,198,217,244. Such domain interactions can
be determined based on different data types. The method considered to have the
highest quality is the analysis of experimentally solved crystal structures that are
stored in the Protein Data Bank (PDB34). The databases 3did251, iPfam116, and
PInS43 use this approach. In addition, a number of prediction algorithms have been
proposed, which are based on the combination of heterogeneous data. Exemplary
data types include protein interactions (potentially creating a circular argument if
PPIs are used to predict DDIs, which in turn are used to validate PPIs), sequence
information, or phylogenetic profiles227,261,415. Integrating a large number of DDI
datasets, Kim et al. were able to explain around 50 percent of the protein interactions
by underlying DDIs198.
4.1.2.8 Protein structure
Three-dimensional protein structures may be used to explain interactions between
proteins on a molecular level, by identifying the particular protein binding inter-
faces9. For example, Aloy et al. have shown that interologous protein pairs tend to
maintain their binding interfaces6, which allows for modeling homologous interaction
pairs based on known structures250. Conversely, structural models may also be used
to identify potential false positives in experimental data, for example, if proteins are
reported to interact directly, although their structures make this interaction highly
unlikely8,106. The experimental determination of high resolution protein structures
using X-ray crystallography, nuclear magnetic resonance spectroscopy, or electron
microscopy is currently not amendable to high-throughput, with the result that the
number of structures stored in the PDB grows slower than most other biological
databases, requiring approaches for computational structure modeling250,402.
4.1.2.9 Multiple data types
The incorporation of multiple data types is based on the underlying assumption that
heterogeneous data can complement each other and account for potential problems
and shortcomings of the individual datasets. The data types used by the different
approaches are very diverse, including, but not limited to, all of the aforementioned
proteomic, genomic, and functional datasets367. The combination is performed using
Bayesian models or networks20,179,217,310,322,395,412 or machine learning approaches
like probabilistic decision trees426. For all these integrative prediction or scoring
techniques, the aforementioned gold standard sets are of critical importance52,178,420.
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4.2 Decentralized scoring systems
In the previous part of this chapter, I discussed the need for independent means
for determining the quality of molecular interaction data. The methods that have
been developed to this end are based on fundamentally different biological aspects of
interactions, including their experimental detection systems, functional annotation
of protein interactors, or evolutionary conservation. Given this diversity and the
finding that no single scoring method is clearly superior367, a comprehensive scoring
solution that incorporates all these approaches is not to be expected. In fact, it
remains questionable whether it will ever exist280.
Centralized frameworks for protein confidence scoring Nevertheless, a number
of computational platforms have been developed that use some of the aforementioned
techniques for scoring interaction data, including EnrichNet137, HIPPIE337, HitPre-
dict284, INStruct244, IntAct190, Interactome3D250, IntSore187, PINA77, PRINCESS217,
MINT220, and STRING121. From this selection, only Interactome3D, IntScore,
PINA, and PRINCESS allow for scoring user-defined interaction data. The others
are limited to pre-defined datasets, essentially making them (aggregate) interaction
databases with added confidence scores (see Section 2.3). Interactome3D is largely
based on protein structure prediction, IntSore, PRINCESS, and PINA all incorpo-
rate functional annotations and network topology, PRINCESS additionally makes
use of evolutionary conservation and domain interactions77,187,217,250.
These scoring platforms use a similar strategy as the aforementioned aggregate
interaction databases, in the sense that they try to make a number of datasets
or methods available at a single location. Since this is done by building central
repositories, a major limitation inherent to these frameworks is that they cannot
easily by changed or extended. The inclusion of a new scoring algorithm or an
update of an existing method can only be accomplished by the central authority.
Like in the previous Chapter 3, this was one of the main arguments why we proposed
solutions based on data decentralization, which will be presented in the remainder
of this chapter.
4.2.1 Confidence scoring with DASMI
Our Distributed Annotation System for Molecular Interactions (DASMI) was de-
signed for the exchange and the annotation of interaction data. Section 3.2 pri-
marily focused on the aspect of data availability, illustrating how scattered sets of
interaction data are queried from and visualized at a single location. Here, I will
describe how the same system can be used for the integration and visualization of
different confidence scoring approaches.
Figure 3.2 illustrates the DASMI architecture that consists of two server types:
interaction servers providing the information that certain molecules interact and
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confidence servers that make additional interaction annotation available in the form
of confidence scores. Both server types use the same data exchange specification
for requests and responses (see Section 3.2.1). The server installation tutorial on
the DASMI websitea, for example, shows how the same interaction data may be
visualized as a normal interaction source or as a quality measure.
4.2.1.1 DASMIweb visualization
A DASMI source that is registered with the label interaction quality measure will
not appear in the DASMI interaction view (see Figure 3.6). Instead, it will be
used to display additional information on top of the existing interaction data (see
Figure 4.2). DASMIweb, for instance, will color the squares that represent particular
interactions accordingly. Scores that have a limited range will be visualized with a
color gradient, scores that cannot be transformed into a gradient will be highlighted,
and all interactions for which there is no score will be greyed out. This visualization is
also available for the confidence scores that are already provided with the respective
original datasets, for example, the aforementioned IntAct or MINT-scores.
DASMIweb enables the confidence scoring of user-defined interaction data by al-
lowing the upload of interactions in the form of PSI-MI XML 2.5 files. For further
analysis in external applications like Cytoscape, the resulting scores are available
for download along with the interaction data41.
4.2.1.2 DASMI confidence scoring servers
Our current setup consists of two DASMI sources that can be used for quality
assessment of molecular interactions (blue rows in Figure 3.8):
• FunSimMat is based on the finding that interaction partners commonly
share similar functions (see Section 4.1.2.4). For each protein in the UniProt
database, FunSimMat precompiles and stores a number of similarity scores us-
ing different measures of semantic similarity340,341. The FunSimMat DASMI
source only uses simRel max scores developed by Schlicker and Albrecht, which
are computed for each of the Gene Ontology (GO) categories: BPscore based
on the biological process (BP) annotation, CCscore for cellular component
(CC) terms, MFscore using molecular function (MF) annotations340. All these
scores range between zero (no similarity) and one (identical annotation) and
are presented by a color gradient if selected in DASMIweb.
• Domain support provides two measures that may help to explain protein in-
teractions by underlying domain-domain interactions (DDIs) (see Section 4.1.2.7).
To this end, it first retrieves the Pfam118 domain annotations for each pro-
tein interactor and tests for the existence of known DDIs. The score named
ahttp://dasmi.de/tutorial.pdf
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Figure 4.2: Visualization of confidence scores in DASMIweb. The selected confidence
score, briefly described in the bottom right of a screen, is used to highlight interactions.
Interactions for which no score is available are greyed out (see Figure 3.6). a) Confidence
score provided by the Human Interactome Map (HIMAP). As this score has no limited
range, all instances are marked in the same color. b) FunSimMat BPscore based on the
biological process (BP) annotation of the Gene Ontology (GO). The zero-to-one range of
the score is indicated by a color gradient, where white represents no similarity and dark
blue indicates perfect similarity. c) FunSimMat MFscore based on GO molecular functions
annotation (MF).
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crystal-structure combines the DDI datasets 3did251, iPfam116, and PInS43,
which have been extracted by analyzing experimentally determined crystal
structures. The score named predicted combines several resources that use
computational algorithms for predicting DDIs (see Table 3.3). Both scores are
unary, indicating with a one those PPIs that might be explained by an under-
lying DDI. The DASMIweb interaction detail view (see Figure 3.7) lists the
particular protein domains, their interactions to other domains, and potential
scores provided by the DDI resource.
4.2.2 PSI Common Confidence Scoring System
DASMI showcased how distributed scoring methods may be made available to re-
searchers at a single location. Therefore, after realizing that a single, comprehensive
scoring solution is not within sight, the HUPO-PSI decided to develop a common
scoring system following DASMI’s decentralization strategy280. A particular require-
ment was that the scoring system should be based on the data exchange formats
defined by the HUPO-PSI, namely PSI-MI XML and MITAB, instead of the DASINT
format used by DASMI. Being responsible for DASMI, we emerged as the lead de-
velopers for this new framework named PSI Common Confidence Scoring System
(PSISCORE)269,272.
Figure 4.3 illustrates the general architecture and the basic workflow of PSIS-
CORE. At the beginning, a HUPO-PSI document is loaded to a PSISCORE client.
The document is then sent to user-selected scoring servers, which compute confi-
dence values and add them to the input file. Each scoring server returns the input
file with the added confidence scores back to the client. In a final step, all individual
results are combined by the client into a single file, which is then returned to the
user.
4.2.2.1 Web service definition
PSISCORE has been implemented as a web service accessible via the Simple Object
Access Protocol (SOAP) (see Section 3.3). The definition of its methods, includ-
ing arguments and return types, is done via a Web Service Description Language
(WSDL) document. Being a community standard, the PSISCORE WDSL has been
developed and discussed over the course of several HUPO-PSI meetings and work-
shops. Apart from our contribution as leading developers, Jules Kerssemakers pro-
vided major feedback and further comments were incorporated from Jens Hanssen,
Javier De Las Rivas, and other workshop attendees.
The PSISCORE WSDL defines the following methods that a PSISCORE server
has to provide, the full document is available in the Appendix:
• getSupportedScoringMethods() returns all scoring algorithms, which a server
offers, as a list of AlgorithmDescriptors. An algorithmDescriptor specifies
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Figure 4.3: PSISCORE architecture and basic workflow. (1) A PSI-MI document is
loaded to a PSISCORE client, which (2) sends it to several scoring servers. The servers
perform their computations, add the confidence scores to the input document, and (3)
return this document. (4) The client unifies the individual responses and provides the
results to the user.
the name and type of a scoring algorithm (e.g. network- or structure-based),
the range of its score (e.g. zero-to-one, zero-to-infinity), optional and required
parameters, and data fields that need to be provided in the input file.
• getSupportedDataTypes() returns the input data types that a server can
handle. At the moment, the two supported formats are PSI-MI XML and
MITAB. For example, a server may require PSI-MI XML documents for scoring
protein complexes or because the XML files contain some data fields that are
unavailable in MITAB documents.
• submitJob() requests the server to score the interactions specified in the data
section of the request. The algorithmDescriptor objects that have been re-
trieved in getSupportedScoringMethods() are used to select specific scoring
algorithms and to provide the required parameters. The method returns a
JobResponse object that contains the identifier of the scoring job and a sug-
gestion after which duration to check if the job is completed. The rationale for
this polling interval is that scoring algorithms that do a database query for pre-
calculated scores have different computing times than scoring algorithms that
do three-dimensional structure alignments or other computationally expensive
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methods.
• getJobStatus() requests the status of the job with the corresponding iden-
tifier. The response is a status code that specifies whether it is still in the
queue, currently being processes, or has finished with or without errors.
• getJob() retrieves the data associated with a certain job identifier after the
scoring has finished. The response contains the scored interactions and a report
that may provide a brief summary, warnings, or other information.
• getVersion() returns the version of the PSISCORE reference implementation
that is used by the scoring server.
The PSISCORE WSDL also defines how the server behaves in unexpected or
erroneous cases using exception objects like the specific JobStillRunningException
and InvalidArgumentException or generic exceptions like PsiscoreException.
Computed scores are added to the respective sections of the input file, preserving
potentially existing scores. For MITAB documents the scores are added to the
confidence column, for PSI-MI XML documents a new confidence element is added
to the confidenceList within the interaction element. In general, we encourage
score providers to normalize their scores into a range from zero to one whenever
possible.
4.2.2.2 Reference implementation
We developed open-source Java-based reference implementations for PSISCORE
server and client that implement the methods specified in the aforementioned WSDL.
The software is available as source code or precompiled packages along with further
documentation from the PSISCORE project websiteb. The core functionality is
modeled after the PSICQUIC reference implementationc that was provided by Bruno
Aranda while he was working at the European Bioinformatics Institute.
Implementation details The central class of the server reference implementation
is DefaultPsiscoreService. This class provides all the methods defined in the
WSDL, maintains the scoring jobs and their mapping to particular score calculator
threads, and unifies the result of each calculator into a final result that is returned to
the client. Compared to PSICQUIC, where all the interactions are stored in a single
MITAB file, the PSISCORE reference implementation has to be more versatile.
While confidence scores might be provided from a MITAB file, they are also retrieved
from database systems, or are computed on the fly, incorporating different elements
from the input data.
bhttp://psiscore.googlecode.com/
chttp://psicquic.googlecode.com
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The common basis for all score calculators is defined by the AbstractScoreCal-
culator, which inherits basic treading capabilities from Java Thread. The Simple-
ScoreCalculator extends this class and provides most of the fundamental func-
tionalities that are required for scoring, like converting the input data, regardless
of whether they are described in MITAB or PSI-MI XML, to a common EntrySet
representation and providing means for iterating through the interactions in this
EntrySets.
The actual score calculator classes only need to extend the SimpleScoreCalcula-
tor, by implementing the two methods getInteractionScores(), which performs
the scoring of individual interactions, and getSupportedScoringMethods(), which
tells the DefaultPsiscoreService what scoring algorithms a calculator provides.
The input to the getInteractionScores() method is an Interaction object of
the EntrySet input representation, which contains references to all its participating
interactors and other interaction details. The method will eventually add computed
scores as new Confidence objects to the Interaction object.
On the client side, the basic methods and query capabilities are defined by the
AbstractPsiscoreClient. Extending this class, the SimplePsiscoreClient pro-
vides all the functionalities to communicate with a particular PSISCORE server,
including methods to submit jobs, get their status, or retrieve finished jobs. The
PsiscoreMetaClient communicates with the registry and creates SimplePsiscore-
Client objects for each of the scoring servers, thus allowing to query multiple scoring
servers in parallel. It further provides methods to submit jobs to multiple scoring
servers, keep track of the different job statuses and identifiers, and unifies the indi-
vidual server responses once the scoring is completed.
The PSISCORE reference implementations of server and client use Apache Mavend
for managing project settings and dependencies. After downloading the reference
implementation from the project website, a simple command is sufficient to download
all required libraries, compile the source code, and package it into a Web Archive
(WAR) file. This file can placed in a Java servlet container like Apache Tomcat in
order to make it publicly available over the internet.
4.2.2.3 Available scoring servers
Using our reference implementation, different PSISCORE servers have been set up
at research institutions in Germany, Italy, Norway, and the United Kingdom. The
following servers are listed in the PSISCORE registry in December 2013.
4.2.2.3.1 MPII The PSISCORE server at the Max Planck Institute for Informat-
ics (MPII) provides five scoring algorithms. The three scores based on functional
similarity (BPscore, CCscore, and MFscore) and the two scores based on domain
dhttp://maven.apache.org/
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interactions (Domain support structure, Domain support inferred) have already been
described in Section 4.2.1.2.
4.2.2.3.2 MINT The Molecular Interaction Database (MINT) offers its MINT-score
and HomoMINT-score via a PSISCORE server. Both scores take into account ex-
perimental evidence associated with the interaction (see Section 4.1.2.1) and range
between zero and one, where one indicates the highest confidence in an interaction.
The scores are pre-calculated and are thus only available for interactions that are
reported in the MINT databases. Detailed information on the scores can be found
in the respective publications65,290 and onlinee.
4.2.2.3.3 MI score The molecular interaction (MI) score is similar to the MINT-
score in the sense that it is also calculated based on the number of publications, the
experimental detection methods, and the interaction types that support a certain
interaction. The score ranges between zero and one, where one indicates the highest
confidence in an interactions. Four different MI scores may be computed by the
PSISCORE server on-the-fly, based on interaction evidence from different sources:
MI score - intact only uses data from the IntAct PSICQUIC server, MI score -
psicquic sources uses all PSISCQUIC servers that are available at the PSICQUIC
registry, MI score - intact plus imex curation combines results from IntAct with
results from other IMEx servers, and MI score - imex curation uses only IMEx
databases. Further information about the score is available at the project websitef.
4.2.2.3.4 iRefIndex iRefIndex provides three scores computed from the publica-
tions that provide evidence for an interaction315. lpr (lowest PubMed identifier
re-use) is the lowest number of interactions that a publication, which provides ev-
idence for a particular interaction, is used to support247. Low values indicate that
at least one of the publications that support an interaction has reported only few
interactions, which is likely the case for low-throughput experiments. hpr (highest
PubMed identifier re-use) is the highest number of interactions that a publication
supporting an interaction is used to support247. High values indicate that a publica-
tion describes many other interactions, which is typical for high-throughput studies.
np (number PubMed identifiers) is the total number of unique publications that sup-
port the interaction. Higher values indicate that an interaction has been reported
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4.2.2.4 PSISCORE registry
The PSISCORE registryg maintains a list of all available scoring servers and the
algorithms they provide. An early prototype of the service has been developed
by Sascha Meiers during an internship in our group at the MPII. The registry is
implemented as a REST-based service (see Section 3.3) that is queried via specific
URLs. The following query parameters are supported, their names and values have
been chosen to correspond to the PSICQUIC registry wherever possible:
• action may be used to select all servers or only those that are active or inactive
using the corresponding values STATUS, ACTIVE, and INACTIVE, respectively.
• format defines how the registry presents the results. If it is not provided, a
human-readable tabular HTML document is generated. To obtain the same
detailed data in a format that is more suitable for computational processing,
a request with the value XML can be made. The value TXT will output a plain
textual representation consisting only of the server name and its URL.
• name may be used to limit the query to a particular scoring server, for instance,
to retrieve details on its scoring methods. If no scoring server with the name
exists, the registry will not show any results.
The following examples show different combinations of these parameters. The
URL http://psiscore.bioinf.mpi-inf.mpg.de/registry?action=active&format=
txt returns all scoring servers that are currently active in a plain text format, con-
sisting of a unique ID and the SOAP URL. The query URL http://psiscore.
bioinf.mpi-inf.mpg.de/registry?name=miscore&format=xml returns a detailed
description of the scoring server with the name ”MI score” as an XML document. In
addition to the server name and URL, the document also contains a brief descrip-
tion of every scoring method the server provides, including a textual description,
keywords, and the range of the score. The same information would be represented
in a human-readable form by removing &format=xml from the query.
4.2.2.5 PSISCOREweb
Based on the client reference implementation, we developed PSISCOREweb as a sim-
ple PSISCORE client to show the potential of decentralized scoring. PSISCOREweb
has not been developed for large-scale analyses like the annotation of whole inter-
actomes. These tasks require downloading the client library from the PSISCORE
project website and running a client locally.
Scoring interactions with PSISCOREweb essentially consists of four steps:
1. uploading the interaction data to PSISCOREweb,
ghttp://psiscore.bioinf.mpi-inf.mpg.de/registry
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Figure 4.4: The user interface of PSISCOREweb is split into four parts that are activated
subsequently. First, the interaction data are uploaded to the client as a valid PSI-MI
document. Then, the scoring servers and their methods are selected and the scoring
process is started. In a last step, the user may check if the scoring jobs have finished and
retrieve the resulting file via a personal download link.
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2. selecting the desired scoring methods,
3. sending the interaction data to all selected scoring servers,
4. retrieving the resulting scored interactions.
Figure 4.4 shows the web interface, where the user is guided through these steps.
The start and end point in PSISCOREweb are valid PSI-MI documents, either PSI-
MI XML2.5 or MITAB2.5 files. The initial file is selected and uploaded to the server.
If it can be parsed successfully, a status message is written and the next block in
the user interface is activated and marked by a strong blue border. The user may
then select the scoring methods that should be incorporated from each server. The
selection here is depending on the servers that are currently available and active in
the PSISCORE registry. By default, all scoring methods are selected. By clicking on
the respective button in the section below, the scoring process is then started. Each
server will perform the requested scoring computations and include the resulting
scores into the input file. By clicking on the request job button in the final section,
PSISCOREweb will retrieve the individual results if all jobs have finished. The
scores are then extracted from the individual response files and inserted into the
user input file, leaving the rest of the file content unchanged. The resulting file can
be downloaded using a personalized link.
4.3 Conclusions
4.3.1 Summary
Molecular interactions are of fundamental importance for understanding the function
of complex systems like the cell. Consequently, more and more research groups are
working in this area, producing an ever-increasing amount of data on the interaction
of molecules. However, the experimental detection techniques or computational pre-
diction algorithms, with which these interactions may be determined, differ greatly,
as each of them has certain strengths and weaknesses. Skepticism and quality issues
have been associated with particular approaches for more than a decade, leading to a
state where independent means to assess individual interactions are required, regard-
less of whether they have been determined by high-throughput screens, small-scale
single-protein studies, or computational predictions.
In response to this, a number of frameworks have been developed for scoring in-
teraction data quality77,187,217,250. The measures that have been proposed to this
end are based on different biological aspects of an interaction, including structural
information, network topology, experimental conditions, similarity of the functional
annotations of the interacting molecules, or evolutionary conservation. It is thus
practically unfeasible that a single, central scoring approach could combine all these
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methods280. Therefore, we proposed a decentralized approach, where multiple scor-
ing servers are hosted at different locations. An instant benefit of this decentraliza-
tion is that such systems can easily be extended if new aspects of molecular inter-
actions are to be scored. In addition, decentralization enables research groups to
focus on their particular strengths. For example, a group with a strong background
on structure modeling may develop a structure-based algorithm, groups with exper-
tise in functional similarity focus only on this aspect, while usability experts and
designers may develop useful and aesthetically pleasing graphical user interfaces.
We first showcased the potential of decentralization by using the Distributed An-
notation System for Molecular Interactions (DASMI) for confidence scoring. Al-
though the main focus of DASMI is on the exchange and annotation of interaction
data, it proved to be useful for integrating and visualizing information about inter-
action data quality, as all DASMI servers use the same data exchange specification.
We set up two scoring servers that may assess the functional similarity of the in-
teracting molecules based on all three categories of the Gene Ontology and that
may explain protein interactions by underlying domain interactions. The DASMI
client DASMIweb can incorporate these and other scoring algorithms and visualize
them with color gradients that promote visual inspection of interaction data. In
addition, DASMIweb enables the scoring of user-defined interaction data and allows
to download the results for further external analyses41.
After realizing that decentralization is a key strategy for interaction confidence
scoring, the Human Proteome Organization Proteomics Standards Initiative (HUPO-
PSI) decided to implement a common confidence scoring system modeled after
DASMI280. We developed this system named PSI Common Confidence Scoring
System (PSISCORE) based on the HUPO-PSI document formats PSI-MI XML and
MITAB. In collaboration with other PSI members, we designed the web service def-
inition, developed reference implementations for servers and clients, and used these
to set up different scorings services14. In addition to the aforementioned servers
providing functional similarity and domain interaction support scores, PSISCORE
servers have been set up in other countries to score interactions based on the ex-
perimental evidence or the publications that support them220,247. In addition, we
developed the exemplary client PSISCOREweb, which may be used to upload an
interaction data file, send this file to multiple scoring servers in parallel, retrieve and
unify the individual scoring results, and provide the final result back to the user.14.
4.3.2 Outlook
Distributed systems have shown their usefulness for interaction data exchange, an-
notation, and confidence scoring. However, the three examples mentioned through-
out this chapter, the Distributed Annotation System for Molecular Interactions
(DASMI), the Proteomics Standards Initiative Common Query Interface (PSIC-
QUIC), and the Proteomics Standards Initiative Common Confidence Scoring Sys-
tem (PSISCORE), have also shown how such systems critically depend on constant
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support if they are to be largely supported. PSICQUIC, which is maintained by
several full-time software developers, has achieved a critical size88. DASMI and
PSISCORE have acquired a number of users, but are both lacking greater public
support on the server side. In order to increase the number of external providers
of PSISCORE servers, additional efforts are required to convince and constantly
support interested service providers.
With PSISCORE being the official successor to DASMI, all future efforts should
be focused on the former. The reference implementations would benefit from op-
timizations to increase the overall performance and further improve the usability.
In addition, PSISCOREweb might be turned into a more versatile scoring platform
by removing the current file size limitation and incorporating visualizations of the
interaction data and the corresponding confidence scores. Developing additional
PSISCORE clients, for example, for Cytoscpape, Galaxy, or the R programming
language, would easily extend the user base of PSISCORE and make the system
available for further analysis workflows.
Thus far, the primary focus of PSISCORE has been on the exchange of interaction
confidence measures. Computed confidence scores were simply added to the input
data. While it remains questionable whether comprehensive scoring solutions will
ever be practical, considering the large variety of different scoring approaches and the
contradicting aspects of molecular interaction that can be assessed, the ultimate goal
is to combine the different scoring schemes in a useful manner. To this end, further
research is needed to develop approaches that combine various scoring algorithms
in a sophisticated manner.
5 Integrative network analyses of
viral host factor screens
This chapter describes applications of different biomedical data integration and anal-
ysis techniques to investigate specific biological questions. In particular, we focus
on the analysis of experimental screens that aim to determine human host factors
required for viral infections. In Section 5.1, an introduction into viruses like the
hepatitis C virus (HCV) is provided, followed by a description of the experimen-
tal systems to determine human host factors. In Section 5.2, the computational
framework that we have implemented for the bioinformatics analysis of the resulting
screen data is presented. This section also contains a functional network analysis
of published HCV host factor screens. Our framework is then used to analyze and
prioritize two independent large-scale screens determining host factors for HCV; the
results are presented in Section 5.3. I will close the chapter by summarizing our
contributions and providing an outlook on future work.
5.1 Introduction
Viruses and the infections they cause pose a major threat to human health. Despite
intense research efforts, the therapy of medically important infections, such as caused
by the human immunodeficiency virus (HIV), Dengue, influenza, or the hepatitis C
virus (HCV), remains a challenging and partly unsolved problem297. The situation
is particularly problematic in developing countries, where knowledge about certain
infections is not widespread, the standards of medical care are lower than in the
industrial nations, and the climatic conditions may promote some viral transmitters
like mosquitos.
5.1.1 Hepatitis C virus
About 180 million people worldwide are chronically infected by the hepatitis C virus
(HCV), which is central to our studies and the rest of this chapter376. HCV is a
blood-borne virus that infects human hepatocytes326. Between 10% and 25% of the
people that get infected manage to clear the virus in the acute infection stage within
the first six month, the remaining 75% to 90% develop a chronic infection in their
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liver141. The reasons why some patients manage to clear the virus, while others
acquire a chronic infections, are not yet fully understood158,376.
HCV is also called a ”silent killer”, as the infection remains largely unnoticed in
the first years100. Over time, however, the permanent infection and inflammation of
the liver may lead to steatosis, also known as fatty liver, and functionless scar tissue,
resulting in liver fibrosis or cirrhosis135. Ultimately, chronic hepatitis may lead to
hepatocellular carcinoma, a form of liver cancer372. In Europe and the United States
of America, HCV is the leading cause for liver transplantation372.
Treatment options Permanent eradication of the virus, measured as sustained viro-
logic response (SVR) 24 weeks after completion of the treatment, can be achieved in
a large number of patients207. Until recently, the recommended treatment regimen
for chronically infected patients was a combination of the immune-system stimu-
lating interferon and the antiviral agent ribavirin157,361. Depending on the viral
genotype, this treatment has a success rate of 5-80%297. However, it frequently
leads to undesired and potentially strong side-effects that may result in patients
aborting the 48-week long treatment131. In 2011, new direct-acting antiviral agents
(DAAs), which target non-structural HCV proteins like the NS3 protease, have been
approved for therapy91. This opened up new treatment options, as DAAs can be
used in shorter treatments combinations, thus leading to less side-effects. In ad-
dition, they generally achieve better SVR rates than the classic treatments390,425.
However, DAAs may lead to the rapid development of resistance mutations in the vi-
ral genome404, which is promoted by the error-prone viral polymerase331. The rapid
turnover, caused by the short lifespan of HCV particles81, may thus lead to viral
populations that are drug-resistant. With new DAAs in the pharmaceutical drug de-
velopment pipelines30,87,283, individual, patient-specific drug combination therapies,
as they are widely used in HIV treatment216, are required85.
HCV genome and proteome HCV was discovered and cloned in 1989 as ”non-A,
non-B hepatitis”71. It is an enveloped, single-stranded RNA virus that is classified
into the hepacivirus genus in the flaviviridae family405. Other flaviviruses, which
share some commonalities in their life cycle, include Dengue or the yellow fewer
virus113. HCV’s genome only has a length of about 9 600 nucleotides and encodes a
single polyprotein that is post-translationally cleaved into three structural and seven
nonstructural proteins248. The structural proteins core and the envelope glycopro-
teins E1 and E2 are required to form the viral particle. The nonstructural proteins
p7, NS2-3, NS3, NS4A, NS4B, NS5A, and NS5B have diverse functions, for instance,
as protease (NS3) or polymerase (NS5B)297. A detailed description of the molecular
biology of HCV is, for example, provided in Brass et al. 47 or Tang and Grise´ 372.
Host factors Viral genomes are very short and encode only a fraction of the genes
that are required during their life cycle293. Consequently, viruses like HCV, which
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only encodes 10 proteins, depend on the human host cell and numerous molecules
like proteins, lipids, nucleic acids, or membrane compartments29,90,372. These hu-
man molecules are known as cellular factors or host factors 202,254. An exemplary
genetic host factor for HCV is a polymorphism upstream of the IL28B gene, which
in genome-wide association studies has been linked with a significant difference in
response to drug treatment and clearance of viral particles131,366,371,376. Another
well-known host factor is the liver-specific microRNA mir-122124,156. In primates,
constant degradation of this essential HCV host factor led to a long-lasting suppres-
sion of HCV infection, without measurable viral resistance mutations or noticeable
side-effects210.
In the following, we will use the term host factor only for referring to human genes
and their proteins that influence the viral life cycle. Depending on their particular
effect on the virus, host factors can be divided into two classes. Host dependency
factors (HDFs) are proteins that are essential for the virus, for example, cellular
receptors that mediate viral entry into human hepatocytes28,334. Host restriction
factors (HDRs) describe proteins that have an oppressing effect and control or re-
strict viral replication, for example, as part of the innate immune response97.
Viral life cycle The life cycle of HCV can be broadly split into four stages (see
Figure 5.1):
1. entry into hepatocytes,
2. replication in the cytoplasm,
3. assembly of viral particles,
4. release of infectious particles.
Two particular characteristics of the HCV life cycle are its strong connections
to the host lipid metabolism10,245,368 and the formation of cellular structures know
as membranous web, formations derived from host membranes that are home to
viral replication complexes372. A detailed description of the individual stages can
be found elsewhere27,248,254,372.
Generally, the two early stages, entry and replication, are better studied and
understood than the latter, assembly and release (see Table 5.1). A reason for this
is that for many years HCV was very difficult to study in vitro, as cultured viruses
did not produce enough infectious viral particles to sustain a permanent infection26.
A major development in this direction was made by subgenomic replicons, self-
amplifying RNA-based systems in hepatoma cells408. These artificial systems allow
studying intracellular parts of the viral replication cycle like RNA amplification, but
do not produce infectious viral particles. A breakthrough in the study of HCV was
made by the discovery of a particular HCV genome in a Japanese patient188, from
which clones could be derived that have very high production rates of infectious
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Figure 5.1: Life cycle of the hepatitis C virus (HCV). First, viral particles bind to specific
receptor molecules on the cell surface. The virus-receptor complex then moves to tight
junctions and enters the cell by means of receptor-mediated endocytosis. In an uncoating
step, the viral nucleocapsid is then released into the cytoplasm and is relocated to the rough
endoplasmatic reticulum (rER), where translation of viral RNA occurs. The translated
polyprotein is post-translationally modified and viral particles are produced within the
membranous web. The viral life cycle is complete when particles exit the host cell through
the secretary pathway. Image modified from Poenisch and Bartenschlager 296.
particles398. From 2005 onwards, such HCV cell culture (HCVcc) systems enable
studies of the whole viral life cycle and the human host factors involved in it.
5.1.2 Host factor determination using RNA interference
Different experimental techniques exist for studying connections between viruses
and their human hosts. RNA interference is the approach that is used in most of
the screens that determine host factors for viral infections. In the next sections, the
mechanism of RNA interference will be briefly introduced, followed by a description
how this can be used in large-scale experiments.
RNA interference RNA interference (RNAi) is a mechanism of post-transcriptional
regulation or gene silencing. Based on studies that exemplified how RNA fragments
with antisense sequence to a target gene can effect its expression, Fire et al. provided
the first model of this gene-regulatory mechanism in 1998119. For this discovery, Fire
and Mello were awarded the 2006 Nobel Prize in Physiology or Medicine. In their
experiments, they found that after injecting double-stranded RNA (dsRNA) into
the worm C. elegans, genes containing a homologous sequence were silenced very
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potently. The inhibition was much stronger than when single-stranded antisense
RNA was introduced, suggesting an underlying cellular pathway for RNA processing.
Elbashir et al. later showed that the effectors of RNAi are single-stranded short
interfering RNA (siRNA) fragments with a length of 21 or 22 nucleotides103. In the
same year, Elbashir et al. proved that RNAi can be triggered in mammalian cell
lines by introducing siRNA dublexes of 21 nucleotides length into the cell102. This
discovery turned RNAi into a powerful technology for studying individual human
gene function via the introduction of siRNAs that are specifically tailored to the
mRNAs of certain target genes.
In the RNAi pathway, which is triggered after dsRNA is introduced into a cell, the
two RNA strands are first processed by an RNAse named Dicer35. The guide strand,
which is sequence complementary to the target mRNA, is incorporated into a multi-
protein complex named RNA-induced silencing complex (RISC)144. By binding to
the target mRNA in a sequence-specific manner, RISC then leads to its degradation
and thus to the temporary silencing of the gene expression. Recently, Lima et al.
have shown that single-stranded siRNA (ss-siRNA) can be modified to exhibit sim-
ilar silencing potency than the ds-RNA that is processed in the RNAi pathway223.
Combining the simplicity of siRNA silencing with the efficiency of the RNAi machin-
ery, Yu et al. were able to use ss-siRNA to silence mutant huntingtin in Huntington
disease patients417.
Loss-of-function studies using RNAi The power of RNAi for loss-of-function stud-
ies of human genes has resulted in the availability of commercial libraries that target
all known or predicted human gene transcripts246. This has resulted in a great num-
ber of RNAi screens investigating fundamentally different processes like endocyto-
sis288, signaling pathways122,246, or host factors for bacterial1 or viral infections70,154.
The particular experimental setups vary between individual RNAi screens, but
most of them follow the same general principles (see Figure 5.2). One approach
of introducing siRNAs into cells is named reverse transfection108. Specific siRNAs
and a transfection reagent that promotes cellular uptake of siRNAs are spotted on
a plate and a defined number of cells along with a nutrition medium are seeded on
each of the spots. This starts the cellular siRNA uptake and results in the temporary
silencing of the target genes46. After a certain duration, the silencing effect can be
determined using different readout methods. Depending on the particular biological
question and the experimental setup, a reporter molecule may have been stained
with a color marker beforehand, allowing the use of immunofluorescence microscopy
for counting or measuring signal intensities of the reporter238. In a statistical post-
processing step, these values are then normalized for variability within and between
experimental repetitions or with respect to negative and positive controls that should
show no or a strong effect, respectively231. Commonly, the effect of a particular
siRNA is quantified as a z-score, which is defined as the difference between the
intensity value for a spot and the mean value of a plate, divided by the standard
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Figure 5.2: Schematic experimental setup of large-scale RNA interference screens105.
First, cells are seeded into the wells of a plate. In each well, cells are then transfected with
siRNAs, leading to temporary silencing of the target gene expression. If the RNAi screen
is used to detect host factors for viral infections, viral particles are added in the next step
and given some time for infection and replication. After a certain duration, phenotypic
changes can be measured. In case of viral host factor screens, this can be achieved by
measuring viral particles and cells with multichannel fluorescence microscopy.
deviation of the plate323. Using statistical tests, a p-value may additionally be
computed to assess the significance of the computed score428. Further information
about different aspects of statistical post-processing including quality control, data
normalization, and hit calling are provided in Amberkar et al. 11.
RNA interference screens for determining viral host factors are similar to the
normal screen setup described above. The essential difference is that, after the
cells have been spotted on the plate and the siRNA has been transfected into the
cell, leading to degradation of the target mRNA, the cells are infected with viral
particles321. Depending on the particular viral study system, such particles may be
complete infectious viruses or engineered pseudo-particles that only consist of viral
envelope proteins. The former would allow studying the complete viral life cycle218,
while the latter may be used to detect host factors required for viral cell entry394.
Side-effects RNAi screens are faced with several challenges. First, the efficiency
of different siRNAs varies strongly, depending on their chemical properties, their
sequence composition, or the accessibility of the target binding site160. In addition,
side-effects or off-target effects of siRNA injections are very common.
Unspecific side-effects, which may occur independent of the particular siRNAs
that are being used, may be triggered by the activation of the interferon system
and thus the stimulation of an immune response351. In addition, the transfection
reagent induces stress on the cells, thus changing normal cell viability. Snijder et al.
have further found that the studied cellular populations may be in different cellular
developmental stages and thus show a variable response to the same treatment353.
Specific side-effects may occur when the siRNA does not only bind to the intended
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mRNA, but has additional complementary targets in the transcriptome175. Since
siRNAs only have a length between 19 and 23 nucletoides, such complementary
sequences appear frequently160. In particular, siRNA binding is largely driven by a
seed region comprising only 2-8 nucleotides, which further increases the number of
potential binding sites36,174. In addition to complementary binding, siRNAs have
also been found to bind to targets that have imperfect sequence complementarity173.
Several of the side-effects may be minimized by sophisticated design of the siRNA,
optimizing its chemical properties in order to maximize the efficiency, while at the
same time minimizing the complementary target sequences96,235,255,265,422. In addi-
tion, it is crucial that for each gene that is tested, multiple different siRNAs are used
such that each siRNA binds to a different sequence in the target mRNA347. Mul-
tiple replications of the same experiment may further account for effects of cellular
variability and produce results that are statistically more robust and relevant. In
summary, the screen design largely influences the quality of the resulting findings.
5.2 Computational framework for analyzing viral
RNAi screens
In order to analyze and prioritized the results of large-scale RNA interference screens,
in particular those determining host factors for viral infections, we built an integra-
tive data warehouse combining multiple heterogeneous datasets.
5.2.1 Datasets
Published host factor screens Of central importance to our analysis are results
from previously published host factor screens, as they allow placing individual re-
sults into a broader context70,154. Table 5.1 lists all RNAi screens for host factors of
the hepatitis C virus that we have collected into our database in a laborious manual
curation process. This unpublished, in-house database of host factors turned out
to be a very valuable resource, allowing us to perform broader analyses and func-
tional studies. Most of the data it contains is not accessible in RNAi databases like
GenomeRNAi344 or VIRsiRNAdb374.
Although several of the screens have been carried out using similar viral study
systems, cell types, and RNA interference protocols, their results are largely com-
plementary and show very little overlap. This has also been found in previous studies
for HCV and other viruses70,430. For example, between four independent influenza
screens, the average pairwise screen overlap was less than seven percent146. A simi-
lar value was found when comparing nine different HIV screens55. This situation is
thus similar to large-scale yeast-two hybrid screens for determining protein-protein
interactions, which also had been questioned after showing very little overlap in their
results (see Section 4.1).
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Table 5.1: Published host factor screens for hepatitis C virus (HCV) stored in our
database. The parts of the viral life cycle that were studied in the screen and the num-
ber of host dependency (# HDF) and host restriction factors (# HRF) that have been
reported in the respective publication are listed.
Reference Year Parts of viral life cycle # HDF # HRF
Berger et al. 33 2009 entry, replication 7 -
Borawski et al. 42 2009 replication 108 38
Chao et al. 63 2012 replication 1 -
Chen et al. 69 2010 replication 1 -
Coller et al. 74 2009 entry 16 -
Coller et al. 75 2012 release 14 -
Hara et al. 147 2009 replication 9 -
Herker et al. 151 2010 assembly 1 -
Jones et al. 184 2010 replication 7 7
Li et al. 218 2009 entry, replication,
assembly, release
237 25
Lupberger et al. 228 2011 entry 58 -
Ng et al. 262 2007 replication 9 -
Randall et al. 314 2007 replication 26 1
Reiss et al. 321 2011 entry, replication 13 -
Supekova et al. 365 2008 replication 3 -
Tai et al. 370 2009 replication 96 -
Trotard et al. 380 2009 entry, replication 5 2
Vaillancourt et al. 383 2009 replication 73 -
Xue et al. 413 2007 replication 3 -
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Hao et al. have recently shown that, although screen overlaps in terms of genes or
proteins are very modest, the screens detect host factors with similar functions146.
The overlap between functional categories that are found is 19% . In addition,
the different result lists are significantly more connected in a protein interaction
network than would be expected by chance146. Based on their statistical model,
they estimated that the low screen overlap is mostly due false negatives, host factors
that are not detected in a screen, and not due to false positives as they might result
from RNAi off-target effects146.
Molecular interaction data In addition to information about previously published
host factors, molecular interaction data are another fundamental resource for our
analyses. To this end, we combine integrated networks of human protein-protein in-
teractions and co-complex associations with information about interactions between
human and viral proteins. The latter dataset largely consists of large-scale yeast-
two-hybrid experiments by de Chassey et al. 84,257. We used different sources for
human protein interaction data, consisting of aggregated data from BioMyn311,312,
STRING369, and iRefIndex315.
Functional annotations BioMyn311,312 has also been used as resource for perform-
ing functional annotations and for computing functional enrichments, either incor-
porating Gene Ontology (GO) or pathway annotations321. In more recent studies,
we also used topGO 4, which, compared to classic enrichment computations, also
accounts for the graph structure of GO, thereby reducing redundancy in the re-
sults. Functional similarities between genes or proteins were retrieved from FunSim-
Mat340,341.
In addition, we used different online services in order to perform specific analysis
tasks. For example, our recent studies used DAVID to annotate gene sets with
UniProt keywords375 and functional GO annotations (see Figure 5.6). While this
functionality in principle is also available via BioMyn, the latter resource was not
available during the time of our study.
5.2.2 Functional network analysis of viral host factors
Several studies have investigated the molecular interaction networks involved in
different viral infections, mostly focusing on topological network parameters. For
example, Navratil et al. found that viral proteins particularly interact with highly
central proteins and those having a high bridging centrality256. Hao et al. found that
while individual screen results do not tend to form network clusters, the combined
set of host factors tends to be highly connected146.
Together with Nora Speicher, we developed a new network-based method to an-
alyze sets of host factor candidates by combining them with molecular interaction
data and functional protein and gene annotations354.
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Materials and methods Based on the hypothesis that viruses require host factors
with defined biological functions in order to fulfill their life cycle (see Section 5.1.1),
host factor proteins may be assumed to be functionally more similar to each other
than randomly chosen human protein pairs. In the following, two host factor can-
didates form a pair if their distance in a molecular interaction network is below a
particular threshold. Here, the network distance of two nodes is measured by the
shortest path length between these nodes303. Briefly summarized, our approach iden-
tifies all pairs of host factor candidates within a particular input set and compares
the functional similarities of these pairs to the functional similarities of randomly
generated protein pairs that lie within the same network distance.
We tested different measures for assessing functional similarity354 and found that
simRel, developed by Schlicker et al.
342, performed best for computing functional gene
and protein similarities based on the available Gene Ontology (GO) annotations15.
We used two integrative datasets as sources for molecular interactions, STRING369
and BioMyn311, in order to explore how the type of interaction data influences the
resulting functional similarities. STRING contains weighted interactions where the
weight reflects the strength of the combined interaction evidence that is derived from
different types of direct physical interactions and functional associations. In order
to exclude spurious interactions, we filtered the network by requiring a weight of at
least 0.4. From the BioMyn database, we used all direct physical protein-protein
interactions.
For our analyses, we selected the host factor determined by Borawski et al. 42, Li
et al. 218, and Tai et al. 370 from all published HCV host factor screens (see Table 5.1).
From these, we derived the two additional sets AllScreens, a union of the host factors
that have been detected in at least one of the screens, and HighConfidenceHits,
containing host host factors that have been found in at least two different screens.
Results After testing our method with artificial protein pairs taken from known
protein complexes354, we applied it to the aforementioned sets of HCV host fac-
tors using different network distances and functional similarity measures. Figure
5.3 exemplarily shows that pairs of host factors derived from the published HCV
host factor sets and those from two additional datasets have higher functional sim-
ilarities than randomly generated pairs. Remarkably, the highest similarities are
found within the HighConfidenceSet. These results were confirmed for pairs with a
maximum network distance ranging from one to four354.
When comparing the different interaction network types, we observed that the
similarities of the pairs identified using the STRING network are lower than the
similarities identified using BioMyn. A possible explanation is that functional asso-
ciations as derived from gene co-expression data, which are contained in STRING
but not in BioMyn, do not necessarily imply strong functional similarity. Neverthe-
less, the same overall tendency can be detected in results using the STRING network,
that is, host factor pairs are more similar to each other than random pairs354.
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Figure 5.3: Normalized, cumulative functional similarity distributions of host factor pairs
with a network distance of at most two354. Borawski42, Li218, and370 denote host factors
determined in the respective publications. The pairwise protein similarity is measured us-
ing simRel based on GO molecular function annotations. Continuous lines display the pairs
identified in the BioMyn network, dashed lines the pairs identified in the STRING network.
Numbers in parentheses denote the number of identified pairs (BioMyn/STRING).
Conclusions Our functional network analyses revealed that pairs of published hu-
man host factors for viral infections are significantly more similar to each other
than randomly selected protein pairs. This finding may be used for the valida-
tion and prioritization of experimentally determined sets of host factor candidates.
Importantly, by integrating different types of biological data, namely, molecular in-
teractions, known host factors, and functional protein annotations, the reliability
of individual experimental results can be measured and improved to gain deeper
insights into the molecular basis of viral infections in human host cells.
5.3 Application studies
This section describes the analysis of two large-scale screens determining host factors
for the hepatitis C virus (HCV). In the following, the experiments described in
Section 5.3.1 will be abbreviated as kinome screen 321, the recent analysis presented
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in Section 5.3.2 will be referred to as druggable screen (Poenisch et al., in prep.∗).
5.3.1 Human kinome screen for host factors required in HCV entry and
replication
Our first application study was the analysis of an RNAi screen investigating the
effect of human kinases on HCV infection321. This kinome screen was performed in
the group headed by Ralf Bartenschlager at the University of Heidelberg.
Experimental details The kinome screen focused on the early stages of the HCV
life cycle, investigating the effect of host factors on viral entry or replication. In
the primary screen, 719 known or predicted human kinases were targeted by three
different small interfering RNAs (siRNAs) per gene. In addition to these 2 157
siRNAs, positive and negative controls were added, for which a strong or no effect
could be expected, respectively. The well-known entry host factor CD8128 and two
siRNAs that directly target HCV were used as positive controls, siRNA sequences
without any complementary target sequence in the genome were used as negative
controls.
Based on the results from twelve screen replicates, z-scores were calculated for
each of the genes and hits were defined having a z − score < −1 or z − score > 1
and a p − value < 0.05. This modest cut-off score resulted in 83 host dependency
factor (HDF) candidates and 95 potential host restriction factors (HRFs) that were
further tested. In a validation screen, these 178 candidates were tested with four
new siRNAs and a more robust experimental setup. A hit was defined as validated,
if at least two out of four siRNAs had a z− score < −2.5 or z− score > 2.5. These
criteria resulted in 13 HDFs that could be confirmed. In a further siRNA screen
using HCV pseudoparticles (HCVpps), the role of the 13 HDFs in viral entry or
replication was tested. No candidate was found to have an effect on HCV entry,
proposing a role in viral replication321.
Annotation of validated host factors The 13 validated HDFs of the kinome screen
are listed in Table 5.2. We annotated the candidates with several functional datasets.
Of particular importance was the overlap with the in-house database of published
host factors and protein interactions with previously known host factors and viral
proteins. A more detailed version of Table 5.2 can be found in the Supplemental
Data of Reiss et al. 321.
Network analysis In order to place the validated HDFs in a cellular context and de-
termine specific pathways, we performed an integrative network analysis, combining
∗Poenisch, M., Metz, P., Blankenburg, H., Ruggieri, A., Lee, J.Y., Rupp, D., Rebhan, I.,
Diederich, K., Kaderali, L., Domingues, F.S., Albrecht, M., Lohmann, V., Erfle, H. and Barten-
schlager, R. Identification of HNRNPK as regulator of hepatitis C virus particle production, in
prep.
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Table 5.2: Host dependency factors validated in the kinome screen321. For each host
factor, the table lists the average siRNA z-score in the validation screen, whether it is
expressed in liver364, and if it was found in a previous host factor screen. In addition,




















1119 CHKA -9.96 X 218 - - -
5297 PI4KA -7.82 X 33,42,218,370,380,383 NS5A - X
10000 AKT3 -5.47 X - - X X
3101 HK3 -2.84 X - - - -
1457 CSNK2A1 -4.551 X - - X X
6725 SRMS -4.15 - - - - -
9874 TLK1 -4.05 X - - - X
53944 CSNK1G1 -3.34 - - - - X
5108 PCM1 -3.45 X - - - X
7075 TIE1 -3.23 X - - - -
79705 LRRK1 -2.41 X - - - X
55750 AGK -2.43 X - - X -
5214 PFKP -2.86 X - - - -
information about protein interactions and complexes with functional annotations.
In particular, we incorporated all previously published HCV host factors that were
available at the time (see Table 5.1). Eight of the 13 validated HDFs were found
to be connected to at least one previously published host factor either by direct
interaction or a co-complex membership (see Figure 5.4). We further investigated,
if validated HDFs are known to be involved in specific cellular pathways. Two of
the 13 HDFs were annotated to be involved in the ERBb pathway, which had been
described as important for flaviviruses before218.
For further analyses, we created a new host factor set by combining our confirmed
HDFs with all previously reported HDFs. This allowed us to identify pathways and
other functional annotations that are overrepresented within this set. A selection of
the pathways found this way are shown in Figure 5.4, the full results can be found
in the Supplemental Data of Reiss et al. 321.
PI4KIIIα Choline kinase alpha (CHKA) and phosphatidylinositol 4-kinase III alpha
(PI4KIIIα), the two validated HDFs that showed the strongest effect in the kinome
screen (see Figure 5.4 and Table 5.2), are both known to be involved in lipid mem-
brane biosynthesis321. While for CHKA no connection to other host factors could
be established, PI4KIIIα had interactions with several previously published host
factors. Importantly, it had been reported in no less than six other RNAi screens for
HCV host factors, which had all been published during the course of the study (see
Table 5.2). However, despite this large body of evidence, the particular mechanism
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Figure 5.4: Network representation of selected hepatitis C virus (HCV) host factors321.
Host factors are depicted as nodes, connecting edges represent direct protein-protein in-
teractions or co-membership in a protein complex. Node shapes symbolize if host factors
were newly identified (octagonal), previously known (oval), or confirmed (rectangular).
The strength of the inhibitory effect in the kinase screen is color-coded in the nodes
(white: not tested; light red: weak effect; deep red: strong effect). A selection of the
cellular pathways that are overrepresented among all HCV host factors are highlighted,
along with the phosphatidylinositol 4-kinase III alpha (PI4KIIIα) host factor.
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by which PI4KIIIα is important for HCV replication was not known.
Using a number of additional experiments, described in detail in Reiss et al. 321,
our experimental collaboration partners could show that the enzymatic activity of
PI4KIIIα is required for HCV replication independently of the HCV genotype. Fur-
ther, they showed that the absence of PI4KIIIα leads to morphological changes in
the membranous web structures, which are central for the establishment of HCV
replication complexes. In particular, they found that HCV directly interacts with
PI4KIIIα, thereby stimulating its kinase activity. All this evidence combined sug-
gest that HCV uses the kinase in order to change cellular structures in a way that
favors its life cycle.
5.3.2 Human druggable-genome screen capturing all stages of the HCV
life cycle
The second large-scale RNA interference screen that we supported with our analysis
pipeline was also performed in the group headed by Ralf Bartenschlager at the
University of Heidelberg. This screen used a different setup in order to test all
stages of the viral life cycle. In particular, the set of genes that were tested for their
potential role in HCV infection was much larger, consisting of more than 9 000 genes
of the so-called druggable genome 159.
Figure 5.5: Score distribution of all siRNAs tested in the HCV druggable primary screen
for entry or replication (left) and assembly or release (right). Hit siRNAs were defined by a
z−score ≤ −2 (green line) for host dependency factors (HDF, green dots) or z−score ≥ 2
(red line) for host restriction factors (HRF, red dots) (Poenisch et al., in prep.).
Primary screen 9 102 genes of an extended druggable genome library were tested
with three siRNAs per gene in the primary screen. The screen was composed of two
parts, the first part investigating the early life cycle stages entry and replication,
the second part focusing on the latter stages assembly and release of viral particles.
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While the first part could be performed as described in the kinase screen (see Sec-
tion 5.3.1), a reinfection of na¨ıve cells with cultured supernatant was required to
test the latter stages of the life cycle. Using a cut-off score of z − score ≤ −2 and
z − score ≥ 2, 78 potential host dependency factors (HDFs) and 29 putative host
restrictions factors (HRFs) were identified (see Figure 5.5).
We characterized the 106 host factor candidates of the primary screen by an-
notating them with GO terms and UniProt keywords (see Figure 5.6). The most
common biological processes were transport, transcription and transcription regula-
tion, whereas the most common molecular functions were hydrolase and transferase.
For UniProt keywords, we did not filter for any particular category, but aimed to
provide a broad overview of the cellular roles.
Meta-analysis The common procedure in RNAi screening is to investigate all hits
from the primary screen, which have been selected using a certain cut-off score crite-
ria, in a smaller validation screen246. Here, we wanted to complement this approach
by selecting only a part of the primary hits and adding other genes for which there
is a strong association to HCV. The rationale is that results will be biologically
more relevant if they have been detected by different experimental protocols and
procedures.
To this end, we conducted a computational meta-analysis that combined the re-
sults of the primary screen with our in-house database of published host factors,
results of a protein-protein interaction study, comparative transcriptome profiles of
HCV-infected and uninfected cells, and analyses of the components of the HCV-
induced replication complexes (Poenisch et al., in prep.). We combined the individ-
ual data sources in a weighted summing approach, individual weight factors were
assigned by the expert virologists of the Bartenschlager group. Considering a reason-
able size of the validation screen, we selected 109 candidates from this meta-analysis
for further validation.
Validation screen The 109 candidates from the meta-analysis were complemented
with 108 hits from the primary screen. As nine genes were present in both lists, a
total of 204 genes were tested in the validation screen. The screen was performed in
a similar layout as the primary screen, but in a smaller, more reliable format. Four
new siRNAs were selected, even changing the siRNA vendor to reduce potential
biases. Candidates were defined as hits in the validation screen if two of their four
siRNAs had a z− score ≤ −2 for HDFs or z− score ≥ 2 for HRFs (see Figure 5.7).
Considering that hits from the validation screen had to be consistent with their
results from the primary screen or the meta-analysis, we confirmed 40 HDFs and
16 HRFs. As three of those were found to be able to act as both HDF and HRF, a
total of 53 host factors were confirmed (see Table 5.3).
In order to gain insights into the cellular pathways involved, we annotated the
confirmed host factors with functional datasets and computed enrichments (see Ta-
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Figure 5.6: Functional annotation of all 106 hits of the druggable primary screen. Top:
Gene Ontology biological process (left) and molecular function (right) terms annotated to
all hits, hits could be annotated with multiple terms (Poenisch et al., in prep.). Bottom:
word cloud representation of UniProt keywords assigned to at least two hits of the primary
screen. The more hits are annotated with a particular term, the larger its font size. The
figure was created with http://www.wordle.net/, the coloring is purely aesthetical.
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Table 5.3: Host factors confirmed in the HCV druggable screen. Each line summarizes
the results from previous screens and our primary, meta, and validation screen. Abbre-
viations used: HDF = host dependency factor; HRF = host restriction factor; I = entry
or replication, II = assembly or release; V = Validaton sceen, M = selected based on
meta-analysis; D/d = HDF with 2 or 1 hit siRNAs; R/r = HRF with 2 or 1 hit siRNAs;
P/p = selected as hit in primary screen with 2 or 1 siRNAs (Poenisch et al., in prep.).
Primary screen Validation screen
Gene I II I II
ID Symbol HDF HRF HDF HRF V-Setup HDF HRF HDF HRF Confirmed Previous
3190 HNRNPK D - - r M,P D - - R DR HRF-II218
9793 CKAP5 d - D - M,P - R D - D HDF-I370
60559 SPCS3 - - D - M,P - R D - D HDF-II218
9424 KCNK6 - - D - P D r d - D -
3679 ITGA7 - - d - M d - D - D HDF- I42,218,370
3851 KRT4 d - d - M - - D - D HDF-I218
4839 NOP2 D - d - P - - D - D HDF-I218
55361 PI4K2A - - D r P - - D - D HDF-I228
6236 RRAD - - D - P - r D - D -
11142 PKIG D - - - P d - D - D -
353274 ZNF445 D - - - P d - D - D -
23341 DNAJC16 - - D - M,P - - D - D HDF-I42
56992 KIF15 - - D - P - - D - D -
7554 ZNF8 - - D - P - - D - D -
7419 VDAC3 - - D - M,P - - D - D -
57463 AMIGO1 - - D - P - - D - D -
377677 CA13 - - D - P - - D - D -
84790 TUBA1C - - - - M - R D - DR HDF-I370
9588 PRDX6 - - - - M - R D - DR HDF-I383
6233 RPS27A - - - - M - r D - D HDF-I42
2130 EWSR1 - - - - M d r D - D HDF-I218
83694 RPS6KL1 - - - - M d - D - D HDF-I42,218
9475 ROCK2 - - - - M - - D - D HDF-I33,74,218
3303 HSPA1A - - - - M - r D - D HDF-I218
10528 NOP56 - - - - M d - D - D HDF-I218
2885 GRB2 - - - - M - r D - D HDF-I314
9789 SPCS2 - - - - M - r D - D HDF-II218
9524 TECR - - - - M - r D - D HDF-I218
7511 XPNPEP1 - - - - M - - D - D HDF-I218,383
2197 FAU - - - - M - - D - D HDF-I42,218
1445 CSK - - - - M - - D - D HDF-I365
3881 KRT31 - - - - M - - D - D HDF-I370
22907 DHX30 - - - - M - - D - D HDF-I383
1147 CHUK - - - - M - - D - D HDF-I218
10847 SRCAP - - - - M - - D - D HDF-I314
65083 NOL6 - - - - M - - D - D HDF-I218
1381 CRABP1 d - d - p D - D - D -
84148 KAT8 d - - R P D - - - D -
348 APOE - r d - p - r D - D -
55679 LIMS2 - - d - p - r D - D -
6428 SRSF3 - - - R P - r - R R -
9775 EIF4A3 - - - R P - R - r R -
7003 TEAD1 - - - R P - R d - R -
81788 NUAK2 - - - - M - R d r R HDF-I218,262,370
8775 NAPA - - - - M - R d R R HDF-I370
5901 RAN d - - - M - R - - R HDF-I370
7186 TRAF2 - - - - M - R d - R HDF-I262
2107 ETF1 - - - - M - R d - R HDF-I218
1213 CLTC - - - - M - R d - R HDF-I380
2052 EPHX1 - - - - M - R d - R -
1314 COPA - - - - M - R - - R HDF-I370
29088 MRPL15 - - - - M - R - - R HDF-I218
2033 EP300 - r - r p - R d - R -
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Figure 5.7: Distribution of all siRNAs tested in the druggable validation screen for entry
or replication (left) and assembly or release (right). Hit siRNAs were defined by a z −
score ≤ −2 (green line) in case of host dependency factors (HDF, green dots) or z−score ≥
2 (red line) in case of host restriction factors (HRF, red dots). Genes targeted by siRNAs
with very potent z-scores are highlighted (Poenisch et al., in prep.).
ble 5.4). Amongst the biological processed that were annotated to the confirmed
hits more frequently than expected was intracellular protein transport or the epi-
dermal growth factor receptor signaling pathway. Both processes have already been
associated with HCV before228,370.
5.3.2.1 Further validation and role of HNRNPK
From the confirmed hits, ten candidates were selected for a more reliable valida-
tion setup. Candidates were selected if they were reported to have a known PPI
with HCV or another previously reported host factor. This was complemented by
Table 5.4: Selection of biological processes enriched among validated hits in the druggable
screen. Enrichments were computed with topGO, based on the total number of annotated
(Annot.), significant (Signif.) and expected (Exp.) terms, using LEAscore ≤ 0.05 as
significance threshold4 (Poenisch et al., in prep.).
GO ID Term Annot. Signif. Exp. LEA
GO:0071702 organic substance transport 1969 18 6.68 4.30E-05
GO:0071840 cellular component organization or biogenesis 4290 28 14.55 6.20E-05
GO:0006886 intracellular protein transport 712 10 2.41 0.00011
GO:0034381 plasma lipoprotein particle clearance 31 3 0.11 0.00015
GO:0007173 epidermal growth factor receptor signaling pathway 160 5 0.54 0.0002
GO:0010988 regulation of low-density lipoprotein particle clearance 7 2 0.02 0.00023
GO:0033036 macromolecule localization 1873 16 6.35 0.0003
GO:0042059 negative regulation of epidermal growth factor receptor signaling pathway 39 3 0.13 0.00031
GO:0032092 positive regulation of protein binding 41 3 0.14 0.00036
GO:0044765 single-organism transport 2775 20 9.41 0.0004
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Figure 5.8: Integrated network visualization of confirmed host factors and enriched bio-
logical processes. Host factors found in the druggable screen (rectangular nodes) and in
previous studies (oval or rectangular nodes with black borders) are shown. Oval nodes
depict host factors that were either not investigated or not confirmed. Confirmed host de-
pendency factors (HDF) are specified in green boxes, host restriction factors (HRF) in red
boxes and factors with unclear function (HDF and/or HRF) in yellow boxes. Lines con-
necting two nodes indicate proteins with known physical interaction. Selected biological
processes for which we found a significant enrichment of HCV host factors are highlighted
by colored areas and listed with their Gene Ontology identifiers below the network in the
correspondingly colored box (Poenisch et al., in prep.).
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promising candidates, for which no role as host factor was reported before.
Figure 5.9: Interaction network of the heterogeneous nuclear ribonuclear protein K (HN-
RNPK), showing all human proteins (ovals and rectangles), viral proteins (diamonds) and
viral RNAs (octagons) with reported interactions with HNRNPK. The depicted molecular
interactions were extracted from the scientific literature by expert virologists (Poenisch et
al., in prep.).
The strongest effect was confirmed for the heterogeneous nuclear ribonuclear pro-
tein K (HNRNPK), which had already been reported in the primary screen and the
meta-analysis. In the stringent validation screen, its role as host restriction factor
(HRF) for viral assembly or release was confirmed. HNRPNK has already been
associated with several different viral infections. For instance, it was reported to
interact with the Sindbis virus54 or the HCV proteins core162 and NS384. Informa-
tion about previously reported interactions with human or viral proteins and nucleic
acids were extracted from the scientific literature by our collaboration partners; the
resulting network is shown in Figure 5.9.
Given the consistent effect of HNRNPK during all stages of the druggable screen
and the reported evidence for a role in viral infections, our experimental collabora-
tion partners in Heidelberg went on to further characterize this host factor. First,
they investigated any potential effects on viral entry or replication and made sure
that the restrictive effect of HNRNPK is independent of the HCV genotype. Un-
like in other viral infections as caused by the aforementioned Sindbis virus54, they
did not found a change in HNRNPK’s subcellular localization after infection. In
additional characterization studies, they found that the two protein domains of the
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modular HNRNPK are particularly required for the restriction of HCV and that
the protein interacts with viral RNA. While the exact mechanism is sill not fully
understood, these results suggest that HNRNPK regulates the production of viral
particles in the assembly process by controlling the availability of viral RNA.
5.4 Conclusions
5.4.1 Summary
Viruses and the infections they cause are a major threat to human health. While
intense research efforts have resulted in improved treatment options205, no vaccines
are yet available for important viruses like those causing the acquired immune defi-
ciency syndrome or hepatitis C24,241. Classic antiviral drugs commonly operate by
activating the immune response, which has limited desired and strong side-effects,
or by targeting parts of the viral genome or proteome233. The pressure of direct
antiviral drugs leads to the emergence of resistance mutations, which due to the
poor viral error-correction in the replication machinery and the rapid turnover may
quickly lead to viral populations that are drug resistant404.
Due to their compact genomes, viruses rely on the human cellular machinery
to fulfill their life cycle245. Consequently, human host factors that are required for
viral infections have emerged as a promising research target. First, knowledge about
these factors will advance our basic understanding of how the virus uses and abuses
the cell113. Second, host factors may provide a new treatment option for antiviral
therapy195. While targeting those host factors may have undesired side-effects for
the normal function of human cells, the virus cannot simply evade this pressure by
developing resistance mutations, but has to completely adapt its life cycle to the
new situation97.
RNA interference (RNAi) is the detection method that has been used in most
experimental screens for determining host factors for different viruses, including
Dengue, West Nile, Human Immunodeficiency, Hepatitis C and Influenza70. RNAi
is a powerful technique that allows investigating the impact of individual genes on
the viral life cycle by temporarily degrading their gene products. However, RNAi
studies are associated with significant false positive and false negative results, mostly
due to undesired off-target effects146. This has resulted in a remarkably low overlap
of studies investigating the same viral systems55. As a consequence, in addition to
a robust experimental setup that includes a sufficient number of replicates and in-
dependent siRNAs per gene, statistical post-processing and bioinformatics analyses
are required to ensure that results have a biological relevance.
To this end, we have developed an integrated analysis pipeline that combines
different data types and analysis approaches. Our in-house database containing
multiple previously published host factor screens turned out to be of particular
importance, enabling us to place individual screen results into a broader context. In
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a small study, we investigated the functional annotations of host factors contained
in this database and found that the pairwise functional similarity of host factors is
significantly higher than for randomly selected pairs354. A high confidence subset
of host factors, which had been found in multiple independent studies, turned out
to have the highest similarities, proposing such an approach as means for validating
the results of individual studies.
We further applied our analysis pipeline to two large-scale screens for host factors
of the hepatitis C virus. In both of these screens, we supported the whole analysis
process and prioritized the most-promising candidates for further characterization
studies. In the more recent druggable screen (Poenisch et al., in prep.), which
investigated the complete viral life cycle, we further influenced the setup of the
validation screen by performing a meta-analysis that contributed additional host
factor candidates that had not been investigated in the primary screen.
Both studies yielded several promising host factor candidates. In particular, Reiss
et al. found that HCV interacts with the lipid kinase phosphatidylinositol 4-kinase
III alpha (PI4KIIIα) that was consistently found to have strong effects in different
RNAi screens, thereby stimulating its kinase activity321. As the absence of PI4KIIIα
resulted in changed morphology of the viral replication complexes, a role of the kinase
in the formation of these complexes is likely. Poenisch et al. recently determined the
role of the heterogeneous nuclear ribonucleoprotein K (HNRNPK) as a restricting
factor in the assembly of viral particles (Poenisch et al., in prep.). While the exact
mechanism is not fully understood, the experiments propose a role in regulating the
availability of HCV RNA in the production of viral particles.
5.4.2 Outlook
Despite greatly improved antiviral treatment options, human host factors for viral
infections will remain an important research target. Most of the host factor screens in
the past have been conducted in a classic approach, where a large primary screen was
used to propose candidates for a more stringent validation screen, and few validated
targets were characterized in detail. While this procedure proved its usefulness in
detecting factors of biological relevance321, it might miss candidates with weaker
effects. For example, host factors that are slightly above or below a z-score cut-
off in the primary screen are not further investigated, even though they might be
of central importance to the virus. Complementing the results of RNAi screens
with additional data types, as we have exemplarily shown with our meta-analysis
approach, may help to uncover such cases.
Integrative analysis approaches may also be used to reduce the importance of
selecting appropriate cut-off scores. Currently, the scores for separating hits from
non-hits are selected more or less arbitrarily, often simply reusing values from pre-
viously published screens. Instead, functional data could be incorporated to flexibly
select cut-off scores in a more objective fashion, for instance, based on changing
functional similarities of host factors.
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Data about specific siRNA sequences are currently not incorporated into anal-
ysis pipelines, although this information could be used to better detect unwanted
off-target effects or to correlate resulting scores with different chemical siRNA prop-
erties350. Buehler et al. even proposed a method for detecting pathway components
purely based on off-target effects53.
A general problem of loss-of-function studies investigating the effect of single-gene
knockouts are potential compensatory effects. Parallel paths in cellular pathways
or genetic redundancy may re-establish the function that was lost as a consequence
of the mRNA degradation. Experimental setups that allow testing two genes in
parallel161 and improved analysis methods that incorporate detailed pathway maps
might be able to improve results in this aspect246.
Further advancement in the integrated network analyses of host factor screens
can be expected from the incorporation of additional data types. Of particular
importance in this regard is high-quality data about drugs and their human targets,
as this would promote finding host factor candidates that can easily be further
experimentally characterized83. In addition, information about disease associations
might be used to complement the functional datasets that are currently used. Instead
of identifying network clusters of host factors that are functionally similar, this would
allow detecting modules of closely connected host factors for which there is a known
disease association.
Our visualizations combining viral host factor networks with functional enrich-
ments, presented in Figures 5.8 and 5.4, were very well received by other bioin-
formaticians, asking for support in creating similar visualizations. As much of the
work currently still involves laborious manual layout adjustments, a Cytoscape plu-
gin that takes over large parts of the layout process would be a great help for many
researchers.
6 Conclusions
This last chapter concludes the thesis by summarizing our methodological develop-
ments and the application studies that have been carried out. In addition, it points
out particular aspects of interactomics, where further advancements may be made.
6.1 Summarizing remarks
This thesis described novel methods for biomedical data integration and their ap-
plications in human systems biology. This interdisciplinary research area utilizes
the combined analysis of different molecular, biological, and medical data types to
discover information that may remain hidden in individual analyses. The data type
that was of central importance to our work was information about the interaction
of proteins with other molecules. As molecular interactions are involved in almost
every aspect of cellular functioning, knowledge of the complete human interactome,
the set of all molecular interactions inside a cell, is crucial for understanding complex
biological systems. Consequently, intense research has resulted in great amounts of
interaction data that have been described in publications or stored in dedicated
databases. The two main problems related to these datasets, which limit their value
for research and applications, are their general availability and the varying qual-
ity. Within this thesis, we we developed new methods that addressed both of these
issues.
Chapter 3 described two systems that were developed in international collabora-
tions to improve the availability of interaction data. Our Distributed System for
Molecular Interactions (DASMI) is built on the concept of decentralization. In-
teraction data are stored in various online repositories and is retrieved, combined,
and visualized upon user request40,41. Compared to static integrative databases like
iRefIndex or STRING, this approach ensures that interaction data can be easily
maintained and kept up-to-date. In addition, interested interaction data providers
may use our software to quickly set up additional servers for making their data
available181. DASMI, developed in the context of the European BioSapiens Net-
work of Excellence123, was the successful prototype that provided the basis for a
follow-up project of the Human Proteome Organization (HUPO) Proteomics Stan-
dards Initiative (PSI). Today, this successor system named PSI Common Query
Interface (PSICQUIC14) has a strong support in the interaction community and is
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used in many projects. This means that the two distributed systems presented in
this chapter profoundly improved the situation of interaction data availability.
Methodological advancements in the assessment of interaction data quality were
described in Chapter 4. The varying reliability of different interaction determination
or prediction techniques necessitated independent means to qualitatively assess the
resulting data. The great number and the diversity of approaches that had been
proposed to this end, renders a comprehensive central scoring solution unfeasible.
Consequently, we applied another decentralization strategy, in which scoring servers
can be made available at remote locations. The servers are accessed from a central
client, where users can upload individual interaction data that are to be scored and
then retrieve the results. Building on experiences gained with a proof-of-concept
scoring solution based on the aforementioned DASMI40,41, we developed the PSI
Common Confidence Scoring System (PSISCORE) in cooperation with the HUPO-
PSI38. Our open-source reference implementations facilitate the incorporation of
new scoring algorithms for assessing different aspects of molecular interactions. The
usefulness of our system was proven by the PSISCORE servers that have been made
available in Italy, Norway, and the United Kingdom14.
Chapter 5 demonstrated with several application studies how interactions and
other types of biomedical data may be jointly analyzed to gain new insights of direct
biological relevance. In particular, the chapter described the work performed in the
analysis, prioritization, and interpretation of data produced by two large-scale RNA
interference screens for determining human host factors for the hepatitis C virus
(HCV), an infection affecting 180 million people worldwide39. These studies proved
that interdisciplinary collaborations between bioinformaticians and experimental re-
search groups are increasingly important in our age of heterogeneous, systems-level
datasets105. Notably, we supported the discovery and functional characterization of
novel host factors for HCV. This expanded our knowledge of the basic viral life cycle
and provided promising new candidates for therapeutic advancements in antiviral
treatments321.
As the focus of this thesis was on the development of new methods for biomedical
data integration, only a selection of the performed application studies were described.
Another study together with research groups in Lu¨beck, Germany, and Bolzano,
Italy, involved an integrative network analysis approach incorporating protein in-
teractions and functional gene similarity networks for the prioritization of potential
interaction partners of Parkin, a key protein in Parkinson’s disease423. Furthermore,
a fruitful collaboration with structural biologists in Budapest, Hungary, determined
and prioritized new putative binding partners of mitogen-activated protein kinases
(MAPKs) and extracellular signal-regulated kinases (ERKs), which form part of the
important cellular MAPK/ERK pathway that transmits extracellular signals to the
nucleus127.
In summary, we developed a number of computational methods that successfully
improved the availability and quality of interaction data and demonstrated how
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novel biomedical data integration techniques may be applied to yield new insights
of direct biological relevance in interdisciplinary collaborations.
6.2 Perspectives
Information about molecular interactions will remain central to our understanding
of the human cell. In particular, it is still a long way towards a complete human
interactome388, as current methods do not adequately reflect its time- and space-
dependent nature, for example, not capturing that two proteins might only interact
in particular cellular organelles after being co-expressed in response to a certain
cellular state. Methodological advancements to detect and incorporate these data
into existing frameworks will be the next challenge in interactomics305. This also
includes the development of new visualization techniques that complement the static
two-dimensional network representations.
The distributed systems for interaction data retrieval, PSICQUIC in particular,
are increasingly being used in large-scale application studies. A further step into this
direction would be made by software solutions that integrate results from PSICQUIC
servers into local data warehouses. This would combine the benefits of decentral-
ization, that is, recent data and the ability to incorporate new servers, with the
superior analysis capabilities of data warehouses58. Incorporating PSISCORE into
such an integration pipeline in order to assess the combined interaction data with
different scoring algorithms would make an additional improvement. For certain
computationally expensive algorithms, like those based on structural modeling, such
a large-scale application might currently not be feasible.
From the two distributed HUPO-PSI systems dealing with molecular interactions,
PSICQUIC has the stronger community support. While this is largely due to the
fact that there are far more providers for interaction data than for scoring routines,
another contributing factor is that PSICQUIC received greater investments in terms
of personnel. We have learned over the years that, until a distributed system has
reached a critical size and importance, a lot of time-consuming support is required to
convince potential service providers to invest the additional effort that is required to
set up an own server. Thus, by investing more manpower in PSISCORE, its support
in the interaction community is likely to grow, resulting in an improved selection of
scoring servers. In addition, new clients for popular bioinformatics platforms like
Cytoscape, Galaxy, or Bioconductor would allow the incorporation of confidence
scoring in many existing workflows. The long-term goal of interaction data quality
assessment, however, is the combination of various confidence scoring approaches
into a meaningful combined score. While the outcome of this endeavor is uncertain,
it will be a challenging research area over the next years.
In our different application studies, we have demonstrated how integrative analysis
approaches yield new insights and aid researchers in answering particular biological
questions. Further means for combining heterogeneous datasets such as statistical
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learning methods might further improve the results. However, this improved per-
formance is often accompanied by sacrificed interpretability, which can ultimately
result in a black box that is no longer accepted by experimental cooperation part-
ners. Generally, improved results in integrative analysis studies can be expected
by incorporating additional data types, for example, information about drugs and
drug targets or disease associations. For sufficiently small hit lists, like the top hits
from our ranked HCV host factors screen results, structural models may be compu-
tationally predicted to elucidate putative interactions between host factor and viral
proteins.
In summary, it can be expected that biomedical data integration will remain an
important research discipline in the future, as new application areas are opened
up by steadily evolving experimental techniques. For example, single-cell pertur-
bations, combining sequencing, imaging, and proteomics experiments, will facili-
tate new large-scale system biological studies99. Another area, which holds great
promises, is the combination of clinical, biological, and molecular data, as it might
be achieved using extended electronic patient records. Such a system would enable
integrating data over multiple different scales, from free-text diagnoses and prescrip-
tions to images created by X-ray or magnetic resonance imaging, from diagnostic
blood parameters to individual patient sequence data and information about disease-
associated single-nucleotide polymorphisms182. However, before this can become re-
ality, a multitude of issues in the areas of data access, standards, and protocols need
to be tackled, along with legal and ethical questions. All in all, interdisciplinary
approaches for combining, processing, analyzing, and prioritizing such complex and
heterogeneous datasets will remain crucial in the foreseeable future.
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1 Technical documents
HUPO PSI MI 2.5 document formats
The following examples contain different representations of a binary protein-protein
interaction between two Arabidopsis thaliana proteins. The representation as HUPO-
PSI-MI XML 2.5 is shown in Listing 1. The same interaction as MITAB2.5 is
shown in Listing 2 and as MITAB2.7 representation in Listing 3. The interac-
tion data in the examples have been retrieved from the IntAct website (http:
//www.ebi.ac.uk/intact/) on 14 December 2014. 
1 <?xml version="1.0" encoding="UTF-8" standalone="yes"?>









10 <primaryRef refTypeAc="MI:0356" refType="identity" id="MI:0486" dbAc="MI:0488" db="psi-mi"/>















26 <primaryRef refTypeAc="MI:0356" refType="identity" id="EBI-6620106" dbAc="MI:0469" db="intact"/>














41 <alias type="go synonym" typeAc="MI:0303">2H</alias>
42 <alias type="go synonym" typeAc="MI:0303">2h</alias>
43 <alias type="go synonym" typeAc="MI:0303">Gal4 transcription regeneration</alias>
44 <alias type="go synonym" typeAc="MI:0303">two-hybrid</alias>
45 <alias type="go synonym" typeAc="MI:0303">yeast two hybrid</alias>
46 <alias type="go synonym" typeAc="MI:0303">2-hybrid</alias>
47 <alias type="go synonym" typeAc="MI:0303">classical two hybrid</alias>
48 <alias type="synonym" typeAc="MI:1041">Y2H</alias>
49 </names>
50 <xref>
51 <primaryRef refTypeAc="MI:0356" refType="identity" id="MI:0018" dbAc="MI:0488" db="psi-mi"/>
52 <secondaryRef refTypeAc="MI:0358" refType="primary-reference" id="1946372" dbAc="MI:0446" db="pubmed"/>
53 <secondaryRef refTypeAc="MI:0357" refType="method reference" id="10967325" dbAc="MI:0446" db="pubmed"/>
54 <secondaryRef refTypeAc="MI:0356" refType="identity" id="EBI-94" dbAc="MI:0469" db="intact"/>










64 <primaryRef refTypeAc="MI:0356" refType="identity" id="MI:0396" dbAc="MI:0488" db="psi-mi"/>
65 <secondaryRef refTypeAc="MI:0356" refType="identity" id="EBI-1465" dbAc="MI:0469" db="intact"/>




70 <attribute nameAc="MI:0634" name="contact-email">dszyman@purdue.edu</attribute>
71 <attribute nameAc="MI:0636" name="author-list">El-Din El-Assal S., Le J., Basu D., Mallery E.L., Szymanski D.B.</attribute>
72 <attribute nameAc="MI:0885" name="journal">Plant J. (0960-7412)</attribute>
73 <attribute nameAc="MI:0886" name="publication year">2004</attribute>
74 <attribute nameAc="MI:0955" name="curation depth">imex curation</attribute>
75 <attribute nameAc="MI:0957" name="full coverage">Only protein-protein interactions</attribute>








84 <fullName>Actin-related protein 2/3 complex subunit 2A</fullName>
85 <alias type="gene name" typeAc="MI:0301">ARPC2A</alias>
86 <alias type="gene name synonym" typeAc="MI:0302">Actin-related protein C2A</alias>
87 <alias type="gene name synonym" typeAc="MI:0302">Arp2/3 complex 34 kDa subunit</alias>
88 <alias type="gene name synonym" typeAc="MI:0302">DIS2</alias>
89 <alias type="gene name synonym" typeAc="MI:0302">Protein DISTORTED TRICHOMES 2</alias>
90 <alias type="orf name" typeAc="MI:0306">T17H7.13</alias>
91 <alias type="locus name" typeAc="MI:0305">At1g30825</alias>
92 </names>
93 <xref>
94 <primaryRef refTypeAc="MI:0356" refType="identity" version="TrEMBL_19" id="Q8LGI3" dbAc="MI:0486" db="uniprotkb"/>
95 <secondaryRef refTypeAc="MI:0360" refType="secondary-ac" version="SP_68" id="Q9SY27" dbAc="MI:0486" db="uniprotkb"/>
96 <secondaryRef id="GO:0005737" dbAc="MI:0448" db="go"/>
97 <secondaryRef id="GO:0005885" dbAc="MI:0448" db="go"/>
98 <secondaryRef id="GO:0042995" dbAc="MI:0448" db="go"/>
99 <secondaryRef id="GO:0007015" dbAc="MI:0448" db="go"/>
100 <secondaryRef id="GO:0030833" dbAc="MI:0448" db="go"/>
101 <secondaryRef id="GO:0010090" dbAc="MI:0448" db="go"/>
102 <secondaryRef id="IPI00521701" dbAc="MI:0675" db="ipi"/>
103 <secondaryRef refTypeAc="MI:0356" refType="identity" id="EBI-1547736" dbAc="MI:0469" db="intact"/>
104 <secondaryRef id="IPR007188" dbAc="MI:0449" db="interpro"/>
105 <secondaryRef id="IPI00521322" dbAc="MI:0675" db="ipi"/>








114 <primaryRef refTypeAc="MI:0356" refType="identity" id="MI:0326" dbAc="MI:0488" db="psi-mi"/>
115 <secondaryRef refTypeAc="MI:0361" refType="see-also" id="SO:0000358" dbAc="MI:0601" db="so"/>
116 <secondaryRef refTypeAc="MI:0356" refType="identity" id="EBI-619654" dbAc="MI:0469" db="intact"/>

















134 <fullName>Actin-related protein 2/3 complex subunit 4</fullName>
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135 <alias type="gene name synonym" typeAc="MI:0302">Actin-related protein C4</alias>
136 <alias type="gene name synonym" typeAc="MI:0302">Arp2/3 complex 20 kDa subunit</alias>
137 <alias type="orf name" typeAc="MI:0306">FCAALL.159</alias>
138 <alias type="orf name" typeAc="MI:0306">dl3115c</alias>
139 <alias type="locus name" typeAc="MI:0305">At4g14147</alias>
140 <alias type="gene name" typeAc="MI:0301">ARPC4</alias>
141 </names>
142 <xref>
143 <primaryRef refTypeAc="MI:0356" refType="identity" id="F4JUL9" dbAc="MI:0486" db="uniprotkb"/>
144 <secondaryRef refTypeAc="MI:0356" refType="identity" id="EBI-1547718" dbAc="MI:0469" db="intact"/>
145 <secondaryRef id="GO:0034314" dbAc="MI:0448" db="go"/>
146 <secondaryRef id="GO:0030041" dbAc="MI:0448" db="go"/>
147 <secondaryRef refTypeAc="MI:0360" refType="secondary-ac" version="SP_18" id="O23274" dbAc="MI:0486" db="uniprotkb"/>
148 <secondaryRef id="GO:0005737" dbAc="MI:0448" db="go"/>
149 <secondaryRef id="IPR008384" dbAc="MI:0449" db="interpro"/>
150 <secondaryRef id="GO:0005885" dbAc="MI:0448" db="go"/>
151 <secondaryRef id="GO:0042995" dbAc="MI:0448" db="go"/>
152 <secondaryRef id="NP_001031632.1" dbAc="MI:0481" db="refseq"/>








161 <primaryRef refTypeAc="MI:0356" refType="identity" id="MI:0326" dbAc="MI:0488" db="psi-mi"/>
162 <secondaryRef refTypeAc="MI:0361" refType="see-also" id="SO:0000358" dbAc="MI:0601" db="so"/>
163 <secondaryRef refTypeAc="MI:0356" refType="identity" id="EBI-619654" dbAc="MI:0469" db="intact"/>



















183 <primaryRef refTypeAc="MI:0356" refType="identity" id="EBI-6620113" dbAc="MI:0469" db="intact"/>




















204 <primaryRef refTypeAc="MI:0356" refType="identity" id="MI:0499" dbAc="MI:0488" db="psi-mi"/>
205 <secondaryRef refTypeAc="MI:0356" refType="identity" id="EBI-77781" dbAc="MI:0469" db="intact"/>











216 <primaryRef refTypeAc="MI:0356" refType="identity" id="MI:0498" dbAc="MI:0488" db="psi-mi"/>
217 <secondaryRef refTypeAc="MI:0356" refType="identity" id="EBI-58" dbAc="MI:0469" db="intact"/>



















237 <primaryRef refTypeAc="MI:0356" refType="identity" id="MI:0499" dbAc="MI:0488" db="psi-mi"/>
238 <secondaryRef refTypeAc="MI:0356" refType="identity" id="EBI-77781" dbAc="MI:0469" db="intact"/>










249 <primaryRef refTypeAc="MI:0356" refType="identity" id="MI:0496" dbAc="MI:0488" db="psi-mi"/>
250 <secondaryRef refTypeAc="MI:0356" refType="identity" id="EBI-49" dbAc="MI:0469" db="intact"/>












263 <primaryRef refTypeAc="MI:0356" refType="identity" id="MI:0915" dbAc="MI:0488" db="psi-mi"/>
264 <secondaryRef refTypeAc="MI:0356" refType="identity" id="EBI-1813147" dbAc="MI:0469" db="intact"/>













Listing 1: HUPO-PSI-MI XML 2.5 representation of a binary PPI
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 
1 #ID(s) interactor A ID(s) interactor B Alt. ID(s) interactor A Alt. ID(s) interactor B Alias(es) interactor A Alias(es) interactor
B Interaction detection method(s) Publication 1st author(s) Publication Identifier(s) Taxid interactor A Taxid interactor B
Interaction type(s) Source database(s) Interaction identifier(s) Confidence value(s)
2 uniprotkb:Q8LGI3 uniprotkb:F4JUL9 intact:EBI-1547736|uniprotkb:Q9SY27 intact:EBI-1547718|uniprotkb:O23274 psi-mi:arc2a_arath(
display_long)|uniprotkb:ARPC2A(gene name)|psi-mi:ARPC2A(display_short)|uniprotkb:Actin-related protein C2A(gene name synonym)|
uniprotkb:Arp2/3 complex 34 kDa subunit(gene name synonym)|uniprotkb:DIS2(gene name synonym)|uniprotkb:Protein DISTORTED
TRICHOMES 2(gene name synonym)|uniprotkb:T17H7.13(orf name)|uniprotkb:At1g30825(locus name) psi-mi:arpc4_arath(display_long)|
uniprotkb:Actin-related protein C4(gene name synonym)|uniprotkb:Arp2/3 complex 20 kDa subunit(gene name synonym)|uniprotkb:
FCAALL.159(orf name)|uniprotkb:dl3115c(orf name)|uniprotkb:At4g14147(locus name)|uniprotkb:ARPC4(gene name)|psi-mi:ARPC4(
display_short) psi-mi:"MI:0018"(two hybrid) El-Din et al. (2004) imex:IM-18781|pubmed:15086808 taxid:3702(arath)|taxid:3702("
Arabidopsis thaliana (Mouse-ear cress)") taxid:3702(arath)|taxid:3702("Arabidopsis thaliana (Mouse-ear cress)") psi-mi:"MI
:0915"(physical association) psi-mi:"MI:0486"(UniProt) intact:EBI-6620113|imex:IM-18781-1 intact-miscore:0.62 
Listing 2: HUPO-PSI-MITAB 2.5 representation of a binary PPI 
1 #ID(s) interactor A ID(s) interactor B Alt. ID(s) interactor A Alt. ID(s) interactor B Alias(es) interactor A Alias(es) interactor
B Interaction detection method(s) Publication 1st author(s) Publication Identifier(s) Taxid interactor A Taxid interactor B
Interaction type(s) Source database(s) Interaction identifier(s) Confidence value(s) Expansion method(s) Biological role(s)
interactor A Biological role(s) interactor B Experimental role(s) interactor A Experimental role(s) interactor B Type(s)
interactor A Type(s) interactor B Xref(s) interactor A Xref(s) interactor B Interaction Xref(s) Annotation(s) interactor A
Annotation(s) interactor B Interaction annotation(s) Host organism(s) Interaction parameter(s) Creation date Update date
Checksum(s) interactor A Checksum(s) interactor B Interaction Checksum(s) Negative Feature(s) interactor A Feature(s)
interactor B Stoichiometry(s) interactor A Stoichiometry(s) interactor B Identification method participant A Identification
method participant B
2 uniprotkb:Q8LGI3 uniprotkb:F4JUL9 intact:EBI-1547736|uniprotkb:Q9SY27 intact:EBI-1547718|uniprotkb:O23274 psi-mi:arc2a_arath(
display_long)|uniprotkb:ARPC2A(gene name)|psi-mi:ARPC2A(display_short)|uniprotkb:Actin-related protein C2A(gene name synonym)|
uniprotkb:Arp2/3 complex 34 kDa subunit(gene name synonym)|uniprotkb:DIS2(gene name synonym)|uniprotkb:Protein DISTORTED
TRICHOMES 2(gene name synonym)|uniprotkb:T17H7.13(orf name)|uniprotkb:At1g30825(locus name) psi-mi:arpc4_arath(display_long)|
uniprotkb:Actin-related protein C4(gene name synonym)|uniprotkb:Arp2/3 complex 20 kDa subunit(gene name synonym)|uniprotkb:
FCAALL.159(orf name)|uniprotkb:dl3115c(orf name)|uniprotkb:At4g14147(locus name)|uniprotkb:ARPC4(gene name)|psi-mi:ARPC4(
display_short) psi-mi:"MI:0018"(two hybrid) El-Din et al. (2004) imex:IM-18781|pubmed:15086808 taxid:3702(arath)|taxid:3702("
Arabidopsis thaliana (Mouse-ear cress)") taxid:3702(arath)|taxid:3702("Arabidopsis thaliana (Mouse-ear cress)") psi-mi:"MI
:0915"(physical association) psi-mi:"MI:0486"(UniProt) intact:EBI-6620113|imex:IM-18781-1 intact-miscore:0.62 - psi-mi:"MI
:0499"(unspecified role) psi-mi:"MI:0499"(unspecified role) psi-mi:"MI:0498"(prey) psi-mi:"MI:0496"(bait) psi-mi:"MI:0326"(
protein) psi-mi:"MI:0326"(protein) go:"GO:0005885"(Arp2/3 protein complex)|go:"GO:0007015"(actin filament organization)|go:"GO
:0030833"(regulation of actin filament polymerization)|go:"GO:0010090"(trichome morphogenesis)|refseq:NP_564364.1|interpro:
IPR007188(Arp2/3 complex, 34kDa subunit p34-Arc)|ipi:IPI00521701|go:"GO:0005737"(cytoplasm)|go:"GO:0042995"(cell projection)|
ipi:IPI00521322 go:"GO:0005885"(Arp2/3 protein complex)|go:"GO:0034314"(Arp2/3 complex-mediated actin nucleation)|refseq:
NP_001031632.1|interpro:IPR008384(ARP23 complex 20 kDa subunit)|go:"GO:0030041"(actin filament polymerization)|ipi:IPI00656811|
go:"GO:0005737"(cytoplasm)|go:"GO:0042995"(cell projection) - - - figure legend:Fig. 4b|curation depth:imex curation|full
coverage:Only protein-protein interactions taxid:4932(yeasx)|taxid:4932("Saccharomyces cerevisiae (Baker’s yeast)") -
2013/04/15 2013/04/15 rogid:3emb7Lf+rsEFn3GRcWEYJ3h4juM3702 rogid:0AxfqY3DADM0UcAGV4KFZE0AG1E3702 intact-crc:FE206A152B1CDEF2
|rigid:zv0hbWzadLtUgqOY1bHdD4otPg0 false - - - - psi-mi:"MI:0396"(predetermined participant) psi-mi:"MI:0396"(predetermined
participant) 
Listing 3: HUPO-PSI-MITAB 2.7 representation of a binary PPI
158 Appendix
DASINT XML Schema Definition
The following listing contains the XML Schema Definition (XSD) of the DASINT
XML format, which defines the response format of a DASMI server. 
1 <?xml version="1.0" encoding="UTF-8"?>








9 <xs:element name="INTERACTOR" maxOccurs="unbounded">
10 <xs:annotation>
11 <xs:documentation>The INTERACTOR element contains general information on the molecules participating in the interactions. The





15 <xs:element name="DETAIL" minOccurs="0" maxOccurs="unbounded">
16 <xs:annotation>




21 <xs:element name="RANGE" minOccurs="0" maxOccurs="unbounded">
22 <xs:annotation>
23 <xs:documentation>Indicating that the father DETAIL element is a positional detail. For example, as a child of an INTERACTOR detail
it can specify domains or strands on the interactor sequence.</xs:documentation>
24 </xs:annotation>
25 <xs:complexType>
26 <xs:attribute name="start" type="xs:int" use="required">
27 <xs:annotation>
28 <xs:documentation>The starting position of the detail in the sequence, e.g., 42.</xs:documentation>
29 </xs:annotation>
30 </xs:attribute>
31 <xs:attribute name="startStatus" type="xs:string" use="optional">
32 <xs:annotation>
33 <xs:documentation>The status of the starting position, e.g., certain.</xs:documentation>
34 </xs:annotation>
35 </xs:attribute>
36 <xs:attribute name="startStatusCvId" type="xs:string" use="optional">
37 <xs:annotation>
38 <xs:documentation> The controlled vocabulary term for the status of the starting position, e.g., MI:0335.</xs:documentation>
39 </xs:annotation>
40 </xs:attribute>
41 <xs:attribute name="end" type="xs:int" use="required">
42 <xs:annotation>
43 <xs:documentation>The ending position of the detail in the sequence, e.g., 91.</xs:documentation>
44 </xs:annotation>
45 </xs:attribute>
46 <xs:attribute name="endStatus" type="xs:string" use="optional">
47 <xs:annotation>
48 <xs:documentation>The status of the ending position, e.g., less-than.</xs:documentation>
49 </xs:annotation>
50 </xs:attribute>
51 <xs:attribute name="endStatusCvId" type="xs:string" use="optional">
52 <xs:annotation>






59 <xs:attribute name="property" type="xs:string" use="required">
60 <xs:annotation>




64 <xs:attribute name="propertyCvId" type="xs:string" use="optional">
65 <xs:annotation>
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66 <xs:documentation>The controlled vocabulary term for the property, e.g., MI:0346. </xs:documentation>
67 </xs:annotation>
68 </xs:attribute>
69 <xs:attribute name="value" type="xs:string" use="required">
70 <xs:annotation>
71 <xs:documentation>The actual piece of information, e.g., prey, human, or 1.0.</xs:documentation>
72 </xs:annotation>
73 </xs:attribute>
74 <xs:attribute name="valueCvId" type="xs:string" use="optional">
75 <xs:annotation>





81 <xs:element name="SEQUENCE" minOccurs="0">
82 <xs:annotation>
83 <xs:documentation>The sequence of the interactor. The coordinate system of the interactor defines whether the sequence contains





88 <xs:attribute name="start" type="xs:string" use="optional">
89 <xs:annotation>
90 <xs:documentation>The starting position of the sequence.</xs:documentation>
91 </xs:annotation>
92 </xs:attribute>
93 <xs:attribute name="end" type="xs:string" use="optional">
94 <xs:annotation>








103 <xs:attribute name="intId" type="xs:string" use="required">
104 <xs:annotation>
105 <xs:documentation>Internal identifier that is used for cross-referencing between interactors and participants.</xs:documentation>
106 </xs:annotation>
107 </xs:attribute>
108 <xs:attribute name="shortLabel" type="xs:string" use="required">
109 <xs:annotation>
110 <xs:documentation>The short name of the interacting molecule, e.g., hd_human or 14-3-3. Further names, like the full name or synonyms
can be stored in additional DETAIL elements. </xs:documentation>
111 </xs:annotation>
112 </xs:attribute>
113 <xs:attribute name="dbSource" type="xs:string" use="required">
114 <xs:annotation>
115 <xs:documentation>The name of the primary referenced database, e.g., uniprotkb.</xs:documentation>
116 </xs:annotation>
117 </xs:attribute>
118 <xs:attribute name="dbSourceCvId" type="xs:string" use="optional">
119 <xs:annotation>
120 <xs:documentation>The controlled vocabulary term for the primary database, e.g., MI:0486.</xs:documentation>
121 </xs:annotation>
122 </xs:attribute>
123 <xs:attribute name="dbVersion" type="xs:string" use="optional">
124 <xs:annotation>
125 <xs:documentation>The version of the database, e.g., SP_26.</xs:documentation>
126 </xs:annotation>
127 </xs:attribute>
128 <xs:attribute name="dbAccessionId" type="xs:string" use="required">
129 <xs:annotation>
130 <xs:documentation>The identifier of the reference in the primary database, e.g., P43246.</xs:documentation>
131 </xs:annotation>
132 </xs:attribute>
133 <xs:attribute name="dbCoordSys" type="xs:string" use="optional">
134 <xs:annotation>







140 <xs:element name="INTERACTION" maxOccurs="unbounded">
141 <xs:annotation>
142 <xs:documentation>The INTERACTION element contains information on a molecular interaction. An interaction is defined as an action





146 <xs:element name="DETAIL" minOccurs="0" maxOccurs="unbounded">
147 <xs:annotation>




151 <xs:attribute name="property" type="xs:string" use="required">
152 <xs:annotation>




156 <xs:attribute name="propertyCvId" type="xs:string" use="optional">
157 <xs:annotation>
158 <xs:documentation>The controlled vocabulary term for the property, e.g., MI:0346. </xs:documentation>
159 </xs:annotation>
160 </xs:attribute>
161 <xs:attribute name="value" type="xs:string" use="required">
162 <xs:annotation>
163 <xs:documentation>The actual piece of information, e.g., prey, human or 1,0.</xs:documentation>
164 </xs:annotation>
165 </xs:attribute>
166 <xs:attribute name="valueCvId" type="xs:string" use="optional">
167 <xs:annotation>





173 <xs:element name="PARTICIPANT" minOccurs="2" maxOccurs="unbounded">
174 <xs:annotation>





179 <xs:element name="DETAIL" minOccurs="0" maxOccurs="unbounded">
180 <xs:annotation>




185 <xs:element name="RANGE" minOccurs="0" maxOccurs="unbounded">
186 <xs:annotation>
187 <xs:documentation>Indicating that the father DETAIL element is a positional detail. For example, as a child of a PARTICIPANT DETAIL
it can indicate a binding site. </xs:documentation>
188 </xs:annotation>
189 <xs:complexType>
190 <xs:attribute name="start" type="xs:int" use="required">
191 <xs:annotation>
192 <xs:documentation>The starting position of the detail in the sequence, e.g., 42.</xs:documentation>
193 </xs:annotation>
194 </xs:attribute>
195 <xs:attribute name="startStatus" type="xs:string" use="optional">
196 <xs:annotation>
197 <xs:documentation>The status of the starting position, e.g., certain.</xs:documentation>
198 </xs:annotation>
199 </xs:attribute>
200 <xs:attribute name="startStatusCvId" type="xs:string" use="optional">
201 <xs:annotation>
202 <xs:documentation> The controlled vocabulary term for the status of the starting position, e.g., MI:0335.</xs:documentation>
203 </xs:annotation>
204 </xs:attribute>
205 <xs:attribute name="end" type="xs:int" use="required">
206 <xs:annotation>
207 <xs:documentation>The ending position of the detail in the sequence, e.g., 91.</xs:documentation>
208 </xs:annotation>
209 </xs:attribute>
210 <xs:attribute name="endStatus" type="xs:string" use="optional">
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211 <xs:annotation>
212 <xs:documentation>The status of the ending position, e.g., less-than.</xs:documentation>
213 </xs:annotation>
214 </xs:attribute>
215 <xs:attribute name="endStatusCvId" type="xs:string" use="optional">
216 <xs:annotation>






223 <xs:attribute name="property" type="xs:string" use="required">
224 <xs:annotation>




228 <xs:attribute name="propertyCvId" type="xs:string" use="optional">
229 <xs:annotation>
230 <xs:documentation>The controlled vocabulary term for the property, e.g., MI:0346. </xs:documentation>
231 </xs:annotation>
232 </xs:attribute>
233 <xs:attribute name="value" type="xs:string" use="required">
234 <xs:annotation>
235 <xs:documentation>The actual piece of information, e.g., prey, human or 1.0.</xs:documentation>
236 </xs:annotation>
237 </xs:attribute>
238 <xs:attribute name="valueCvId" type="xs:string" use="optional">
239 <xs:annotation>






246 <xs:attribute name="intId" type="xs:string" use="required">
247 <xs:annotation>
248 <xs:documentation>Internal identifier used to link an interactor participating in an interaction (-&gt; PARTICIPANT) to its






254 <xs:attribute name="name" type="xs:string" use="required">
255 <xs:annotation>
256 <xs:documentation>"The name of the interaction, e.g. exo1-msh2.</xs:documentation>
257 </xs:annotation>
258 </xs:attribute>
259 <xs:attribute name="dbSource" type="xs:string" use="required">
260 <xs:annotation>
261 <xs:documentation>The name of the referenced database, e.g., mint.</xs:documentation>
262 </xs:annotation>
263 </xs:attribute>
264 <xs:attribute name="dbSourceCvId" type="xs:string" use="optional">
265 <xs:annotation>
266 <xs:documentation>The controlled vocabulary term for the database, e.g., MI:0471.</xs:documentation>
267 </xs:annotation>
268 </xs:attribute>
269 <xs:attribute name="dbVersion" type="xs:string" use="optional">
270 <xs:annotation>
271 <xs:documentation>The version of the database, e.g., SP_26.</xs:documentation>
272 </xs:annotation>
273 </xs:attribute>
274 <xs:attribute name="dbAccessionId" type="xs:string" use="required">
275 <xs:annotation>











Listing 4: DASINT XML Schema Definition
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PSISCORE Web Service Description Language
The following listing contains the PSISCORE Web Service Description Language
(WSDL) that defines how PSISCORE servers can be accessed programmatically. 
1 <?xml version=’1.0’ encoding=’UTF-8’?>
2 <wsdl:definitions name="PsiscoreService" targetNamespace="http://psi.hupo.org/mi/psiscore" xmlns:ns1="http://cxf.apache.org/bindings/
xformat" xmlns:soap="http://schemas.xmlsoap.org/wsdl/soap/" xmlns:tns="http://psi.hupo.org/mi/psiscore" xmlns:wsdl="http://
schemas.xmlsoap.org/wsdl/" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
3 <wsdl:types>
4 <xs:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://psi.hupo.org/mi/psiscore" xmlns:
ns1="http://psi.hupo.org/mi/mif" xmlns:tns="http://psi.hupo.org/mi/psiscore" xmlns:xs="http://www.w3.org/2001/XMLSchema">
5 <xs:import namespace="http://psi.hupo.org/mi/mif" />
6 <xs:element name="getJob" type="tns:getJob" />
7 <xs:element name="getJobResponse" type="tns:getJobResponse" />
8 <xs:element name="getJobStatus" type="tns:getJobStatus" />
9 <xs:element name="getJobStatusResponse" type="tns:getJobStatusResponse" />
10 <xs:element name="getSupportedDataTypes" type="tns:getSupportedDataTypes" />
11 <xs:element name="getSupportedDataTypesResponse" type="tns:getSupportedDataTypesResponse" />
12 <xs:element name="getSupportedDbAcs" type="tns:getSupportedDbAcs" />
13 <xs:element name="getSupportedDbAcsResponse" type="tns:getSupportedDbAcsResponse" />
14 <xs:element name="getSupportedScoringMethods" type="tns:getSupportedScoringMethods" />
15 <xs:element name="getSupportedScoringMethodsResponse" type="tns:getSupportedScoringMethodsResponse" />
16 <xs:element name="getVersion" type="tns:getVersion" />
17 <xs:element name="getVersionResponse" type="tns:getVersionResponse" />
18 <xs:element name="submitJob" type="tns:submitJob" />











30 <xs:element name="id" type="xs:string" />
31 <xs:element maxOccurs="unbounded" minOccurs="0" name="algorithmType" type="xs:string" />
32 <xs:element maxOccurs="unbounded" minOccurs="0" name="parameterSpecifier" type="tns:parameterSpecifier" />
33 <xs:element maxOccurs="unbounded" minOccurs="0" name="requiredDataFields" nillable="true" type="xs:string" />





39 <xs:element name="id" type="xs:string" />
40 <xs:element name="type" type="xs:string" />





46 <xs:element name="code" type="xs:int" />





52 <xs:element maxOccurs="unbounded" minOccurs="0" name="algorithmDescriptor" type="tns:algorithmDescriptor" />
53 <xs:element name="inputData" type="tns:resultSet" />





59 <xs:element minOccurs="0" name="entrySet" type="ns1:entrySet" />











70 <xs:element name="jobId" type="xs:string" />









































112 <xs:element name="resultSet" type="tns:resultSet" />










123 <xs:element name="resultType" type="xs:string" />
124 <xs:element default="0" name="firstResult" type="xs:int" />


















143 <xs:element name="dbAc" nillable="true" type="xs:string" />
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144 <xs:element name="id" type="xs:string" />
145 </xs:sequence>
146 </xs:complexType>
147 <xs:element name="PsiscoreException" nillable="true" type="tns:psiscoreFault" />
148 <xs:element name="InvalidArgumentException" nillable="true" type="tns:psiscoreFault" />
149 <xs:element name="JobStillRunningException" nillable="true" type="tns:psiscoreFault" />
150 </xs:schema>
151 <xs:schema elementFormDefault="qualified" targetNamespace="http://psi.hupo.org/mi/mif" version="1.0" xmlns:tns="http://psi.hupo.org/
mi/mif" xmlns:xs="http://www.w3.org/2001/XMLSchema">
152 <xs:element name="entrySet" type="tns:entrySet" />
153 <xs:complexType name="entrySet">
154 <xs:sequence>
155 <xs:element maxOccurs="unbounded" name="entry" type="tns:entry" />
156 </xs:sequence>
157 <xs:attribute name="level" type="xs:int" use="required" />
158 <xs:attribute name="version" type="xs:int" use="required" />




163 <xs:element minOccurs="0" name="source" type="tns:source" />
164 <xs:element minOccurs="0" name="availabilityList" type="tns:availabilityList" />
165 <xs:element minOccurs="0" name="experimentList" type="tns:experimentDescriptionList" />
166 <xs:element minOccurs="0" name="interactorList" type="tns:interactorList" />
167 <xs:element name="interactionList" type="tns:interactionList" />





173 <xs:element minOccurs="0" name="names" type="tns:names" />
174 <xs:element minOccurs="0" name="bibref" type="tns:bibref" />
175 <xs:element minOccurs="0" name="xref" type="tns:xref" />
176 <xs:element minOccurs="0" name="attributeList" type="tns:attributeList" />
177 </xs:sequence>
178 <xs:attribute name="release" type="xs:string" />




183 <xs:element minOccurs="0" name="shortLabel" type="xs:string" />
184 <xs:element minOccurs="0" name="fullName" type="xs:string" />






191 <xs:attribute name="typeAc" type="xs:string" />






198 <xs:element minOccurs="0" name="attributeList" type="tns:attributeList" />











210 <xs:attribute name="name" type="xs:string" use="required" />






217 <xs:element name="primaryRef" type="tns:dbReference" />






223 <xs:element minOccurs="0" name="attributeList" type="tns:attributeList" />
224 </xs:sequence>
225 <xs:attribute name="db" type="xs:string" use="required" />
226 <xs:attribute name="dbAc" type="xs:string" />
227 <xs:attribute name="id" type="xs:string" use="required" />
228 <xs:attribute name="secondary" type="xs:string" />
229 <xs:attribute name="version" type="xs:string" />
230 <xs:attribute name="refType" type="xs:string" />





















252 <xs:element minOccurs="0" name="names" type="tns:names" />
253 <xs:element name="bibref" type="tns:bibref" />
254 <xs:element minOccurs="0" name="xref" type="tns:xref" />
255 <xs:element minOccurs="0" name="hostOrganismList" type="tns:hostOrganismList" />
256 <xs:element name="interactionDetectionMethod" type="tns:cvType" />
257 <xs:element minOccurs="0" name="participantIdentificationMethod" type="tns:cvType" />
258 <xs:element minOccurs="0" name="featureDetectionMethod" type="tns:cvType" />
259 <xs:element minOccurs="0" name="confidenceList" type="tns:confidenceList" />
260 <xs:element minOccurs="0" name="attributeList" type="tns:attributeList" />
261 </xs:sequence>


















280 <xs:element minOccurs="0" name="names" type="tns:names" />
281 <xs:element minOccurs="0" name="cellType" type="tns:openCvType" />
282 <xs:element minOccurs="0" name="compartment" type="tns:openCvType" />
283 <xs:element minOccurs="0" name="tissue" type="tns:openCvType" />
284 </xs:sequence>









294 <xs:element name="names" type="tns:names" />
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295 <xs:element minOccurs="0" name="xref" type="tns:xref" />





301 <xs:element name="names" type="tns:names" />














































348 <xs:element name="unit" type="tns:openCvType" />










359 <xs:element name="names" type="tns:names" />
360 <xs:element minOccurs="0" name="xref" type="tns:xref" />
361 <xs:element name="interactorType" type="tns:cvType" />










371 <xs:element minOccurs="0" name="sequence" type="xs:string" />
372 <xs:element minOccurs="0" name="attributeList" type="tns:attributeList" />
373 </xs:sequence>









383 <xs:element minOccurs="0" name="names" type="tns:names" />
384 <xs:element minOccurs="0" name="xref" type="tns:xref" />
385 <xs:element minOccurs="0" name="availability" type="tns:availability" />
386 <xs:element minOccurs="0" name="availabilityRef" type="xs:int" />
387 <xs:element minOccurs="0" name="experimentList" type="tns:experimentList" />
388 <xs:element name="participantList" type="tns:participantList" />
389 <xs:element minOccurs="0" name="inferredInteractionList" type="tns:inferredInteractionList" />
390 <xs:element maxOccurs="unbounded" minOccurs="0" name="interactionType" type="tns:cvType" />
391 <xs:element minOccurs="0" name="modelled" type="xs:boolean" />
392 <xs:element default="false" minOccurs="0" name="intraMolecular" type="xs:boolean" />
393 <xs:element default="false" minOccurs="0" name="negative" type="xs:boolean" />
394 <xs:element minOccurs="0" name="confidenceList" type="tns:confidenceList" />
395 <xs:element minOccurs="0" name="parameterList" type="tns:parameterList" />
396 <xs:element minOccurs="0" name="attributeList" type="tns:attributeList" />
397 </xs:sequence>
398 <xs:attribute name="imexId" type="xs:string" />




403 <xs:choice maxOccurs="unbounded" minOccurs="0">
404 <xs:element name="experimentRef" type="xs:int" />











416 <xs:element minOccurs="0" name="names" type="tns:names" />
417 <xs:element minOccurs="0" name="xref" type="tns:xref" />
418 <xs:element minOccurs="0" name="interactionRef" type="xs:int" />
419 <xs:element minOccurs="0" name="interactor" type="tns:interactor" />
420 <xs:element minOccurs="0" name="interactorRef" type="xs:int" />
421 <xs:element minOccurs="0" name="participantIdentificationMethodList" type="tns:participantIdentificationMethodList" />
422 <xs:element minOccurs="0" name="biologicalRole" type="tns:cvType" />
423 <xs:element minOccurs="0" name="experimentalRoleList" type="tns:experimentalRoleList" />
424 <xs:element minOccurs="0" name="experimentalPreparationList" type="tns:experimentalPreparationList" />
425 <xs:element minOccurs="0" name="experimentalInteractorList" type="tns:experimentalInteractorList" />
426 <xs:element minOccurs="0" name="featureList" type="tns:featureList" />
427 <xs:element minOccurs="0" name="hostOrganismList" type="tns:hostOrganismList" />
428 <xs:element minOccurs="0" name="confidenceList" type="tns:confidenceList" />
429 <xs:element minOccurs="0" name="parameterList" type="tns:parameterList" />
430 <xs:element minOccurs="0" name="attributeList" type="tns:attributeList" />
431 </xs:sequence>














446 <xs:element maxOccurs="unbounded" name="experimentalPreparation" type="tns:experimentalPreparation" />










456 <xs:element minOccurs="0" name="interactor" type="tns:interactor" />
457 <xs:element minOccurs="0" name="interactorRef" type="xs:int" />










468 <xs:element minOccurs="0" name="names" type="tns:names" />
469 <xs:element minOccurs="0" name="xref" type="tns:xref" />
470 <xs:element minOccurs="0" name="featureType" type="tns:cvType" />
471 <xs:element minOccurs="0" name="featureDetectionMethod" type="tns:cvType" />








480 <xs:element minOccurs="0" name="attributeList" type="tns:attributeList" />
481 </xs:sequence>




486 <xs:element name="startStatus" type="tns:cvType" />
487 <xs:element minOccurs="0" name="beginInterval" type="tns:interval" />
488 <xs:element minOccurs="0" name="begin" type="tns:position" />
489 <xs:element name="endStatus" type="tns:cvType" />
490 <xs:element minOccurs="0" name="endInterval" type="tns:interval" />
491 <xs:element minOccurs="0" name="end" type="tns:position" />





497 <xs:attribute name="begin" type="xs:unsignedLong" use="required" />















513 <xs:element name="experimentRef" type="xs:int" />
514 </xs:sequence>






521 <xs:attribute name="term" type="xs:string" use="required" />
522 <xs:attribute name="termAc" type="xs:string" />
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523 <xs:attribute name="unit" type="xs:string" />
524 <xs:attribute name="unitAc" type="xs:string" />
525 <xs:attribute name="base" type="xs:short" />
526 <xs:attribute name="exponent" type="xs:short" />









536 <xs:element maxOccurs="unbounded" name="participant" type="tns:inferredInteractionParticipant" />





542 <xs:element minOccurs="0" name="participantFeatureRef" type="xs:int" />




547 <xs:restriction base="xs:string" />
548 </xs:simpleType>
549 <xs:simpleType name="label">
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616 <wsdl:input message="tns:getSupportedScoringMethods" name="getSupportedScoringMethods">
617 </wsdl:input>
618 <wsdl:output message="tns:getSupportedScoringMethodsResponse" name="getSupportedScoringMethodsResponse">
619 </wsdl:output>




624 <wsdl:input message="tns:submitJob" name="submitJob">
625 </wsdl:input>
626 <wsdl:output message="tns:submitJobResponse" name="submitJobResponse">
627 </wsdl:output>
628 <wsdl:fault message="tns:InvalidArgumentException" name="InvalidArgumentException">
629 </wsdl:fault>




634 <wsdl:input message="tns:getSupportedDataTypes" name="getSupportedDataTypes">
635 </wsdl:input>
636 <wsdl:output message="tns:getSupportedDataTypesResponse" name="getSupportedDataTypesResponse">
637 </wsdl:output>




642 <wsdl:input message="tns:getVersion" name="getVersion">
643 </wsdl:input>
644 <wsdl:output message="tns:getVersionResponse" name="getVersionResponse">
645 </wsdl:output>




650 <wsdl:input message="tns:getJobStatus" name="getJobStatus">
651 </wsdl:input>
652 <wsdl:output message="tns:getJobStatusResponse" name="getJobStatusResponse">
653 </wsdl:output>
654 <wsdl:fault message="tns:InvalidArgumentException" name="InvalidArgumentException">
655 </wsdl:fault>




660 <wsdl:input message="tns:getJob" name="getJob">
661 </wsdl:input>
662 <wsdl:output message="tns:getJobResponse" name="getJobResponse">
663 </wsdl:output>
664 <wsdl:fault message="tns:JobStillRunningException" name="JobStillRunningException">
665 </wsdl:fault>
666 <wsdl:fault message="tns:InvalidArgumentException" name="InvalidArgumentException">
667 </wsdl:fault>




672 <wsdl:binding name="PsiscoreServiceSoapBinding" type="tns:psiscoreService">
673 <soap:binding style="document" transport="http://schemas.xmlsoap.org/soap/http" />
674 <wsdl:operation name="getSupportedScoringMethods">
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675 <soap:operation soapAction="getSupportedScoringMethods" style="document" />
676 <wsdl:input name="getSupportedScoringMethods">
677 <soap:body use="literal" />
678 </wsdl:input>
679 <wsdl:output name="getSupportedScoringMethodsResponse">
680 <soap:body use="literal" />
681 </wsdl:output>
682 <wsdl:fault name="PsiscoreException">




687 <soap:operation soapAction="submitJob" style="document" />
688 <wsdl:input name="submitJob">
689 <soap:body use="literal" />
690 </wsdl:input>
691 <wsdl:output name="submitJobResponse">
692 <soap:body use="literal" />
693 </wsdl:output>
694 <wsdl:fault name="InvalidArgumentException">
695 <soap:fault name="InvalidArgumentException" use="literal" />
696 </wsdl:fault>
697 <wsdl:fault name="PsiscoreException">




702 <soap:operation soapAction="" style="document" />
703 <wsdl:input name="getSupportedDataTypes">
704 <soap:body use="literal" />
705 </wsdl:input>
706 <wsdl:output name="getSupportedDataTypesResponse">
707 <soap:body use="literal" />
708 </wsdl:output>
709 <wsdl:fault name="PsiscoreException">




714 <soap:operation soapAction="" style="document" />
715 <wsdl:input name="getVersion">
716 <soap:body use="literal" />
717 </wsdl:input>
718 <wsdl:output name="getVersionResponse">
719 <soap:body use="literal" />
720 </wsdl:output>
721 <wsdl:fault name="PsiscoreException">




726 <soap:operation soapAction="getJobStatus" style="document" />
727 <wsdl:input name="getJobStatus">
728 <soap:body use="literal" />
729 </wsdl:input>
730 <wsdl:output name="getJobStatusResponse">
731 <soap:body use="literal" />
732 </wsdl:output>
733 <wsdl:fault name="InvalidArgumentException">
734 <soap:fault name="InvalidArgumentException" use="literal" />
735 </wsdl:fault>
736 <wsdl:fault name="PsiscoreException">




741 <soap:operation soapAction="getJob" style="document" />
742 <wsdl:input name="getJob">
743 <soap:body use="literal" />
744 </wsdl:input>
745 <wsdl:output name="getJobResponse">
746 <soap:body use="literal" />
747 </wsdl:output>
748 <wsdl:fault name="JobStillRunningException">
749 <soap:fault name="JobStillRunningException" use="literal" />
750 </wsdl:fault>
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751 <wsdl:fault name="InvalidArgumentException">
752 <soap:fault name="InvalidArgumentException" use="literal" />
753 </wsdl:fault>
754 <wsdl:fault name="PsiscoreException">





760 <wsdl:port binding="tns:PsiscoreServiceSoapBinding" name="DefaultPsiscoreServicePort">




Listing 5: PSISCORE Web Service Description Languge (WSDL)
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AIDS Acquired immune deficiency syndrome
AJAX Asynchronous JavaScript and XML
AP Affinity purification
APID Agile Protein Interaction DataAnalyzer
ATP Adenosine triphosphate
BIND Biomolecular Interaction Network Database
BP Biological process
CC Cellular component
CHKA Choline kinase alpha
CSS Cascading Style Sheet
CV Controlled vocabulary
DAA Direct-acting antiviral agent
DAS Distributed Annotation System
DASMI Distributed Annotation System for Molecular Interac-
tions
DDI Domain-domain interaction
DIMA Domain Interaction Map
DIP Database of Interacting Proteins
dsRNA double-stranded RNA
DNA Deoxyribonucleic acid
DTD Document Type Definition
DWR Direct Web Remoting
EBI European Bioinformatics Institute
EMBL European Molecular Biology Laboratory
ENCODE ENCyclopedia Of DNA Elements
FRET Fluorescence/Fo¨rster resonance energy transfer
GO Gene Ontology
HCV Hepatitis C virus
HDF Host dependency factor
HIMAP Human Interactome Map
HIV human immunodeficiency virus
HRF Host restriction factor
HNRNPK Heterogeneous nuclear ribonuclear protein K
HPRD Human Protein Reference Database
HTML Hypertext Markup Language
HUPO Human Proteome Organization
HTTP Hypertext Transfer Protocol
IMEx International Molecular Exchange Consortium
LUMIER Luminescence-based mammalian interactome mapping
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MAPPIT Mammalian protein-protein interaction trap
MF Molecular function
MI Molecular Interaction
MIQL Molecular Interaction Query Language
MiMI Michigan Molecular Interactions
MIMIx Minimum information required for reporting a molecular
interaction experiment
MINT Molecular Interaction database
MPIDB Microbial protein interaction database
MPII Max Planck Institute for Informatics
mRNA Messenger RNA
MS Mass spectrometry
NCBI National Center for Biotechnology Information
NMR Nuclear magnetic resonance
OBO Open Biomedical Ontologies
PDB Protein Data Bank
PI4KIIIa Phosphatidylinositol 4-kinase III alpha
PINA Protein Interaction Network Analysis
PPI Protein-protein interaction
PSI Proteomics Standards Initiative
PSICQUIC PSI Common Query Interface
RELAX NX REgular LAnguage for XML Next Generation
REST Representational state transfer




SLM Short linear motif
SOAP Simple Object Access Protocol
STRING Search Tool for the Retrieval of Interacting Proteins
SVR Sustained virologic response
TAP Tandem affinity purification
TrEMBL Translated EMBL
UniHI Unified Human Interactome
UniProt Universal Protein Resource
UniProtKB UniProt Knowledgebase
URI Uniform Resource Identifier
URL Uniform Resource Locator
W3C World Wide Web Consortium
WAR Web archive
WSDL Web Service Description Language
XML Extensible Markup Language
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XSD XML Schema Definition
Y2H Yeast-two hybrid
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